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ABSTRACT 
The purpose of this study was to establish hypertensive patients' levels of 
adherence to treatment regimen, factors influencing adherence and describe the 
relationship between treatment adherence and hypertension control.  
Quantitative, descriptive design was used to investigate relationship between 
treatment adherence and hypertension control in patients who attend Queen 
Elizabeth Central Hospital Hypertension Clinic.  Data collection was done using a 
structured interview schedule that was researcher administered face-to-face to 
480 eligible hypertensive patients. Simple random sampling method was used.  
Data was analyzed using SPSS version 19.0.  Descriptive and linear regression 
statistics test for trend was done to investigate the relationship between 
demographic factors and adherence levels.  The p- value was used to test the 
null hypothesis of no relationship.  Alpha, 0.05 was used to determine 
significance.  The dependent variable was adherence and independent variables 
were, gender, age, culture, religion, educational level and distance to the health 
facility, perceived susceptibility, perceived severity, perceived benefits, and 
perceived barriers.  Findings revealed areas that may improve current treatment 
guidelines and strategies to improve adherence levels in hypertensive patients 
with outcome of hypertension control. 
KEY CONCEPTS: Treatment adherence, hypertension, hypertension control. 
 
 
    FACTORS INFLUENCING TREATMENT ADHERENCE AMONGST 
HYPERTENSIVE PATIENTS AT QUEEN ELIZABETH CENTRAL HOSPITAL, 
BLANTYRE, MALAWI 
 
ABSTRACT 
 
Background  
Hypertension is a global public health problem, a risk factor for 80.0% of 
cardiovascular diseases, accountable for 6.0% of deaths. Although much 
literature exists about hypertension risk factors and disease burden, treatment 
adherence remains a challenge, in both developed and developing countries, 
especially in sub Sahara Africa. 
Objective  
This study aimed to establish treatment adherence levels, and identify factors 
influencing adherence levels among hypertension patients at Queen Elizabeth 
Central Hospital (QECH) in Blantyre, Malawi. 
Methods  
A quantitative, descriptive, cross-sectional study was used and structured 
interviews were conducted with 480 eligible randomly selected hypertension 
patients treated at the QECH hypertension clinic. The Morisky Medication 
Adherence Scale was used to measure patients’ adherence levels. Descriptive 
statistics, univariate and multivariate analyses were computed using Stata version 
13.0 with 5% level of significance. 
Findings 
Out of the 480 respondents, 77.7%, were females, the mean age was 54.9 years 
(SD 11.6) and  42.7% had low, 39.6% had moderate and 17.7% had high anti-
hypertensive treatment adherence levels. In adjusted analyses; respondents 
whose parents were on hypertension treatment were 2.8 times more likely to have 
high adherence levels compared to those whose parents were not on such 
treatment (adjusted odds ratio [OR] 2.36; 95% confidence interval [CI]: 1.19; 4.67; 
p=0.014). Respondents who were knowledgeable about hypertension had 1.43 
increased OR of high adherence levels compared to respondents who lacked 
such knowledge (OR 1.43; 95% CI: 1.08, 1.81; p=0.012). Lower levels of 
adherence were significantly associated with taking herbs during the preceding 
three months (OR 0.53;95% CI: 0.34, 0.81; p=0.004); and long waiting times to 
get medication refills, resulting in 48% reduced adjusted odds ratio of having high 
adherence levels (OR 0.62; 95% CI: 0.38, 1.03; p=0.063). 
Conclusions 
Only 17.7% of the respondents had high rates of adherence at the QECH 
hypertension clinic. Further research is required to develop interventions to 
increase patients’ anti-hypertensive treatment adherence at the QECH clinic. 
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ABSTRACT 
The study established hypertensive patients' levels of adherence to their treatment 
regimens and identified factors influencing adherence. A quantitative, descriptive design 
was used and structured interviews were conducted with 480 hypertension patients at 
the Queen Elizabeth Central Hospital (QECH) hypertension clinic. The Health Belief 
Model was used to contextualise the findings. There were no significant correlations 
between treatment adherence levels and gender, age, culture or religion. 
 
Only 17.7% of the patients had high treatment adherence rates, while 39.6% had 
medium and 42.7% had low adherence rates.  The average anti-hypertension treatment 
adherence rate at the clinic was 33.3%, implying that 66.7% of the patients using the 
clinic’s services did not benefit from their treatment and remained at risk of incurring 
complications from hypertension such as cardiac arrests or strokes.  Although 91.7% of 
the respondents knew that hypertension can be controlled, they did not translate this 
knowledge into treatment adherence behaviours. 
 
Health care system-related factors impacted negatively on the respondents’ adherence 
levels.  The long waiting times at the clinic and the fact that this clinic’s pharmacy could 
not always supply the prescribed anti-hypertensive medicines made patients question 
the value of attending the clinic. 
vi 
 
Anti-hypertensive treatment adherence could be improved if individual patients translate 
their knowledge about hypertension into enhanced adherence behaviours.  The clinic’s 
waiting times should be reduced.  The pharmacy’s problem in supplying prescribed anti-
hypertensive medicines must be addressed effectively.  Without medications, 
hypertension cannot be treated and patients cannot be adherent to their treatment.   
 
KEY CONCEPTS: health services in Malawi, anti-hypertension treatment adherence, 
hypertension, hypertension control, Health Belief Model 
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    CHAPTER 1 
INTRODUCTION AND BACKGROUND INFORMATION 
 
1.1 INTRODUCTION 
 
Blood pressure is defined as the force exerted by the blood against the inner walls of 
the arteries, during the different phases of the contraction of the heart (World Health 
Organization [WHO] - International Society of Hypertension [ISH] 2003:1988). It is a 
product of cardiac output and systemic vascular resistance that is generated by cardiac 
contraction against vascular resistance according to Ohms’ Law (Gilbert 2009:2; Lewis, 
Dirksen, Heitkemper, Bucher & Camera 2011:739; Lilley, Collins, Harrington & Snyder 
2011:383; Smeltzer, Bare, Hinkle & Cheever 2008:1021).  Ohm's Law states that the 
electric current flowing in a conductor is directly proportional to the potential difference 
between its ends. The blood pressure has to be maintained within normal limits for 
healthy homeostasis, usually accepted to be 120/80 mmHg, considering specific 
factors such as age and lifestyle (Lilley et al 2011:384).   
 
Hypertension poses global, regional and national health challenges. Globally, one in 
three adults and an estimated one billion people live with hypertension. It is a leading 
risk factor of 80.0% of the global cardiovascular disease mortality. Hypertension is 
globally one of the major non-communicable diseases including cancer and diabetes 
that cause deaths in both developed and developing countries, among males and 
females (Gerin, Tobin, Schwartz, Chaplin, Rieckmann, Davidson, Goyal, Jhalani, 
Cassells, Feliz, Khalida, Diaz-Gloster & Ogedegbe 2007:460; Mensah 2008b:698).  It 
is accountable for more than 5.8% of deaths worldwide, in both men and women, but 
especially among black persons (Hussain, Boonshuyar & Ekram 2011:9; Mahawish & 
Heikinheimo 2011:9; Mensah 2008b:836; Middleton 2009:13).  In Sub Saharan Africa 
(SSA), hypertension is a public health epidemic for both men and women, amongst the 
upper and lower socio-economic income groups (Addo, Smeeth & Leon 2007:1012). In 
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Malawi, hypertension is a public health problem with a prevalence rate of 32.9% 
(Msyamboza, Ngwira, Dzowela, Mvula, Kathyola, Harries & Bowie 2011:20316:3). 
 
Hypertension, a common chronic condition, is defined as the persistently increased 
systemic vascular resistance against the cardiac output (Lewis et al 2011:742) and is 
also referred to as high blood pressure.  Hypertension can be controlled by adopting a 
healthy lifestyle and taking prescribed medication regularly (Lewis et al 2011:741). It is 
classified in three categories based on the level of blood pressure reading. Pre-
hypertension (mild) if the blood pressure level is 120/80-139/89 mmHg; stage1 
(moderate) if the blood pressure level is 140/90-159/99 mmHg and stage 2 (severe or 
crisis) if the blood pressure level is more than 160/100 mmHg (Woodrow, Colbert & 
Smith 2011:470).   
 
In some patients with mild and moderate hypertension, only lifestyle modifications are 
required to control their blood pressure. But in patients with severe hypertension, both 
lifestyle modifications and medicines are required to control it. When patients follow the 
lifestyle modifications and take prescribed medicines everyday of their lives, 
hypertension might be controlled and the benefits of a controlled blood pressure might 
be experienced (Adams, Holland & Urban 2011:300,304; Addo et al 2007:1013; 
Hussain et al 2011:9; Mahawish & Heikinheimo 2010:25; Mweene, Banda, Andrews, 
Mweene & Lakhi 2010:254; Osterberg & Blaschke 2005:488; Pires, Sebastiao, Langa 
& Nery 2013:95; Spratto & Woods 2012:2010; Sulaiman et al 2009:39; WHO-ISH 
1999:151). 
 
Some patients get tired of taking medicines, a problem that has been attributed to a 
lack of knowledge about the complications of hypertension (Weber 2012:738). When 
treatment is stopped, the blood pressure might be raised to dangerous levels and can 
cause complications to the brain, eyes, heart and kidneys (Lewis et al 2011:743).  
Hence, there is a dire need for patients with hypertension to adhere to lifestyle 
modifications and anti-hypertensive medications consistently for life. The patients need 
to understand that lifestyle modifications and anti-hypertension drugs do not cure 
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hypertension, but maintain the blood pressure within the normal range as long as the 
patient adheres to the prescribed treatment (Lilley et al 2011:384; Smeltzer et al 
2008:1022) 
 
The nurses also need to understand hypertension, its control mechanisms, 
complications, and the importance of treatment adherence. They need to provide  
specific health education to the patients which will help these patients to perceive their 
susceptibility to complications of hypertension, perceive their benefits of treatment 
adherence and motivate the patients to adhere to their  treatment regimens (Mahawish 
& Heikinheimo 2010:25; Metcalfe 2005:59).   
 
On the other hand, if patients adhere to their prescribed anti-hypertensive treatment 
regimens daily, blood pressure might be controlled and these patients could lead 
relatively normal lives. Cardiovascular and renal disease and strokes (cerebrovascular 
incidents) could be prevented if hypertensive patients’ blood pressure levels are 
controlled. Nurses could play a major part in helping patients to attain and maintain 
hypertension control through providing effective health education (Aminoff & Kjellgren 
2001:582; Chang, Fritschi & Kim 2012:127; DeCola, Benton, Peterson & Matebeni 
2012:323).  
 
The importance of health education cannot be overemphasised as even in developed 
countries people seem to need health education to combat hypertension-causing 
conditions (Cohen & Townsend 2012:143).  Reportedly. “… 122 million people in 
America are overweight or obese, consume large amount of dietary sodium and 
alcohol and do not eat adequate amounts of fruits and vegetables, less than 20% 
exercise regularly… Direct and indirect costs for stroke management and ongoing care 
are estimated at $56.8 billion [in the USA]” (Monahan, Sands, Neighbors, Marek & 
Green 2007:858).  Unfortunately similar statistics could not be obtained for Malawi, but 
similar factors might also influence hypertension patients’ treatment adherence levels 
in this country, and might be identified during the data collection phase of this study. 
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1.2 BACKGROUND INFORMATION ABOUT HYPERTENSION AND PATIENTS' 
ADHERENCE TO THEIR ANTI-HYPERTENSIVE TREATMENT REGIMENS   
 
Hypertension patients’ blood pressure can be controlled by adhering consistently to 
their prescribed lifestyle changes and the anti-hypertension medications, jointly 
referred to as anti-hypertension regimens. 
 
1.2.1 Hypertension as a health problem 
  
At the general assembly of 2011, countries committed themselves, that they would 
take action by developing Health Sector Strategic Plans for the Management of Non-
communicable Diseases from 2011 till 2020 (WHO 2011). The World Health Assembly 
(WHA) and WHO Regional Committee for Africa (RCA) (2003:1983), in the seventh 
report, requested the countries in SSA to develop country specific guidelines for the 
management of hypertension. These should include the prevention of complications 
such as strokes, eye problems, heart failure, renal failure and peripheral vascular 
diseases. In addition, countries were requested to identify hypertension patients who 
do not adhere to prescribed treatment, the leading factor underlying uncontrolled 
hypertension, and intervene accordingly to prevent complications (Addo et al 2007 
1012; Krousel-Wood, Thomas, Muntner & Morisky 2004:357; Lemogoum, Seedat, 
Mabadeje, Mendis, Bovet, Onwubere, Blackett, Lenfant, Kabangu, Block, Belhocine & 
Degaute 2003:1993; Mufunda, Chatola & Ndambakuwa 2006:52).  
 
Previously, hypertension was viewed as a disease of rich people but now it affects the 
rich medium and low income groups of people. The main factors behind the epidemic 
in lower income communities include that these people follow lifestyles similar to those 
of the Western world, such as the increased use of salt in their food, excessive tobacco 
smoking, higher intake of calories, low potassium intake, a sedentary lifestyle, poverty 
and stress (Addo et al 2007:1012; Smeeth & Leon 2007:1012, 1015). Hypertension’s 
associated risk factors are tobacco smoking (14.1%), alcohol consumption (16.9%), 
overweight (21.9%) and physical inactivity (9.2%). Alcohol consumption and cigarette 
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smoking are more common in males than females (Mahawish & Heikinheimo 2010:25). 
Grodensky, Golin, Ochtera and Turner (2012:899) conducted a systematic review on 
the effect of alcohol intake on adherence to outpatient medication regimens for four 
chronic diseases, namely: diabetes, hypertension, depression and HIV/AIDS.  Out of 
60 eligible studies on hypertension, only 3% addressed hypertension medication 
adherence. The mean number of subjects was 245 (range: 5761, 511). Six out of the 
seven high quality studies reported significant associations between alcohol taking and 
outpatient treatment regimen adherence. 
 
At Queen Elizabeth Central Hospital (QECH), where the study was conducted, in 2005 
to 2008 the number of patients registered with hypertension increased from a total of  
3 291 to 3 899 implying an increase of 18.5% (n=608). From 2005 to 2010 the number 
of patients treated for hypertension increased by 4 979 from 3 291 to 8 270, implying 
an increase of 151.3% (n=1 688).   
 
Patients who were admitted to the QECH due to hypertension increased markedly by 
882 from 1 887 to 2 769 implying an increase of 46.7% from 2005 to 2008. 
Furthermore, the number of deaths resulting from complications attributable to 
hypertension at QECH increased by 40 from 54 to 95 or by 74.1% from 2005 to 2008.  
From 2008 to 2010 it increased from 95 to 97 deaths, an increase of only 2.1% (QECH 
Hypertension Annual Reports 2008:13; 2010:15).  
 
Hypertension can occur at any age, in young, middle aged and old persons. Some 
patients experience symptoms such as headaches, dizziness and heart palpitations. 
Other patients might not experience any symptoms.  Due to the absence of symptoms, 
patients might not seek medical help until they experience complications which could 
cause disability and sudden death, explaining why hypertension is referred to as a “ 
silent killer” (Hussain et al 2011:9; Nelms, Sucher, Lacey & Roth 2011:289).  
 
A population-based study (Herttua, Tabak, Martikainen,  Vahtera & Kivimaki  
2013:2933)  estimated the risk of strokes associated with non-adherence to 
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antihypertensive drug therapy prior to the first stroke encounters in hypertensive adults. 
Out of 73 527 hypertensive patients, those who did not adhere to their medication had 
a nearly four-fold increased risk of dying from strokes during the second year after their 
initial anti-hypertensive drug prescriptions to control their blood pressure, and a three-
fold increased risk in the tenth year, compared with adherent patients. The patients 
who didn't take their medication correctly had a higher risk of hospitalisation.  The 
findings suggested that poor adherence to antihypertensive therapy increased the 
patients’ risk of strokes.  
 
1.2.2 Systems and factors that regulate the blood pressure 
 
Several mechanisms interact to regulate blood pressure (Lilley et al 2011:383). These 
mechanisms include cardiac output (vascular volume) and peripheral resistance 
(systemic vascular resistance) peripheral sympathetic and autonomic nervous system. 
They work in co-ordination through the autonomic nervous system, the sympathetic 
vasomotor centre, located in the brain to maintain normal blood pressure under various 
conditions (Lewis et al 2011:740).  Any alteration, in any of these conditions, may 
cause the blood pressure to rise.  
 
The renin-angiotensin system in the kidneys plays a major role in the regulation of 
blood pressure, by controlling the sodium excretion rate. Any disturbance of this 
system produces impaired sodium excretion and hypertension results due to salt 
retention which results in fluid retention. Rennin is a glycoprotein enzyme produced by 
the juxtaglomerular apparatus of the kidneys. It converts angiotensinogen to 
angiotensin I. This is further converted by angiotensin converting enzyme in the lungs 
to angiotensin II. This is a vasoconstrictor, and it increases the peripheral resistance 
causing hypertension. Angiotensin II also stimulates the release of aldosterone from 
the adrenal cortex. Aldosterone causes retention of sodium ions in the extracellular 
fluid compartment, leading to fluid overload causing hypertension (Lewis et al 
2011:742).   
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1.2.3 Technique for the measurement of blood pressure 
 
Blood pressure is measured with the right size cuff covering 80.0% of the upper arm, 
using manual mercury in a glass rode or the manual aneroid sphygmomanometer.  
Both of these require a stethoscope to read the blood pressure and a health worker 
who has been trained to measure blood pressure.  The patient should have rested for 
10 minutes and be relaxed, not anxious or apprehensive. These might cause transient 
elevation of blood pressure. The cuff is inflated 20-30 mmHg above the point of 
disappearance of the KorotKoff sounds, seen as oscillations in the mercury column of 
the sphygmomanometer. The brachial artery is located and a stethoscope’s diaphragm 
is placed on the brachial artery to read the blood pressure. The pressure in the heart 
chambers is measured against the pressure in the sphygmomanometer.   
 
There is another type of a sphygmomanometer that is digital and uses battery or 
electric power.  It does not require a stethoscope nor input from a health care worker, 
and can be easily operated by any person.  It is worn on the wrist or upper arm. It has 
an on/off button and a screen. At the touch of the button it starts recording the blood 
pressure, pulse rate and respirations which are automatically displayed on the 
machine's screen (Lewis et al 2011:745). The digital sphygmomanometer has the 
potential to increase patients' responsibility for monitoring their condition and actively 
participating in the management of their hypertension.  Measurement should be done 
on both arms initially, noting any difference. The arm with the higher reading should be 
the one used for subsequent measurements, usually the right one (Chobanian, Bakris, 
Black, Cushman, Green, Izzo, Jones, Materson, Oparil, Wright & Rocella 2003:1213). 
 
1.2.4 The five phases of blood pressure readings and their sounds  
 
The phases are heard only when the mercury manual sphygmomanometer is being 
used. (Chobanian et al 2003:1213).  When the blood pressure cuff of the mercury 
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sphygmomanometer is inflated, there are different pressures within the heart 
chambers. The pressures are recorded in five phases, designated as K1 to K5.   
• Phase 1 (K1) is the onset of the pressure level at which the first faint consistent 
tapping, KorotKoff sounds, are heard and are reported as the systolic blood 
pressure. The sounds gradually increase in intensity as the cuff is deflated. This 
occurs as a result of the cardiac contraction forcing the blood volume out of the 
heart’s left ventricle into the aorta and arterial system.  
• Phase 2 (K2) is when the cuff is rapidly deflated when a murmur of swishing 
sounds is heard until the palpable pulse disappears at 6 mm Hg, then increased 
by 10 mm Hg.   
• Phase 3 (K3) is the period when the sounds are crisper and increase in intensity 
as the cuff is slowly deflated at 2mm per second noting the time at which the 
palpable pulse reappears.   
• Phase 4 (K4) is when distinct abrupt, muffling of sounds, with a soft blowing 
quality, continues up to zero without disappearing in some people and is 
reported as a diastolic blood pressure.   
• Phase 5 (K5) is the point at which the last regular sound is heard before zero 
and is reported as the diastolic blood pressure. Phases 4 and 5 are both 
accurate diastolic blood pressures reported as the cardiac relaxation and the 
filling of the right atrium of the heart with systemic blood.  The blood pressure is 
recorded as K1/K4 or K1/K5, systolic number/diastolic number (Izzo & Black      
2003:346).   
 
1.2.5 Variations in blood pressure readings 
 
Blood pressure readings vary according to the time of the day (Chobanian et al 
2003:1213). The readings are higher during the day when a person is awake, active 
and exposed to stimulations. The readings are lower at night when a person is asleep 
and. There is a drop of 10-20% in blood pressure at night.  Patients who do not have 
such drops at night are at geater risk of developing cardiovascular complications 
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because the pressures remain high.  In the early hours of morning, while waking up,  
there is a  sharp increase of blood pressure.  Blood pressure readings vary according 
to posture. The standing blood pressure reading is higher than the sitting one, and the 
sitting one is higher than the lying one, and it is higher in a doctor's office and lower at 
home. This is a result of the influence of the environment called “white coat 
hypertension”.   
 
There are also variations in the blood pressure readings, according to the 
sphygmomanometer that is used. The electronic digital ones give higher readings than 
the mercury ones.  It  also varies according to the arm  that has been used.  The right 
arm usually registers a higher reading than the left one (Chobanian et al 2003:1213).   
 
The brachial artery blood pressure is highest when the patient is sitting upright, 
intermediate in the supine position, and lowest in the left lateral position (Khatib & 
ElGuindy 2005:18). Therefore, for consistency in interpreting the patient's blood 
pressure readings, the same sphygmomanometer should be use at the same time of 
the day, putting  the patient in the same posture and applying the cuff to the same arm.  
 
The diagnosis of hypertension is confirmed by two or three elevated blood pressure 
readings on different occasions (Nelms et al 2011:288,289). The WHO-ISH 
(2003:1983) listed two types of hypertension. These are primary and secondary 
hypertension, based on the cause (Lewis et al 2011:741; Mancia, De Backer & 
Dominiczak 2007:88). 
 
1.2.6 Primary hypertension 
 
Primary hypertension is also called essential or idiopathic hypertension. It has no 
identifiable aetiology, with onset in the 40 to 50 year age group. It has a genetic 
predisposition or a family history and racial patterns in 70-80% of hypertensive 
patients, accounting for 90-95% of all hypertension patients (Gilbert, 2009:2). There 
are certain risk factors associated with primary hypertension which can be modified 
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hence referred to as modifiable risk factors (Lewis et al 2011:742). These risks include 
cigarette smoking (Talukder, Johnson, Varadharaj, Lian, Kearns, El-Mahdy, Liu, & 
Zweier 2011:388), excessive dietary sodium, elevated serum lipids, excess alcohol 
intake, diets low in calcium and potassium, overweight, stress and sedentary lifestyles 
(Addo et al 2007:1016).  This is how these risk factors trigger hypertension: 
 
• Cigarette smoking 
 
Cigarette smoking causes hypertension from the nicotine that is contained in 
cigarettes. Smoking is a major risk factor for cardiovascular diseases  Worldwide, it is 
estimated that more than five million people die yearly from tobacco smoke related 
illnesses (Talukder et al 2011:388).  Nicotine is a stimulant that releases adrenaline 
from the adrenergic fibres of the adrenal glands. The adrenaline will cause persistent 
stimulation of the sympathetic nervous system leading to peripheral vasoconstriction, 
which will result in the elevation of blood pressure (Kaplan 2005:29). The sympathetic 
nervous system plays a role in acute changes in blood pressure (McCance, Huether, 
Brashers, & Rote 2010:467). Renin is released, an angiotensinogen I converting 
enzyme, to angiotensinogen II, to aldosterone then increase in the circulatory volume 
resulting in raised blood pressure. 
 
A study was conducted by Li, Tong, Wang, Lin, and Zhang (2010:93) in China, to 
investigate the effects of cigarette smoking on blood pressure, stratified by basal 
metabolic index in a Mongolian population in two adjacent townships. There was a total 
of 2 589 Mongolian people who signed consent to participate in the study. A standard 
questionnaire was used to collect data. The findings showed that those who smoked 1-
9 and 10-19 cigarettes per day were more likely to have lower prevalence of 
hypertension compared with non-smokers, but there was no significant difference 
between smokers who smoked more than 20 and non-smokers. The data did not 
provide support that smoking was a risk factor of hypertension.  Gu, Kelly, Wu, Chen 
Samet, Huang and Zhu (2009:155) published their findings regarding the relationship 
of smoking with death in China, a large prospective cohort study in a nationally 
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representative sample of 169 871. Their baseline data showed that male smokers had 
a lower prevalence rate of hypertension than male non-smokers. There was no 
significant positive association or there was a negative association between smoking 
and hypertension.  
 
 
 
• Excessive salt consumption 
 
Consumption of large amounts of salt is a risk factor for hypertension physiologically, 
biologically and genetically.  Physiologically, salt has properties that retain fluids in the 
body. The retained fluids increase the circulatory volume which raises the blood 
pressure (Addo et al 2007:1016; Lewis et al 2011:746; Smeltzer et al 2008:1021). 
Biologically and genetically, Gibbs, Beevers and Lip (1999:188) reported that 
individuals with hypertension possess a "salt sensitive gene", which occurs more 
frequently among black than among white people. This explains why hypertension is 
more common and challenging to control in black people than in whites.  
 
Kuller (2007:1004) reported that the hypertension epidemic in SSA is driven by the 
greater use of processed canned foods which contain a lot of salt.  There is also an 
increased use of cars which has led to a more sedentary lifestyle for many people. The 
epidemic started in the urban areas but now occurs in the rural areas as well.  Healthy 
adults’ salt intake should be restricted to less than 1 500mgs a day.  In addition, 
patients should not add raw salt in their cooked food, as it is more harmful than cooked 
salt (Addo et al 2007:1016; Thrift, Srikant, Fitzgerald, Kalyanram, Kartik, Hoppe, 
Walker & Evans 2010:80). 
  
• Elevated serum lipids 
 
High serum lipids accumulate as fat deposits in the vessel lumen which leads to the 
thickening and hardening of the vessels, referred to as atherosclerosis. This interferes 
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with the contractility of the smooth muscles which increases the peripheral resistance, 
and cause a raised blood pressure. People who eat lots of animal meat and fat are 
more prone to develop atherosclerosis than people who eat less animal protein and fat 
and more fruit, vegetables, fish and chicken (Addo et al 2007:1016; WHO 2003:107).  
 
 
• Excessive alcohol consumption 
 
Excess alcohol intake is a risk factor associated with hypertension and its 
complications (Manandhar, Koju, Sinha & Humagain 2012:36; Hillbom, Saloheimo & 
Juvela, 2011:209). Alcohol consumption leads to generalised excitement and 
increased activity including renal activity. Rennin is released, an angiotensinogen I 
converting enzyme, to angiotensinogen II to aldosterone which increases the 
circulatory volume resulting in raised blood pressure. Wang Lee, Fabsitz, Devereux, 
Best, Welty and Howard (2006:408) conducted a study, which revealed that alcohol 
consumers were 1.22 times more likely to develop hypertension than non-consumers.  
It was noted that for men, consuming more than 20g and women 10g of ethanol per 
day was sufficient to cause a rise in blood pressure.  This is because alcohol contains 
a stimulant that leads to the release of adrenaline (Miller, Anton, Egan, Basile & 
Nguyen 2007:347), a peripheral vasoconstrictor, from the adrenergic fibres of the 
adrenal glands. Grodensky, Golin, Ochtera and Turner (2012:899) found that alcohol intake 
had an effect on adherence to outpatient medication regimens for chronic diseases.   
 
• Sedentary lifestyle 
 
Sedentary lifestyle has a close relationship with hypertension. Lack of physical 
exercise poses a risk of fat deposits in the arteries.  As a result the arteries become 
thick and hard losing their elasticity. This condition is referred to as atherosclerosis. 
The vascular lumen narrows with increased peripheral resistance which raises the 
blood pressure (Addo et al 2007:1016; Smeltzer et al 2008:1021). 
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Obesity 
 
Obesity is associated with hypertension, because weight gain comes with fat deposits 
in all body structures including the blood vessels. These result in narrowing of the 
lumen causing atherosclerosis. This increases the peripheral resistance causing 
hypertension (Lewis et al 2011:742). 
• Stress and environment 
 
Stress is believed to be a risk factor for hypertension through the sympathetic nervous 
system’s stress reactions. Gianaros, Jennings, Sheu, Derbyshire and Matthews 
(2007:134) reported that when an individual stresses and/or worries persistently, there 
is a release of adrenaline from the adrenergic fibres of the adrenal glands. This is a 
stimulant and a vasoconstrictor, which increases peripheral resistance resulting in 
raised blood pressure.  A strange environment is a good example of a stressor that can 
raise blood pressure.  Some patients have registered a raise in blood pressure in the 
doctor’s office, but a normal blood pressure in the home environment (Lilley et al 
2011:383). The doctor in a white coat, in the office, might present a fearful environment 
to the patients. This is the reason that diagnosis of hypertension is not made from one 
reading only, but with two or more readings, on different occasions in different 
environments with additional laboratory diagnostic results, such as blood urea and 
electrolytes (Ester, Schwarz & Alvarenga 2008:178; Lewis et al 2011:744). In primary 
hypertension, patients require a change in their lifestyle, referred to as, lifestyle 
modification, to combat the risks of developing complications as a result of persistent 
hypertension.     
 
Knowledge of the risk factors of primary hypertension might help patients to acquire the 
ability to perceive themselves as being at risk of developping the condition and the 
consequent complications and their severity.  The ability to perceive the potential risks 
of hypertension might motivate them to follow a healthy lifestyle, to prevent the 
dangerous complications (Hussain et al 2011:12). 
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1.2.7 Secondary hypertension 
 
Secondary hypertension is a raised blood pressure that has resulted from a specific cause with 
an identifiable aetiology. This type of hypertension accounts for 5-10% of all hypertensive 
patients (Dao, Essalihi, Bouvet & Moreau 2005:307).  
 
There are disease processes and conditions that affect factors which regulate cardiac 
output and peripheral resistance, which get disrupted causing hypertension (Lilley et al 
2011:383; Smeltzer et al 2008:1022).  Once the diseases and conditions are treated, 
the blood pressure is reduced.  Examples of such diseases are: 
 
Renal diseases 
 
The kidney is a major organ in the body. One of its functions is regulation of normal 
blood pressure through the renin-angiotensin mechanism (Thrift et al 2010:80). When 
there is kidney disease, the renal functions will be impaired.  This process is explained 
in section 1.2.8.4. 
 
• Other conditions 
 
Some of the conditions that may cause secondary hypertension include: pre-eclampsia 
and eclampsia in pregnancy, liver cirrhosis and kidney failure.  For example, the kidney 
plays an important role in the control of arterial pressure and in the pathogenesis of 
hypertension.  In addition, contraceptive pill use, in some individuals might raise the 
blood pressure through physiological fluid retention. This occurs as a result of 
hormonal changes, which influence physiological changes that cause retention of 
fluids.  This increases the circulatory volume which increases the blood pressure (Thrift 
et al 2010:80). 
• Age  
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Age is a risk factor for secondary hypertension. The older patient might have a greater 
risk for developing hypertension. This occurs as a result of the large arteries which 
thicken and stiffen, with fat deposits, narrowing the vessel lumen and reducing its 
elasticity. This is atherosclerosis, which reduces arterial capacity, increasing the 
peripheral resistance causing hypertension (Lilley et al 2011:383).  
 
Knowledge of the risk factors for primary and secondary hypertension is essential.  
Such knowledge might help patients to perceive that they are susceptible to the 
condition hence take responsibility to participate in prevention efforts and treatment 
which might keep the condition controlled and prevent complications. This is vital for 
older people as 88% of all people suffering from strokes in the USA were 65 or older 
(Monahan et al 2007:1423). 
 
1.2.8 Complications of  hypertension 
 
Hypertension on its own is an innocent condition. When death occurs in an individual 
with hypertension it is not from hypertension. Death would be from its complications 
that lead to failure in organ function. According to Lewis et al (2011:743) this is referred 
to as "end organ damage". Cerebral, ocular, cardio-vascular and/or renal complications 
can result from uncontrolled hypertension. 
 
1.2.8.1 Cerebral  complications 
 
Hypertension increases the risk of a stroke, defined by Monahan et al (2007:1422) as 
“… a focal neurologic deficit that has a sudden onset as a consequence of a 
disturbance in circulation or cerebral ischemia that lasts for more than 24 hours, it may 
cause irreversible brain damage”. Hypertension causes the development of 
atherosclerotic plaques in the cerebral vascular system. This eventually occludes a 
cerebral vessel causing an ischaemic stroke due to anoxia.  This also facilitates the 
development of an aneurysm, which could rupture causing haemorrhagic stroke and 
even death depending on the extent of the haemorrhage (Kaplan 2005:152; Monahan 
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et al 2007:1422). Brain injury occurs when persistant hypertension causes rupture of a 
blood vessel that supplies the brain. The blood forms a clot (lesion) which occupies a 
space in the brain.  In the brain every space has a functional area. The left brain 
controls the right body and vice-versa.  If the lesion is on the left side of the brain, there 
would be weakness on the right side of the body and vise versa (McCance et al 
2010:1155).  The lesion impairs the function. Hemiplegia means weakness of one side 
of the body.  Weakness might be either on the left side or the right side depending on 
the location of the lesion in the brain. This would lead to left or right hemiplegia.  
 
The individual who experiences this is said to have  sufferred a stroke.  When the 
lesion is on the left side of the brain the person will have right sided weakness and loss 
of speech because the speech centre is on the left side of the brain. When the lesion is 
on the right side of the brain the person will have left sided weakness and loss of 
swallowing reflex because the swallowing centre is on the right side of the brain.  
Depending on the size of the lesion and site of occupacy the person will manifest  the 
loss like memory, coordination of vision and thinking.  If no treatment is provided these 
complications could cause disability or actual death. This has direct and indirect costs 
for the individual, the family and community as a whole as well as to the health care 
system in managing the disability (Monahan et al 2007:1422).  
 
1.2.8.2  Ocular complications   
 
Hypertension causes rupture of the ocular vessels resulting in haemorrhage in the 
retina. This causes clot formation which leads to inflammation and retinopathy. This 
might further lead to partial or even total blindness (Kaplan 2005:164). The eye is an 
organ of sight.  Eye injury occurs when there is persistant hypertension causing rupture 
of a blood vessel supplying the eye. The blood leaks out and forms a clot which 
occupies a space on the optic area or retina or the fundus.  This area is responsible for 
reception of light and interpretation and registers visual images and the individual sees.  
Pressure on this area by the lesion would impair its function.  The individual who 
experiences this is referred to as having suffered blurred or total loss of vision, 
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blindness, depending on the size of the lesion (Lewis et al 2011:1409; McCance et al 
2010:1155). 
 
1.2.8.3 Cardiovascular complications  
 
The heart is a major organ which supplies oxygen and nutrients to all parts of the body. 
When the blood pressure gets persistantly high, the heart becomes overworked, and 
there is reduced blood supply through the coronary arteries to supply the cardiac 
muscles. This overwork initially results in hypertrophy of the myocardial fibres of the left 
ventricle as a compensatory effort. The hypertrophy leads to left sided congestive 
cardiac failure, the coronary arteries become sclerotic, diminishing blood supply to the 
heart resulting in ischemic heart disease, myocardial infarction occurs, leading to poor 
oxygenation to all the major organs, the brain, lungs, liver and kidneys will fail and 
finally death may occur (Lewis et al 2011:765; McCance et al 2010:1155; Vlasnik, 
Alliotta & DeLor 2005:47; Zhang 2013:291).  
 
1.2.8.4  Renal complications   
 
Kidneys are major organs modulating systemic blood pressure by adjusting the sodium 
excretion rate. When there is hypertension, the mechanism of modulation is impaired 
resulting in impaired sodium excretion. This sodium accumulation further retains and 
increases the circulatory volume, raising the blood pressure.  In addition, the 
accumulated sodium contributes to the development of atherosclerotic plagues in the 
lumen of the arteries supplying the kidneys, resulting in poor oxygenation to the kidney, 
impaired function, with consequent renal failure (Gilbert 2009:12). The failing kidneys 
release rennin which converts angiotensin I to angiotensin II, to aldosterone which 
retains fluids raising the blood pressure.  It is therefore, important for hypertensive 
patients to adhere to their anti-hypertensive treatment to prevent these complications 
(Smeltzer et al 2008:1024).  
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An elevation of plasma creatinine and blood urea nitrogen is referred to as azotemia 
(retension of toxic wastes) which is accompanied by fatigue, anorexia, nausea, 
vomiting, pruritus and neurologic changes (McCance et al 2010:1386). Kidney failure 
may be acute or chronic.  In the acute phase, there is a rapid progression within hours, 
and the process may be reversible.  While as, in the chronic phase, there is slow 
progression over a period of months or years and the process is irreversible. The 
common cause is hypertension (McCance et al 2010:1389).   
 
This will stimulate renin hormone release. Renin will convert angiotensinogen I to 
angiotensinogen II, with the converting enzyme, to aldosterone which increases the 
circulatory volume resulting in raised blood pressure (Lewis et al 2011:746). The 
examples of these diseases are glomerulo-nephritis, renal artery stenosis, renal failure 
and kidney tumours.  
 
The same mechanism occurs, in congestive heart disease, anaemia, intestinal worms, 
liver cirrhosis, cancer, diabetes mellitus, and malnutrition including the use of 
contraceptives. After a period of time, these conditions, might eventually cause the 
heart to become congested with a consequent impaired function. This will lead to 
impaired blood circulation to the kidneys and renin will be released and the same 
process of angiotensin conversion will raise the blood pressure. This is true for 
diabetes mellitus. In addition, in older patients there is increased collagen content and 
stiffening of the myocardium, decreased adrenergic receptor sensitivity; baroreceptors 
reflex blunting, decreased renal function. This releases renin and the renin angiotensin 
mechanism takes over and the blood pressure is raised. However, in contraceptive pill 
use, the risk could be reduced with the use of low dose hormonal contraceptives. but 
can be compounded by the use of antiretroviral drugs (ARVs), alcohol and anti-
parasitic drugs such as anti-malarias, anti-bilharzias, cytotoxic drugs and steroids 
because all these drugs are detoxicated by the liver and excreted by the kidneys. With 
continued use of these cytotoxic drugs, the kidneys become overworked and release 
rennin which raises the blood pressure (Lewis 2011:746; Mancia, De Backer & 
Dominiczak 2007:88). 
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1.2.9  The management of hypertension 
 
Hypertension can be managed with non-pharmacological (lifestyle modification) and 
pharmacological approaches (drugs) depending on whether hypertension is classified 
as being pre, mild, moderate or severe hypertension. The goal of management, 
lifestyle modification and prescribed drugs, is to control the blood pressure to prevent 
complications that might occur due to uncontrolled hypertension, like strokes and heart 
conditions (Andrade 2004:484; Clifford-Middel 2004:11; MoH 2010:1; Monahan et al 
2007:858).  
 
The mechanism of action of all anti-hypertension drugs is on the blood pressure 
regulators to inhibit or block their regulation to control the blood pressure, but no drugs 
can cure hypertension (Adams et al 2011:301). Therefore, the doctors prescribe 
treatment and give the patients review appointments in Malawi (MoH 2010:10). The 
review visits give the doctor a chance to assess the patient’s responce to the 
treatment.  Based on the patient’s response, treatment is continued or changed. Good 
responses to treatment usually depend on adherence to the treatment regimen. 
 
1.2.9.1   Non-pharmacological approach to the management of hypertension     
 
The non-pharmacological approach to the management of hypertension involves 
interventions, such as actions and behaviours prescribed to modify risky behaviour that 
expose a person to hypertension (Adams et al 2011:300; Bosworth 2008:345). These 
include: limiting alcohol, reducing sodium and cholesterol intake, stopping cigarette 
smoking, increasing aerobic exercise and reducing weight. Once the risk factors have 
been modified, the blood pressure might reduce (Kastarinen, Puska, Korhonen, 
Mustonen, Salomaa, Sundvall, Tuomilehto, Uusitupa & Nissinen 2002:2505; Smeltzer 
et al 2008:1025; Weber, Schiffrin, White, Mann, Lindholm, Kenerson,  Flack,  Carter, 
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Materson, Ram, Cohen, Cadet, Jean-Charles, Taler, Kountz, Townsend, Chalmers, Ramirez, 
Bakris, Wang, Schutte, Bisognano, Touyz, Sica, Harrap 2014:3). 
 
Lifestyle modification 
 
There is another group of patients who can be managed by lifestyle modifications and 
anti-hypertensive medicines, although they had persistent hypertension. They require 
behaviour change, and taking prescribed anti-hypertensive medicines every day, for 
the rest of their lives (Addo et al 2007:1016; Jallinoja, Absetz, Kuronen, Nissine, Talja, 
Uutela & Patja 2007:127; Lewis et al 2011:765). Therefore, health workers should 
provide health education to the patients regarding the condition, the cause, 
pathophysiology, signs and symptoms treatment and complications.  When patients 
understand this, their knowledge base could help them to accept  the condition and 
perceive the benefits of treament, severity of the potential dangers of complications of 
the condition. If  patients understand the potential complications of hypertension and 
the dire necessity for adhering to their prescribes medications and lifestyle changes,it 
will help them to actively participate in the management of their condition, and will 
create a good patient/health care provider relationship.  As such the goal of 
hypertension management, which is to control hypertension and minimise the 
occurrence of complications, could be achieved.  Hypertension can be managed with 
non-pharmacological and pharmacological approaches, depending on whether it is 
classified as being pre, mild, moderate or severe hypertension (Adams et al 2011:300; 
Drevenhorn, Bengtson & Kjellgren 2009:350; Spratto & Woods 2012:2010).   
 
Lifestyle modification programmes include interventions that provide strategies to help 
the patients develop self motivation, dedication and self determination to change the 
risky predisposing lifestyle such as reduction of cigarrette smoking, alcohol intake, 
sodium consumption, and the intake of saturated fat. The increase of fresh fruits and 
vegetables consumption and aerobic physical activity could be beneficial.  
Furthermore, the application of coping strategies to reduce the effects of stress, and to 
maintain optimum weight will be beneficial for reducing hypertension in some persons 
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(Adams et al 2011:300). Once the risk factors have been modified, the blood pressure 
might reduce (Adams et al 2011:301; Brobeck, Odencrants, Bergh & Hildingh 
2013:375; Smeltzer et al 2008:1025; WHO-ISH 2003:107). It is also referred to as the 
first line of hypertension management.   
 
In primary hypertension all the risk factors are associated with behaviour and lifestyle. 
This is why they are referred to as modifiable risk factors; because individuals can 
modify their behaviour and lifestyle to reduce the risk of developing hypertensions 
(Lewis et al (2011:742).  Lifestyle modification, is a behaviour, and an attitude that 
requires self motivation, self determination and dedication in order to achieve the goal 
(Adams et al 2011:300).  Lifestyle modification for a patient with hypertension requires 
behaviour changes, life habits or practices from predisposers to new ones, that reduce 
the risk (Iyalomhe & Iyalomhe  2010:71). This helps to achieve the goal of hypertension 
control. Some patients with hypertension have been controlled without anti-
hypertension drugs but by adhering to healthy behaviours (Ham & Bong 
2011:1252; Qvarnström, Wettermark, Ljungman, Zarrinkoub, Hasselström, Manhem, 
Sundström & Kahan 2011:488).  
 
There are some patients who have had their blood pressure controlled with lifestyle 
modification and prescribed anti-hypertensive medicines.  With time, they no longer 
required anti-hypertensive medicines.  However, they are required to check their blood 
pressures regularly to ensure that it remains controlled.   
 
The anti-hypertension drugs should not be taken together with anti-inflammatory 
agents, including Brufen, Indocid and Diclofenac because they could cause bleeding in 
all people, but in patients that are taking anti-hypertension drugs, the risk of bleeding is 
greater because anti-hypertension drugs could make the blood thin and dilate the 
blood vessels. Therefore, these effects combined with those of anti-inflammatory drugs 
erode the gastrointestinal lining increasing the bleeding tendency. In addition to the 
bleeding, there are many other problems such as kidney failure when anti-inflammatory 
drugs are combined with ACE inhibitors and diuretics.  The anti-inflammatory drugs 
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oppose the effects of medicines for hypertension and stop them working effectively, 
including ACE inhibitors, beta blockers and diuretics.   
 
Low-dose aspirin or corticosteroid medicines, such as predinisorone, increase the risk 
of gastrointestinal ulceration or bleeding.  As an additional caution, patients on anti-
hypertension drugs should stop consuming alcohol because it irritates the stomach 
lining therefore regular drinking of alcohol while taking anti-inflammatory and/or anti-
hypertension drugs may increase the risk of gastrointestinal damage and bleeding 
(Woodrow et al 2011:173).   
 
1.2.9.2 Pharmacological approach to the management of hypertension  
 
The pharmacological approach to the management hypertension refers to the use of 
prescribed anti-hypertension drugs by a physician based on the blood pressure reading 
using the stepwise approach. This approach starts with those drugs that produce few 
and minor side effects ending with those that might produce more and serious side 
effects (WHO-ISH 2003:1983). 
 
1.2.9.2.1 The WHO approach to hypertension management 
 
The anti-hypertension drugs are grouped according to their mechanisms of action in 
reducing blood pressure. These are diuretics, calcium channel blockers, and 
angiotensin converting enzyme inhibitors, beta and alpha adrenergic blockers, 
angiotensin II receptor blockers and centrally acting drugs; targeting the blood pressure 
regulators, to reduce the blood pressure (Adams et al 2011:304; Gibbs et al 1999:189; 
Smeltzer et al 2008:1026; Spratto & Woods 2012: 2014). The WHO classification of 
these drugs is useful for guiding health workers to identify the right treatment 
combination for specific patients based on every individual patient’s assessment data. 
This also requires that the patients’ blood pressure be classified as being mild, 
moderate or severe and the patient is informed about the required lifestyle 
modifications.   
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Stage 1 implies that the blood pressure is mild.  In stage 4 if the patient has severe 
hypertension. This classification guides countries to identify drugs that the specific 
country can manage to provide since countries are at different economic levels. In 
addition drugs are classified according to those with few side effects which should be 
prescribed initially, followed by drugs with more side effects, and the same is the case 
for the cost of drugs and accessibility and patients’ treatment tolerance levels (WHO 
2003:107). 
 
 
1.2.9.2.2 The United Kingdom’s ABCD approach to hypertension management  
 
In United Kingdom (UK) more than 65.0% of people with moderate to severe 
hypertension were treated with a single blood-pressure-lowering drug (monotherapy) 
but their blood pressures were poorly controlled (William 2003:521). Clinical trials were 
done which demonstrated that moderate and severe hypertensive patients require 
more than one drug to achieve blood pressure control. 
Brown, Cruickshank, Dominiczak, MacGregor, Poulter, Russell, Thom and Williams 
(2003:82) advocated that better blood pressure control requires drug combinations. 
The ABCD algorithm was suggested based on the trial results and simple principles 
representing the groups of anti-hypertension drugs and their mechanisms of actions 
which have achieved better blood-pressure control than monotherapy. William 
(2003:522) launched the ABCD algorithm to provide advice on the combinations and 
sequencing of anti-hypertension drugs:- 
• ‘A’ drugs are the angiotensin converting-enzyme inhibitors or angiotensin 
receptor blockers 
• ‘B’ drugs are the beta blockers.  
• ‘C’ drugs are the calcium channel blockers.  
• ‘D’ drugs are the diuretics.  
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This is not a restrictive template but it offers some choice within a structured framework 
according to specific countries’ policies. The principles underlying this approach are 
that:  
• younger people below 55 respond better to drugs that block the renin system 
which include ‘A’ drugs, and ‘B’ drugs   
• black people older than 55 respond better initially to ‘C’ drugs or ‘D’ drugs  
• the majority of people will require more than one drug, and it is logical to 
combine A or B with C or D; it is not logical at step 2 to combine A with B or C 
with D  
• triple therapy with A+C+D or B+C+D  
• where there is no cost disadvantage, at step 2 fixed-dose combinations are 
appropriate to reduce the number of medications    
• the patient can be offered an individual treatment plan that sets out the 
objectives and the strategy required to reduce his or her blood pressure.  
 
However, it was clarified that improvement of blood-pressure control would not come 
from the ABCD algorithm approach but the process of implementation (Brown et al 
2003:82). In SSA, the WHO-ISH 2003:107), requested the countries to commit 
themselves to address vascular diseases. They were requested to engage population-
based non-pharmacological interventions against the growing hypertension epidemic.  
This would assist patients to modify their behaviour, such as, reduction of weight, 
alcohol, sodium and cholesterol, increase aerobic exercises and quite cigarette 
smoking.  The benefits to the patients would be that the increase in physical exercises 
would burn fats and carbohydrates, thereby removing fat deposits from the vessel 
lumen, reducing the peripheral resistance, reducing the blood pressure. The countries 
were given liberty on pharmacological management; according to the WHO (2003:107) 
treatment guidelines or The UKs ABCD approach based on the countries’ economic 
realities (Brown et al 2003:82).    
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In Malawi, the “Malawi Standard Treatment Guideline” (MSTG), of Ministry of Health 
(MOH) (MSTG, MOH 2008:16) adopted from the WHO (2003:107) guidelines is 
currently in use. The following are some of the drugs used to treat hypertension in 
Malawi: Hydrochlorothiazide (HCT), Propranolol, Nifedipine, Lisinopril and Methyldopa 
and are free in government facilities and are for sale in private health facilities and 
pharmacies.  
 
Bendrofluazide: a thiazide diuretic, it inhibits sodium reabsorption at the distal 
convoluted renal tubes increasing fluid loss thereby reducing the circulatory volume, 
reducing the blood pressure. The side effects are hyperuricaemia, hyponatraemia, 
postural hypotension and impotence (Spratto & Woods 2012:2014; Woodrow et al 
2011:234). 
 
Hydrochlorothiazide (HCT): a thiazide diuretic, sensitive sodium chloride human 
inhibitor, which inhibits sodium reabsorption in the renal tubules; allowing lots of water 
loss decreasing the circulatory volume, reducing the blood pressure. The dose is 12.5 
mgs orally daily. The side effects are hypokalaemia, hyponatraemia and 
hypochloraemic alkalosis. All diuretics target the kidney for circulatory volume 
reduction (Imming, Sinning & Meyer 2006: 828; Spratto & Woods 2012:2014).  
 
Flusemide: is a potassium human inhibitor, it inhibits potassium re-absorption at the 
ascending limb of the loop of Henle in the renal tubules; the dose is 40 mgs orally.  The 
side effects are thirst, weakness, dry mouth, fatigue, hypokalaemia, hyponatraemia, 
hypochloraemic alkalosis and hypomagnesaemia (Smeltzer et al 2008:1026; Spratto & 
Woods 2012:2011).  
 
Spironolactone: is an aldosterone antagonist, and a potassium sparing diuretic, the 
dose is 25mg daily, orally. The side effects are insomnia, weakness, fatigue, 
hyponatraemia, hypokalaemia, gastro-intestinal tract disturbances, impotence and 
menstrual irregularities (Imming et al 2006:826; Smeltzer et al 2008:1027).  
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Lisinopril: is an angiotensin converting enzyme inhibitor; it blocks the conversion of 
angiotensin I to angiotensin II, a potent vasodilator which decreases the vascular 
resistance reducing the blood pressure.  The side effects are hypotension, persistent 
dry cough, angioedema, alopecia, and impotence (Imming et al 2006:826; Petkow-
Dimitrow 2007:5; Spratto & Woods 2012:1928).  
 
Ateneral: is a beta adrenoreceptor blocker. It blocks the beta-adrenoreceptor in the 
heart, peripheral bloodvessels of the pancreas, liver and the bronchi leading to 
vasodilatation, decreasing the blood pressure. The side effects are gastro-intestinal 
tract disturbances, bradycardia, hypotension and bronchospasm. This reduces 
peripheral resistance reducing the blood pressure (Imming et al 2006:826). 
 
Propranolol: is a beta-adrenergic blocking agent, receptor antagonists and 
adrenoceptors. The mechanism of action is that it blocks the effects of epinephrine and 
nor-epinephrine, thereby a decreasing the myocardial response, decreasing the heart 
rate and the blood pressure. The dose is 40-80mg twice a day. The side effects are 
headaches and dizziness and bradycardia and hypotension (Imming et al 2006:826). 
 
Amlodipine: is a calcium channel blocker, which blocks the inward flow of calcium ions 
through active cell membranes. It is an angiotensin receptor blocker. Angiotensin 
attachment to the receptors causes the blood vessels to constrict which leads to an 
increase in blood pressure and a raise in blood pressure. Amlodipine blocks the 
angiotensin receptors, dilates the blood vessels thereby reducing the blood pressure. 
The dose is 5-10mgs orally daily and the side effects are bradycardia, A-V block, 
hypotension, sleep disturbances and pedal oedema, dizziness fatigue, and headache 
(Imming et al 2006:826; Woodrow et al 2011:4).  
 
Methyldopa: Adams et al (2011:314) define methyldopa as a centrally acting agent, an 
alpha-adrenergic receptor stimulant. It stimulates the alpha adrenergic receptors in the 
brain thus inhibiting the sympathetic nervous system thereby reducing the peripheral 
resistance and reduces the blood pressure. The dose is 250-500mgs orally three times 
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a day. The side effects are gastrointestinal disturbances, dry mouth, nasal congestion, 
stomatitis, hypersensitivity reactions, impotence, failure to ejaculate, drowsiness and 
decreased libido (Woodrow et al 2011:473). 
 
The list of drugs presented is only a few of the many anti-hypertension drugs. They are 
of different groups, mechanisms of action, side effects, price with different types of 
responses of patients to the drugs.  Different patients will respond differently to the 
same drugs in terms of blood pressure control and type or severity of side effects.  
Hence the dire need for nurses and doctors to be knowledgeable about the different 
groups of drugs their mechanisms of action, side effects and cost price.  They also 
need to have adequate time to assess each patient, to get a thorough history and to 
determine the patients’ educational level, possibly influencing the level of health 
education required, and his/her ability to pay for the anti-hypertension drugs for the rest 
of his/her life. Once the anti-hypertensive drug has been initiated there should be 
regular interactions between the health worker and the patient to assess the patients’ 
response to the anti-hypertension drugs. The reason is that different people respond 
differently to the same drug. For example, a drug that may be tolerated very well by 
one patient may not be tolerated at all by another person. If the patient has not 
responded favourably to one drug, he/she should be changed to another one until a 
patient feels better and the blood pressure is controlled. 
  
1.2.10.  Adherence to anti-hypertension treatment regimens   
 
Treatment adherence is a complex and dynamic behavioural process (Osterberg & 
Blaschke 2005:487; Saleem, Hassali, Shafie, Award & Bashir 2010:126).  It is strongly 
influenced by each patient's characteristics, the patients’ support system, the 
environment, the practices of health care providers, and the characteristics and 
processes of the health care delivery system (Kulger, Vlaminck, Haverich & Maes 
2005:28; Higgins 2006:28; Ramli, Ahmad & Paraidathathu 2011:614). The most 
common barriers to adherence are under each patient's control.  Therefore, there is a 
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need to focus attention on each individual patient’s circumstance and to be actively 
involved in his/her treatment adherence. 
 
Adherence to medication regimens predicts a better outcome for patients. Treating 
hypertension with medication, combined with lifestyle modifications can substantially 
reduce the risk of complications, hence the dire need for treatment adherence in 
patients with hypertension. When there is treatment adherence, there is proper control 
of hypertension. There is also a better quality of life with reduced risks of 
complications. Yet, treatment adherence in patients with hypertension remains a major 
public health challenge in many developing countries. The health professionals should 
help patients with hypertension, to adhere to their anti-hypertension treatment 
regimens (Osterberg & Blaschke 2005:488; Vlasnik et al 2005:47). 
 
1.2.10.1 Non-Adherence to anti-hypertension treatment regimens 
 
Non-adherence to prescribed treatment regimens (including life style changes and 
taking medicines) is associated with uncontrolled hypertension. The consequences are 
the increased risks of developing complications (Campbell, Petrella & Kaczorowskis 
2006:599). The management of these complications is very expensive for the 
individual, family, community and the nation as a whole (Osterberg & Blaschke 
2005:488). This is why it is important for hypertension patients to adhere to treatment 
regimens to have healthy and productive lives. To combat the problem of non-
adherence the WHO (2003:107) published evidence-based guidelines on treatment 
adherence. The countries were requested to develop country standardised guidelines 
for hypertension management. These guidelines were developed for use by clinicians, 
health care managers, policy makers and hypertensive patients with emphasis on 
prevention, early diagnosis, treatment and treatment adherence (Chobanian et al 
2003:1990). Treatment non-adherence might cause many complications. These 
include strokes, vision impairment, heart attack, kidney disease, disability and 
morbidity and mortality.  The factors influencing non-adherence may be patient-related. 
These may include level of education and knowledge, family income, cultural beliefs 
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and understanding regarding hypertension and its consequences, side effects of the 
drugs, inability to perceive the benefits of controlling their blood pressure, no escort to 
go to the hospital, no patient education regarding complications by the health care 
providers. It is necessary to identify such factors from the hypertensive patients’ 
perspectives and develop strategies to improve their adherence levels to limit 
complications (Krousel-Wood, Thomas, Muntner & Morisky 2004:357). 
 
However, treatment adherence levels and the influencing factors among hypertensive 
patients, at the QECH hypertension clinic in Blantyre, are not known. This study 
investigated treatment adherence and the factors influencing such adherence levels in 
patients with hypertension at QECH. 
 
1.2.11 Malawi’s attempts to diagnose and treat hypertension through its health 
services delivery system 
 
The discussion in this section focuses on the diagnosis and treatment of hypertension 
in Malawi as attempted by Malawi’s MoH.  Private health care practices fall beyond the 
scope of the current study. 
 
1.2.11.1 Health services delivery in Malawi 
 
Malawi’s MoH has the overall responsibility of providing leadership, co-ordination of 
policy development and provision of health services in Malawi. It is the largest provider 
of health services and covers 60.0% of all health services. The health care delivery 
system is organised at three levels, which are primary, secondary and tertiary, linked 
through a referral system, according to the Malawi National STEPS Survey (MoH/WHO 
2010:9).  
 
The primary level of health care provision is where a patient makes an initial contact 
with the health care provider at the nearest health facility, provided through outreach 
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programmes, dispensaries/health posts, health centres as well as community hospitals.  
The health care provider is a medical assistant, who undergoes a two year clinical 
learning programme. The services mostly focus on the prevention of diseases with 
prescription of basic drugs. There is also a nurse technician with a certificate or 
diploma, health surveillance assistant and an attendant. If there is no improvement, the 
patient is referred to the secondary level care (MoH/WHO 2010:9).  
 
Secondary level care is offered at a district hospital. The health care provider is a 
clinical officer, who undergoes a three year clinical learning program. The services are 
mostly curative, following a detailed assessment and laboratory investigations. There is 
a wider range of drugs for the diseases and conditions. If there is no improvement, the 
patient is referred to a tertiary level of health care.  Secondary level health care is 
provided through the district and Christian Health Association of Malawi (CHAM) 
hospitals.  The provider of care is the clinical officers who undergo three year training 
programmes. The services are mostly curative with a moderate level of prescribed 
drugs (MoH/WHO 2010:9).  
 
Tertiary level health care is provided at referral hospitals and at four central hospitals, 
one in the north, one in the centre and two in the south.  The services provided at 
central and referral hospitals are mostly curative following assessments using modern 
technology including laboratory investigations and radiography. The health care 
providers are doctors and/or specialists.   
 
However, this categorisation of health care levels of services is a guide but due to the 
unavailability of alternative facilities within the catchment areas, the district, CHAM 
hospitals and central hospitals also provide primary level care step (MoH/WHO 
2010:9).  Hypertension is managed at primary level where prevention messages are 
given to people. It is managed at secondary level, where (once diagnosed with 
hypertension), lifestyle modification and anti-hypertension drugs are prescribed. 
Patients who have experienced complications of hypertension such as strokes, heart 
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attack, vision impairment and kidney failure are referred to the tertiary level for 
specialist management and rehabilitation. 
 
1.2.11.2  Malawi’s geographic location 
 
Malawi is a land locked country in the Southern-Central Africa. Its land area comprises 
about 118 484 square kilometres. It is 901kilometers long and 180 kilometers wide. 
One third of the land is occupied by Lake Malawi. The 2010 Populations and Housing 
Census estimated Malawi’s population to be about 13 million (MDHS 2010:2). Of this 
population, 85.0% live in rural areas. Malawi shares boundaries with Tanzania to the 
north and northeast, Zambia to the west, Mozambique to the southeast, south and 
south west. Malawi is divided into three regions, northern, central and southern. The 
regions are further divided into 28 districts. One of the districts in the southern region is 
Blantyre where the study was conducted (Report of Malawi National/WHO STEPS 
Survey 2010:7).  
1.3  STATEMENT OF THE PROBLEM 
 
In Blantyre at QECH, the adult medical wards reported 55 admissions due to strokes 
between January and March 2007, 58.0% were females, and 42.0% were males with 
an inpatient mortality rate of 23.0% (Mahawish & Heikinheimo 2010:25). Hypertension 
can have potentially life-threatening complications which can be avoided if 
hypertension is treated successfully, provided that patients adhere to their prescribed 
treatment regimens.  Non-adherence to prescribed treatment increases the patient’s 
risk for complications secondary to uncontrolled hypertension.  Despite these statistics, 
no study had been done at QECH, Blantyre, to establish hypertensive patients' levels 
of treatment adherence and the factors influencing patients adherence levels to their 
anti-hypertensive treatment regimens.  The principal questions that needed to be 
answered were: “What are hypertension patients’ treatment adherence levels? What 
factors influence hypertension patients’ treatment adherence at QECH hypertension 
clinic?"  
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1.3.1  Purpose of the study 
 
The principal questions that needed to be answered were: “What are hypertension 
patients’ treatment adherence levels? What factors influence hypertension patients’ 
treatment adherence at QECH hypertension clinic?" The purpose of the study was to 
investigate levels of adherence to anti-hypertensive treatment regimens, and to identify 
the factors influencing hypertension patients’ adherence levels at QECH in Blantyre.   
 
The research findings could help policy-makers and health care providers to address 
factors influencing hypertensive patients’ low levels of adherence to their treatment 
regimens. Enhanced adherence levels to anti-hypertensive treatment regimens could 
help to reduce patients’ blood pressure levels, and reduce their risks of hypertension-
related complications, including strokes. 
 
 
1.3.2. Specific objectives 
 
The first objective of this study was to establish hypertensive patients’ levels of 
adherence to their treatment regimes.  The other objectives attempted to provide a 
factual basis for determining the potential influence of specific factors on the 
hypertensive patients’ treatment adherence levels, by calculating correlations of 
specific variables.  These objectives aimed to: 
• identify hypertensive patients’ knowledge of hypertension and of, non- 
pharmacological and pharmacological  management of hypertension      
• identify hypertensive patients' perceived susceptibility to potential complications 
attributable to hypertension 
• identify hypertensive patients’ perceptions of the severity of hypertension 
complications 
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• determine hypertensive patients’ understanding of benefits of treatment 
adherence 
• describe hypertensive patients’ perceived  barriers to treatment adherence  
• describe hypertensive patients’ cues to action and self-efficacy for treatment 
adherence 
 
1.3.3  Significance of the study  
 
The findings from this study might: 
 
• reveal treatment adherence levels among patients suffering from hypertension 
at QECH and shortcomings in the Malawi's current hypertension management 
guidelines, strategies and education interventions and their evaluation plans. 
These revelations might inform policy, which might improve treatment 
adherence, knowledge of perceived susceptibility, and severity of complications, 
and perceived treatment benefits amongst patients with hypertension at QECH 
in Blantyre as a follow-up activity after the current study. 
• expose motivators and barriers affecting patients’ treatment adherence which 
might inform interventions at QECH 
•  provide research-based inputs to the national policy-makers concerned with 
non-communicable diseases. 
• generate topics for future research. 
 
By using the HBM (developed in the USA) to contextualise this study’s findings, the 
usefulness of the HBM for enhancing the understanding of hypertensive patients’ 
adherence behaviours has been demonstrated.  The use of the MMAS-8 scale (also 
developed in the USA), translated into the local language, demonstrated that similar 
factors influence patients’ adherence behaviours in different parts of the world.  
Hypertensive patients had the opportunity to voice their opinions about the 
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management of their treatment and these findings could help health care providers to 
prescribed appropriate anti-hypertensive regimens. 
 
The significance of enhancing the adherence of hypertensive patients to their treatment 
regimens cannot be overemphasised.  Reductions in hypertension have been 
correlated with reductions in the incidence and recurrence of strokes (Monahan et al 
2007:1422). In the USA approximately 500 000 first time stroke episodes are reported 
annually.  Although the mortality rate is 15%, “…stroke leaves about 30% of its victims 
with mental and physical disabilities that require ongoing assistance with activities of 
daily living… This leaves a pool of more than 1 million people who are currently 
partially or totally disabled from stroke [in the USA]…” (Monahan et al 2007:1422).    
 
1.4  THEORETICAL FRAMEWORK: THE HEALTH BELIEF MODEL   
 
The Health Belief Model (HBM) was used as a theoretical framework that guided the 
study. It guided the development of the research objectives, the development of the 
structured interview schedule, the organisation of the literature, the presentation and 
discussion of the results.  
 
1.4.1 The importance of a theoretical framework 
 
Burns and Grove (2011:239) stated that every quantitative study has a framework. In 
this study the HBM provided the theoretical framework (Glanz, Rimer & Lewis 
2002:42).  The importance of a theoretical framework is that it guides the research 
process.  According to Polit and Beck (2010:209) the theoretical framework guides the 
formulation of study objectives, the search and presentation of literature, the 
development of the data collection instrument, presentation of results, and discussion. 
Burns and Grove (2011: 238) state that the framework enables the linkage of the 
findings of the study to nursing’s existing body of knowledge. The framework is also an 
indication that the quantitative study was well-developed.  
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This thesis was guided by the HBM because it states that health behaviour is 
influenced by a person's perception that a health problem poses a threat. It has a 
systematic method to explain and predict preventive health behaviours (Glanz et al 
2002:44).  It was relevant and applicable and guided the study about patients’ 
hypertension treatment adherence levels and factors influencing such treatment 
adherence levels. To meet these objectives it was necessary to identify patients' 
knowledge of hypertension, non-pharmacological and pharmacological management; 
identify patients’ perceived susceptibility for complications; identify patients’ 
perceptions of severity of hypertension; determine patients’ perceptions of benefits of 
treatment adherence; describe patients’ perceived barriers to adhering to treatment 
and describe the relationship between patients’ treatment adherence levels and 
hypertension control.  
 
1.4.2 Origin and contributions of the Health Belief Model 
 
The Health Belief Model (HBM) was developed by three social psychologists, namely, 
Hochbaum, Rosenstock, and Kegel who were working in the United States Public 
Health Service. These social psychologists developed the HBM to learn how 
individuals make decisions about health-related behaviours. The authors wanted to 
understand:  why some people take specific actions to avoid illness, while others fail, 
what determines health behaviour, why they do not adhere to other kinds of health care 
regimens; and finding ways to stimulate positive behaviour changes (Glanz et al 
2002:42). They wanted to understand the people’s failure to engage in preventive 
health measures and the minimal connection between patients’ symptoms and their 
adherence to medical regimens.   
 
The theory was developed with a philosophical basis that health related-behaviour is 
influenced by a person’s perception that a health problem poses a threat, thus a value 
attached to actions aimed at reducing the threat, a value-expectancy theory. The value 
expectancy theory concepts were reformulated in the context of health behaviours. The 
interpretations were that, the desire to avoid illness or to get well is a value.  While as, 
36 
 
the belief that a specific health action available to a person would prevent illness is an 
expectation. This implies that in a patient with hypertension, the desire to prevent 
complications is a value. While as, the belief that adhering to a treatment regimen 
would prevent complications is an expectation. The expectation was further broken 
down and described as the individuals’ estimation of personal susceptibility to and the 
severity of an illness, and the likelihood of being able to reduce or prevent the threat 
through a sustained activity (such as, taking anti-hypertensive medications as 
prescribed).  The model development was also influenced by Lewin’s theory which 
states that it is the world of the perceiver that determines what an individual will and will 
not do; the individual is the locus of change (Janz, Champion & Strecher in Glanz, 
Rimer & Lewis 2002:47).  
 
1.4.3 Components of the Health Belief Model  
 
The major components of the HBM are displayed in figure 1.2 and will be discussed in 
the following sections. 
 
1.4.3.1 Perceived susceptibility  
 
This is one’s belief, and /or one’s assessment regarding the risk of contracting a health 
condition or problem (Glanz et al 2002:48). In case of medically established illness, it 
includes the individual’s acceptance of the diagnosis, complications and individual 
estimates of re-susceptibility to the illness.  
 
1.4.3.2 Perceived severity  
 
This HBM component refers to one's belief of how severe a condition and its 
consequences are (Glanz et al 2002:48).  People tend to act when they are afraid of a 
pending consequence.  
 
1.4.3.3   Perceived benefit  
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This HBM component implies one's belief that a given treatment will cure the illness or 
help to prevent it.  A belief that the advised behaviour will reduce the risk or 
seriousness of impact (Glanz et al 2002:48), will help people to remain motivated to 
adhere to the advised behaviour(s).  
 
1.4.3.4   Perceived barriers  
 
These aspects are potential negative aspects to undertaking the recommended 
behaviour. This means that an individual undergoes an unconscious cost benefit 
analysis whereby, these actions' expected effectiveness are weighed against the 
perceived cost  and/or unpleasantness; then behaviour might be omitted to avoid the 
current unpleasant experience (Glanz et al 2002:48). Thus if an individual's own 
analysis makes him feel that there is a current hindrance or a potential negative aspect 
to following the behaviour, he/she will avoid the potential negative consequences and 
will not adhere to the recommended health behaviour.  
 
1.4.3.5 Cues to action  
 
Cues to action refer to one's readiness, motivation and courage to change behaviour 
based on external influences that are available to promote the desired behaviour(s) 
(Glanz et al 2002:48).   
 
1.4.3.6 Likelihood to taking recommended treatment  
 
This aspect imply the motivation and self-confidence to change the habitual behaviours 
and to trust one's ability to do something (Glanz et al 2002:48).   
 
1.4.3.7   Modifying factors  
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Modifying factors are the demographic variables, age sex religion ethnic group and 
psychosocial variables, educational level occupation and marital status 
 
 
 
Figure 1.1: The Health Belief Model (Source: Janz et al in Glanz et al 2002:45)  
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Figure 1.2: The adapted Health Belief Model (from Janz et al in Glanz et al 2002:45).  
  
Likelihood of action.  
Hypertension patients modifying factors are demographic 
and psychosocial variables: gender, age, tribe, religion, 
culture; educational level, occupation, and marital status 
 
Hypertension patients’ perceptions 
Perceived susceptibility: hypertension patients’ belief that 
they can develop complications from the hypertension Hypertension patient’s 
likelihood of following the 
behaviour of: 
  
 adherence or non-adherence  
to prescribed anti-hypertensive 
treatment regimen. 
Perceived severity: hypertension patients’ belief about 
seriousness of hypertension complications such as a parent 
who died from a stroke 
Perceived benefit: hypertension patients’ belief that a given 
treatment will prevent complications (feeling of wellbeing after 
treatment, being productive, prevent heart disease)
 
Perceived barriers: hypertension patients’ belief about 
negative aspects to undertaking the recommended behaviour 
(side effects of drugs, long distance to clinic, long waiting time 
or high cost of drugs) 
Cues to action: hypertension patients’ motivation and 
courage (cues include family support health education 
messages, health workers’ support) 
 
Self-efficacy: hypertension patients’ motivation and self -
confidence in following the prescribed behaviour 
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1.4.4.   The adapted Health Belief Model and operational concepts’ definitions  
 
In the following sections, the HBM’s major components will be operationalised and 
applied to the current study. 
 
1.4.4.1   Modifying factors that could influence patients adherence to anti-   
    hypertension treatment  
 
In this study, the modifying factors for the patients suffering from hypertension include 
the demographic factors such as gender, age, tribe, religion, educational level, 
occupation and marital status and beliefs about the seriousness of potential 
complications of suffering from hypertension. Modifying factors include the patients 
psychosocial factors such as educational level, occupation and marital status of the 
patients suffering from hypertension (see figure 1.2). 
 
1.4.4.2  Patients’ perceived susceptibility to complications of hypertension 
 
The patients’ perceived susceptibility referred to their acceptance of the condition of 
hypertension and risk of ensuing potential complications.  If patients suffering from 
hypertension do not perceive and believe that the condition has a risk of complications, 
they might not adhere to the treatment. But if risk is perceived as potential, the patient 
might engage in certain behaviours to reduce the risk of complications (Chen, Tsai & 
Lee 2009:2234).  
 
Therefore, the study investigated patients’ acceptance of the condition, knowledge of 
its symptoms, the diagnosis and management, and risks of complications; how the 
knowledge influenced their adherence to the prescribed lifestyle modifications, and 
anti-hypertensive treatment regimens for controlling their blood pressure levels (see 
figures1.1 and 1.2). 
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1.4.4.3   Patients’ perceived severity of complications of hypertension 
 
If patients with hypertension perceive the complications of hypertension to be severe, 
fear might influence their adherence to preventive behaviours. On the contrary if 
patients do not perceive the complications of hypertension to be severe (including 
death from strokes), they will probably not engage in preventive behaviours and might 
not adhere to their treatment.  Therefore, this study investigated whether patients 
believed that complications from hypertension were perceived to be severe and how 
that influenced their likelihood of adherence to their prescribed treatment. 
 
1.4.4.4 Patients’ perceived benefits of adhering to their anti-hypertension 
treatment regimens 
 
If the patients suffering from hypertension believed that there was a benefit in taking 
the drugs, and in acting as advised, they might adhere to treatment and to the advice 
given to them. Therefore, this study investigated what patients perceived to be benefits 
of adhering to prescribed treatment, and how these benefits influenced their adherence 
behaviours (see figure 1.2).  
 
1.4.4.5 Patients’ perceived barriers to adhering to anti-hypertension 
treatment regimens 
 
If the patients with hypertension perceived negative aspects of treatment, for example 
the side effects or the cost of the drugs, then they might choose the action of being 
non-adherent. Therefore, the study investigated the patients' perceived barriers 
(negative aspects) to adhering to the recommended behaviours and how they 
influenced patients’ adherence behaviours. 
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1.4.4.6   Patients’ cues to action to adhere to their prescribed anti-hypertension 
treatment regimens  
 
Family support and health care workers’ support, education messages on 
hypertension, its treatment and complications are some cues to action. Therefore, this 
study investigated hypertensive patients’ cues to action, and whether the cues 
influenced them to adhere to their prescribed treatment regimens (see figure 1.2). 
 
1.4.4.7  Patients’ intentions to adhere to their anti-hypertensive treatment 
regimens 
 
The hypertensive patients’ motivation, self confidence and trust in their ability to 
change negative to positive behaviours comprise the self-efficacy to adhere to their 
prescribed anti-hypertension treatment regimens.  Therefore, the study investigated 
hypertensive patients’ self-confidence and ability to adhere to their prescribed 
treatment regimens (see figure 1.2). The six concepts (perceived susceptibility, 
perceived severity, perceived benefits, perceived barriers, cues to action and self-
efficacy) guided the development of the study’s objectives, organisation of the literature 
review and development of the structured interview schedule (see      C & D). They 
also guided the presentation of study results and the discussion of the findings.  
 
1.5  RESEARCH METHODOLOGY 
 
The research methodology will be discussed in detail in chapter 3 of this thesis.  Only 
the major aspects will be summarised in the following sections of this chapter. 
 
1.5.1  Quantitative descriptive research design 
 
A quantitative descriptive research design refers to the measurement in quantitative 
ways; the information is collected in quantities/numbers (Maltby, Williams, McGarry & 
Day 2010:22; Polit & Beck 2008:248; Polit & Beck 2010:235; Schmidt & Brown 
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2012:147).  This study used a quantitative descriptive design to identify factors that 
influence treatment adherence in patients with hypertension at the QECH hypertension 
clinic. A structured interview schedule comprising 101 questions was used for data 
collection and is discussed in Chapter 3. 
 
1.5.2 Ethical considerations 
 
The main ethical considerations in this study included voluntary participation, reduction 
of risks, avoiding harm, obtaining informed consent and ensuring privacy and 
confidentiality of respondents. The ethical considerations, as applied to this study, are 
discussed in detail in chapter 3. 
 
1.6  STRUCTURE OF THE THESIS 
 
The thesis has the following structure: 
 
Chapter 1: Introduction and background information.This chapter provides the 
introduction to and background information about hypertension and treatment 
adherence, problem statement, and significance of the study. This is followed by a 
presentation of the purpose of the study, objectives guiding the study, an explanation 
of the HBM, definitions of terms used in the thesis, research methodology and ethical 
considerations. 
 
Chapter 2: Literature review. This chapter presents information that is already known 
about hypertension problems, aetiology and impact, treatment adherence, tools for 
measuring adherence, models of adherence, factors influencing adherence, modifying 
factors, demographic and psychosocial variables and treatment adherence, cigarette 
smoking and hypertension, stress and hypertension, treatment adherence in patients 
with hypertension, hypertension patients’ perceived susceptibility to potential 
complications of hypertension, perceived severity of complications of hypertension, 
perceived benefits of treatment adherence, perceived barriers to treatment adherence 
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and patients cues for adherence to treatment, patients self-efficacy and likelihood of 
adherence and contextualising the literature within the HBM.  
 
Chapter 3: Research Methodology. The chapter presents the research design: the 
study setting, study population, sample, sampling design, sampling frame, selection 
and calculation of sample size, sampling, sample selection procedure, research 
instrument, data collection procedure, pre-testing the research instrument, refinement 
of the instrument, data collection technique, validity and reliability, data analysis 
dissemination of findings, ethical considerations and limitations of  the study. 
  
Chapter 4: Analysis, presentation and description of the research findings. The 
chapter presents data analysis, the computer programme that was used, presentation 
of results in tables, figures, bar graphs, discussion of results in relation to similarities 
and/or differences with those reported in the literature review; including the patients’ 
adherence, factors that influence adherence as per concepts of the HBM. Unexpected 
results are also discussed.   
 
Chapter 5: Conclusions and recommendations. The chapter presents the synthesis of 
the research findings in relation to the research problem and objectives, the HBM, 
limitations of the study, recommendations and suggestions for future studies. 
 
1.7 SUMMARY   
 
This chapter has provided a general background to blood pressure and the problem of 
hypertension, its prevalence, complications, treatment and treatment adherence and its 
importance. It has given an overview of the study on treatment adherence amongst 
patients with hypertension using the HBM as a framework. The aim and objectives of 
the study are stated. The significance of the study to global health is stated, as well as 
the needs of Malawi have been provided. The quantitative descriptive research design 
and method have been summarised. The HBM's concepts of perceived susceptibility, 
perceived severity, perceived benefits, perceived barriers, cues to action and self-
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efficacy have been explained.  A structure of the thesis has been presented.  The next    
chapter will present an overview of literature reviewed concerning patients’ adherence 
to anti-hypertension treatment 
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CHAPTER 2 
LITERATURE REVIEW 
 
                                                                                                          
2.1    INTRODUCTION  
 
This chapter presents the review of literature on hypertension and about patients’ 
treatment adherence, measurement and models of adherence, demographic and 
psychosocial variables and their influence on adherence, individual perceptions and 
other factors that influence adherence, barriers to treatment adherence, analysis, 
synthesis and conceptualisation of the literature.  Studies done globally, regionally and 
locally in Malawi will be reviewed.  
 
The search terms included: hypertension, OR hypertension OR contributing factors; 
OR factors AND compliance OR adherence OR drug adherence; AND Malawi; OR 
adherence AND Africa OR Sub Saharan Africa OR adherence AND globally; 
perceptions OR knowledge of drugs AND adherence; AND culture AND adherence OR 
contributing factors AND adherence.  
 
The search engines were used for the literature search to access research articles 
related to treatment adherence and the influencing factors in hypertensive patients. 
These were PubMed Open Access through Google, Google Scholar, Hindawi and 
Google databases.  In addition, the medical, surgical, community nursing books and 
journals’ articles from the libraries at the University of South Africa (Unisa) and the 
Kamuzu College of Nursing (in Blantyre, Malawi) and the College of Medicine (of 
Malawi) were used.   
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2.1.1 The purpose of the literature review 
 
The review of literature available internationally and nationally provided the context for 
the intendend study. It gave insight into the depth of the existing body of knowledge 
about hypertension, treatment and adherence to treatment, measurement of 
adherence, adherence levels and factors influencing treatment adherence. In addition it 
showed how the area and topic have been previously researched. Furthemore, it 
helped to identify a gap in the findings of similar studies that were conducted previously 
elsewhere. The search for literature focussed on articles which were published in 
English between 2003-2013.  
 
2.2 HYPERTENSION  
 
Hypertension as a global health problem is increasing rapidly. It has been researched 
widely by the WHO (1999:151), and by the World Health Assembly (WHA) and the 
WHO Regional Committee for Africa (RCA 2003:1983). Worldwide, the WHO 
(2011:207) reported that over 80.0% of deaths were caused by non-communicable 
diseases and hypertension was one of the major causes of these deaths. Hypertension 
may be prevented because its risk factors are known. The risk factors include tobacco 
smoking, harmful use of alcohol, physical inactivity, obesity, diets high in saturated fats 
and sodium, low intake of fruits and vegetables (Addo et al 2007:1012; Middleton 
2009:15; WHO 2003:1983; Msyamboza et al 2010:87; Msyamboza et al 2011:3; 
Maher, Waswa, Baisley, Karabarinde & Unwin 2011:1061).   Hypertension occurs in 
low and middle income countries (Holmes Jr., Hossain, Ward, & Opara 2013:5).  
 
During 2003, the WHO indicated that even in the developing countries of the world, 
hypertension and its risk factors were causing a rise in untimely deaths (WHO 
2003:1983). More deaths might be due to hypertension than in the developed  
countries (Addo et al 2007:1015).  
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Previously, hypertension was considered to be a health problem of the developed 
countries. This might explain why many developing countries did not list hypertension 
as a priority health problem and did not devote the attention hypertention required in 
their health departments (Hareri & Abebe 2013:6). Hypertension remains a neglected 
health problem because acute conditions get more attention with the largest portion of 
the budgets in health departments and hypertension continues to be neglected while it 
continues to kill people silently (Addo et al 2007:1012; Middleton 2009:13).  
 
In SSA hypertension has been more prevalent in urban than in rural populations (Addo 
et al 2007:1012). The hypertension prevalence rate in SSA remains high with a rate of 
5-20%. In many African countries, basic information regarding the condition of 
hypertension is lacking, because of the lack of policy and/or the lack of the 
implementation of existing policies at the health care delivery sites (Addo et al 
2007:1014; Ambaw, Alemie, W/Yohannes, Mengasha 2012:282; (Hareri and Abebe 
2013:5; Kusuma 2009:267; Msyamboza et al 2011:6; Mweene et al 2010:252; 
Mufunda, et al 2006:521; Saleem et al 2011: 834).  It was believed that hypertension 
was a condition of the wealthy and the elderly acquired from risks which are expensive 
to control. Therefore,  priority was given to interventions for infectious diseases which 
are more easily controlled than the chronic condition of hypertension (Holmes Jr et al  
2013:1).  In south west Uganda the prevalence of hypertension was reportedly 22% 
both in men and women (Maher et al 2011:106).  
 
In Malawi, hypertension is a public health problem with a prevalence rate of 32.9% with 
no national policy on hypertension management (Msyamboza et al 2010:88). The 
QECH, in Blantyre, reported a range of patient admissions with hypertension from 2 
769 in 2008 to 2 817 in 2010; and a range of deaths from hypertension complications 
from 95 in 2008 to 97 in 2010 with no national policy on hypertension (Mahawish & 
Heikinheimo 2010:25, QECH Report 2008:13; QECH Report 2010:14).  At the QECH 
hypertension clinic, a nurse led intervention study  was conducted in 2010 (Starichi, 
Dreyer & Allain 2011:24). The objective of the intervention study was to examine the 
effect of an education intervention to patients taking treatment for hypertension control. 
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Thirty seven hypertension patients were invited to attend a mean of 3.5 individual one-
to-one counselling sessions on hypertension, its treatment, and the importance of 
adhering to treatment. The patients attended counselling sessions over a mean of 
118.5 days.  The results showed that the proportion of patients reporting that they took 
their medication on the day of their clinic visit increased from 47% to 86%.   
 
2.2.1 The aetiology and impact of hypertension on patients’ quality of life 
 
The aetiology of hypertension is unknown.  However, there are factors that predispose 
a person to hypertension. These are referred to as risk factors.   For primary 
hypertension the risk factors are stress, excessive cigarrette smoking, consumption of 
alcohol, sodium and saturated fat, obesity and lack of excercise (Addo et al 2007:1012; 
Halanych, Safford, Kertesz, Pletcher, Kim, Person, Lewis & Kiefe 2010:532; Maher et 
al 2011:1061. The risk factors for secondary hypertension are diseases and conditions, 
such as, age and race (Lewis et al 2011:741).  
 
Worldwide, almost 6.0% of deaths are caused by complications of hypertension and it 
also impacts physically, socially, financially and psychologically on patients’ quality of 
life (Saleem et al 2011:834). Physically the condition causes a reduction in the ability to 
carry out their activities of daily living due to heart palpitations, weakness, dizziness 
and headaches. Socially and financially, the impacts are on patients’ inability to 
socialise as the patients lose income because they have to quit their current jobs due 
to weakness when they suffer a complication such as a stroke, heart attack or kidney 
disease. In addition, life adjustment is done to accommodate costs of physicians, 
diagnostic tests and medicines which could make life more difficult for the patient and 
his/her family.  Psychologically, the patient feels disturbed and isolated, because of the 
negative impacts of the condition limiting her/his ability to work, to socialise and 
incurring costs on the family members. But when patients adhere to their treatment the 
negative impacts could be minimised.  
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2.2.2  Treatment adherence 
 
The WHO defines treatment adherence as the extent to which a patient's behaviour of 
taking medications, following a diet and/or executing lifestyle changes, corresponds 
with the recommendations of the health care provider (Chobanian et al 2003:1213; 
Lilley et al 2011:386). Generally, treatment adherence is higher among patients with 
acute conditions. This is because the treatment is taken for a short period of time and 
the patient expects the acute condition to be cured after a limited period of adhering to 
his/her treatment regimens. However, in patients with chronic conditions, such as 
hypertension, adherence is lower because the treatment has to be taken every day for 
the duration of the patient’s life. Therefore, patients could discontinue their medication 
within six months of taking them as they might regard swallowing drugs to be  
tiresome.  
In some trials there have been adherence rates of 43.0-78.0% among patients 
receiving treatment for chronic conditions.  
 
The mean adherence rate for anti-hypertensive patients in developping countries is low 
and it ranges from 50.0-70.0%. Adherence to lifestyle modifications has been reported 
to be as low as 10.0% which is inadequate to cause any blood pressure reduction 
(Osterberg & Blaschke 2005:487).  A WHO report estimates that adherence to anti-
hypertensive medications ranges from 52.0%-74.0% when adherence is defined as 
possession of a medication  at least 80.0% of the time (Sabate 2003:207).  The 
following are the rates of adherence that have been reported for other countries; 53.0% 
in Atlanta  (Gatti, Jacobson, Gazmararian, Schmotzer & Kripalani  2009:659); 74.0% in 
Egypt (Mweene et al 2010:259), 49.0% in Malaysia  (Sulaiman et al 2009:38).  In 
Pakistan it was reportedly 77.0% (Hashmi, Afridi, Abbas, Sajwani, Saleheen, Frossard, 
Ishaq, Ambreen & Ahmad 2007:1315), 69.2% in Addis Ababa, 75.0% in Nigeria, 73.0% 
in India, 72.0% in Turkey (Hareri & Abebe 2013:5), 46.0% in the Seychelles, Praslin 
Island (Edo & De Villiers 2012:4), and 76.0% in Zambia, Lusaka (Mweene et al 
(2010:259).   
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These reported rates of adherence in most of these countries are inadequate to effect 
blood pressure control (Osterberg & Blaschke 2005:488). However,  other studies, that  
focused on anti-hypertensive drug adherence have reported that there is no standard 
for what constitutes adequate adherence, but an adherence rate of 80.0% to 95.0% is 
considered adequate to control hypertension (Higgins 2006:28; Osterberg & Blaschke 
2005:490; Ramli et al 2010:214; WHO 2003:1983). In Scotland the adherence rate was 
reported to be 91.0% (Inkster, Donnan, MacDonald, Sullivan & Fahey 2006:295), and 
88.6% in Kuwait (Hareri & Abebe 2013:5). According to the WHO (2003:488), an 
adherence rate of more than 90.0% is desirable for effective control of hypertension 
and for the prevention of complications. 
 
2.2.3 Tools for the measurement of patients’ adherence to anti-hypertension     
treatment  
 
Different tools have been used to measure patients’ adherence to anti-hypertension 
medication. The methods of measuring adherence can be divided into direct (objective) 
and indirect (subjective) ones.  Adherence to medication, pertains to  records indicating 
whether the patient had taken the prescribed doses at the correct times or not. The 
challenge is that it is difficult to measure adherence accurately because there is no 
best measuring tool for medication adherence as each one has its advantages and 
disadvantages (Osterberg & Blaschke 2005:488). The following are some of the 
measuring instruments that were used in this study: the 8-item Morisky Medication 
Adherence Scale, fivepoint Likert scale and retrospective medication record reviews.   
 
2.2.3.1  The 8-item Morisky Medication Adherence Scale (MMAS-8)  
 
The MMAS-8 is an adherence measuring tool. It was originally a four-item self-reported 
questionnaire to assess medication adherence. Through research it was later improved 
to eight-items (Morisky, Ang, Krousel-Wood, & Ward 2008:348).  It is a structured, self-
reported scale. The instrument comprises closed-ended questions. The closed-ended 
questions require the patient to tick from the predetermined response options of No=1 
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or Yes=0 for 7 items. The last item is a five point Likert scale.  The items, once scored 
by the patient, are coded in reverse response in a positive direction for item number 5, 
and according to the standardised code for item 8 (0-4) resulting in a scale from low 
adherence to high adherence. The total scale has a range of 0 to 8.0. If a patient 
scores <6, it indicates low adherence, 6 to <8 indicates medium adherence, =8 
indicates high adherence.  
 
2.2.3.2 Five point Likert scales 
 
In a five point Likert scale, the patient must rate him/herself on a scale of 0-5 for each 
item. The scores are, strongly agree-5, moderately agree-4, agree-3, strongly disagee-
2, moderately disagree-1, disagree-0. The same is done for all the items and then the 
total score is obtained by adding all the scores selected by the patient. It is objective, 
simple and easy to score if the participants are literate. But if the patient is illiterate the 
five points might be difficult to differentiate the parameter of agree and moderately 
agree, strongly agree.  For illiterate persons, the three point scale is easier to rate, 
agree-3, disagree-2 and don’t know-1. 
 
2.2.3.3  Retrospective medication record reviews 
 
This method makes use of the patients’ diaries where all previous records regarding 
prescribed treatments are recorded. Therefore, the patients’ adherence is measured 
against the duration of time when the patient comes for review versus the number of 
tablets supplied to the patient. It is objective, simple and easy. However the argument 
remains that the previous medication in the patient’s record does not guarantee that 
the drugs were actually taken.  
 
2.2.4 Models of adherence 
 
According to Osterberg and Blaschke (2005:490) there are two models of adherence,  
guiding the description of factors that influence treatment adherence in patients with 
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chronic conditions and diseases (Kalogianni 2011:157; Mweene et al 2010:253). There 
is a chronic care model that describes the provider factors affecting adherence 
(Barksdale 2009:53). The model is subjective in that it only focuses on the provider 
factors. Barksdale (2009:55) described the model with emphasis on cultural 
competency, sensitivity, awareness, knowledge, skill, encounters, desire, barriers, and 
cultural context as characteristics a provider should possess to achieve treatment 
adherence. Culture means a group of people who share beliefs, values, and customs, 
practices or behaviours (Wild, Grove, Martin, Eremenco, McElroy & Verjee-Lorenzo 
2005:96). 
 
There is a three-factor model of adherence in the SSA region.  It refers to the three 
factors that influence treatment adherence that focuses on the patient/family factors, 
disease factors and treatment regimen factors. The model is subjective in that it only 
focuses on the three factors when there are more players involved in treatment 
adherence in chronic patients. In addition to this there is a six factor model that focuses 
on the patient/family, health care system, health care provider, medication-related 
issues, disease-related issues and the nature and availability of services. In this thesis 
the six model factor was adopted to describe factors that influence treatment 
adherence in patients suffering from hypertension (Ambaw et al 2012:285; Kalogianni 
2011:157; Mazzaglia, Ambrosioni, Alacqua, Filippi, Sessa, Immordino,  Borghi, 
Brignoli, Caputi, Cricelli & Mantovani 2009:1598; Mweene et al 2010:252; Osterberg & 
Blaschke 2005:487; WHO-ISH (2003:1988). The six factor model of adherence is 
objective in that it focuses on six factors of treatment adherence which is a behaviour, 
an attitude and a practice issue.  
 
The process of achieving high treatment adherence rates requires efforts from all multi-
fasceted factors. The patient and the doctor should develop a mutual relationship of 
trust and openness, the health care system and nature of service, should be patient-
centred by responding to the needs of the patients timely. This would help nurses and 
other health care providers to understand the determinants of adherence to prescribed 
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anti-hypertensive treatments in patients with hypertension. The facility should allocate 
a budget that enables patients to get their anti-hypertensive drugs throughout the year.  
 
 
2.2.5 Factors influencing patients’ anti-hypertension treatment adherence 
contextualised within the major tenets of the HBM 
 
The HBM has been adapted to describe characteristics and perceptions of patients 
with hypertension at QECH and how their perceptions influence their behaviour to 
adhere to the prescribed anti-hypertensive treatment regimens.  Patients will follow a 
behaviour in fear of/or avoidance of the pending threat or for an expected benefit 
resulting from a specific behaviour.  In the process of following the behaviour a benefit 
will follow, such as, a reduced blood pressure reading. This benefit will be perceived by 
the patient since there will be no dizziness, heart palpitations and headaches, 
associated with hypertension. With the patients’ perceived susceptibility, regarding a 
chance of getting a condition, and/or complications, and the benefit he/she might be 
more likely to adopt a behaviour to minimise complications and get some expected 
benefits.  
 
Perceived severity implies that a patient with hypertension, who believes in the 
seriousness of the complications of hypertension, might be more likely to change 
his/her behaviours to minimise the complications from occuring. The combination of 
susceptibility and severity has been termed perceived threat. A perceived benefit 
implies that if a patient perceives gain, or comfort he/she will be more likely to adhere 
to a health action, such as reducing salt intake and engaging in excercises and taking 
medications consistently to benefit from a reduction in hypertension. Patients who 
expect a benefit from an activity, for example,  a reduction in hypertension following a 
reduction in weight,  are more likely to change their risky behaviour for health actions 
without coercion (Farsi,  Jabari- Morouei, Ebadi Abas & Asad Zandi 2009:61; Fingeld, 
Wongvatunyu, Conn, Grando & Russell  2003:288; Janz et al in Glanz, et al 2002:47).     
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The contribution of the HBM is that it has been previously used by other researchers to 
guide their research. Mei-Fang, Ruey-Hsia, Joanne, Chung-Ting, Donald Dah-Shyong 
Min-Nan and Li-Jen (2011:40), conducted a study in China to understand caregiver 
factors influencing childhood influenza immunisations. The results showed that those 
caregivers, who perceived their children to be at risk of contracting the disease took 
their children for immunisation, and those who did not, did not take their children for the 
immunisation. Rawlett (2011:18) conducted an analytical evaluation of the HBM and 
the vulnerable population's conceptual model applied to a medically underserved, rural 
population of Conowingo, Maryland in the USA. The results showed that even in the 
medically underserved rural populations, those who perceived a benefit of the service, 
used it but those who did not expect any benefits decided not to use the service. Glanz 
et al (2002:47) conducted a study to investigate the relationship between perceived 
susceptibility to tuberculosis and perceived benefits from obtaining a mobile x-ray 
screening.  
 
It was discovered that amongst those who reported a perceived susceptibility to 
develop tuberculosis and a perceived benefit of x-ray screening, 82.0% had x-rays 
taken.  But, amongst those who perceived the opposite, only 20.0%  accepted  to 
undergo  the x-ray screening test. The model has since been used by various 
researchers conducting studies amongst various populations to explain the factors and 
the behaviours, thereby, intervene accordingly, to benefit the populations.  Chen, 
Wang, Schnuder, Tsai, Jiang, Hung and Lin (2011:32) conducted a study that was 
guided by the HBM. The purpose of the study was to understand the factors that 
influenced the caregivers to take their under-five children for the childhood influenza 
vaccinations. This model was chosen as being suitable for this study because it 
consideres various individual perceptions that direct a person’s choice of behaviour 
(Janz et al 2002:45). Using this model might provide a more comprehensive approach 
to understanding patients with hypertension and their treatment adherence behaviours 
at QECH. 
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Holt, Muntner, Joyce, Webber and Krousel-Wood (2010:482) conducted a study in 
South Eastern Louisiana in the USA, to examine the association between health-
related quality of life and anti-hypertension medication adherence among older adults 
with hypertension.  The results showed that those patients who perceived a benefit in 
taking anti-hypertension medication and experienced the quality of life adhered to their 
anti-hypertension drug regimens, while those who did not perceive the benefit did not 
adhere to their anti-hypertension drug regimens. The model is based on the idea that 
people behave according to what they feel will benefit them, make them feel 
comfortable and not threatened, will avoid any negative consequences. This model 
was chosen by the researcher as suitable for this study because it looks at various 
individual perceptions that direct a person’s choice of behaviour (Janz et al in Glanz et 
al 2002:45). Using this model might provide a more comprehensive approach to 
understanding patients with hypertension and factors influencing their level of 
treatment adherence at QECH.  
  
2.3 MODIFYING FACTORS INFLUENCING TREATMENT ADHERENCE; 
DEMOGRAPHIC AND PSYCHOSOCIAL VARIABLES  
 
The patients with hypertension in developed and developing countries experience 
specific problems related to the nature of the disease and the patients’ perceptions of 
the condition. Since they are centered on the patients’ characteristics and individuals’ 
perceptions, they are referred to as patient-centered factors that influence anti-
hypertension treatment adherence. These characteristics and individuals’ perceptions 
form a basis or a frame of reference upon which their life decisions, actions and/or 
behaviours are grounded, which might be associated with their intentions and 
behaviours to adhere to anti-hyertensive treatment regimen. The factors which 
influence treatment adherence are associated with demographic variables, such as 
gender, age, tribe, religion, and psychososiol variables such as educational level, 
occupational and marital status. 
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Patient/family-related factors 
 
These demographic variables might influence patients’ perceptions of the condition, its 
treatment, complications and benefits of treatment. For example, the patient’s level of 
education might help him/her to perceive the benefits of treatment to reduce the risk of 
complications such as heart failure. The patient’s education level could also assist 
him/her to understand the severity of potential complications of hypertension (Mweene 
et al 2010:253). Understanding patients’ perceptions of hypertension treatment 
adherence requires a model that could explain why people behave the way they do 
(Glanz et al 2002:42). It is important for health workers to understand their patients’ 
knowledge, educational level, strengths and weaknesses and use that to help them to 
perceive the benefit (importance) of treatment adherence to reduce the risk of 
complications from hypertension.  Patients’ knowledge levels about hypertension might 
improve their perceptions and their treatment adherence levels. This could be achieved 
through health education.  Providing information is a health worker’s responsibility, and 
a patient’s human right because information empowers the patient to make informed 
decisions regarding their health and life (Schmidt & Brown 2012:26). However, 
Middletons’ study (2009:12) reported that among  African-Americans, factors related to 
uncontrolled hypertension did not include a lack of knowledge nor a lack of  access to 
health care services due to costs.  Although these persons were knowledgeable about 
hypertension and they had health insurance,  their hypertension was not controlled.  
The factors that caused non-adherence to treatment regimens thus excluded a lack of 
knowledge and the inaccessibility of health care services. This is why it is important to 
involve the patients themselves in the management of their hypertension to understand 
their perceptions. 
 
Socio-economic and structural factors also influence treatment adherence and requires 
social support and an environment conducive to treatment adherence.  Most health 
facilities lack effective social support networks for chronic conditions such as 
hypertension.  If the environment is intended for acute conditions, patients with chronic 
conditions might be ignored, because preference might be given to patients with acute 
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conditions. This creates an unfavourable environment that might negatively affect 
patients’ adherence to treatment. Lack of effective social support networks and 
unstable living circumstances are additional factors that could create an unfavourable 
environment for ensuring adherence to treatment. People who are hard to reach such 
as the homeless, the unemployed and the poor and those who live far away from the 
health facilities might encounter more problems to adhere to their treatment than other 
persons (Mazzaglia et al; 2009:1598; Mweene et al 2010:252; Osterberg & Blaschke 
2005:487).   
 
Culture is referred to in various contexts pertaining to the anti-hypertension treatment 
adherence. The description of culture includes cultural knowledge, awareness, 
encounters, skills, desires, preferences and barriers (Barksdale 2009:55). Some patients 
might not be aware of or believe in the need and importance for treatment of an 
asymptomatic condition and culture might influence these patients’ decisions and/or 
perceptions. Health workers need to be culturally sensitive, so that they provide 
culturally sensitive and competent services and advice to patients with hypertension to 
enhance these patients’ treatment adherence levels. Cultural sensitivity refers to being 
receptive to differences between and among cultural groups and skilfully interacting 
with patients who have different cultures from their own. Cultural competency is a 
process of delivering health care within the context of patients’ beliefs, values and 
customs.  Patients suffering from hypertension might have their own beliefs about their 
condition and treatment. If health care providers are good listeners, they could learn 
much that could improve patients’ treatment adherence levels. 
 
Culture does not only have a group definition, it has an individual one.  Culture plays 
an important role of shaping peoples’ behaviour and practices (Kazembe 2007: 48).  One  
of the cultural practices is the use of traditional medicines made from herbs as well as 
from plant and animal materials (Kazembe 2007:58; Robinson & Zhang 2011:2).   
 
People with hypertension have their own way of describing their hypertension and its 
treatment and complications. There are some people within the communities who 
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assist others with traditional healing and are referred to as spiritualists (Kazembe 
2007:59). The spiritualists specialise in diagnosing and prescribing traditional medicine 
based on beliefs and values. 
 
In African cultures, many patients suffering from hypertension, would seek traditional 
counselling and medicines before they visit Western health care services.  These two 
cultural beliefs might cause conflicts in the patient who could quit his/her prescribed 
Western anti-hypertension treatment. Some traditional dealers could advise their 
patients to take both traditional and Western medicine as they complement each other 
(Kazembe 2007:59).  This might not be the case as very limited research has been 
done about cultural treatment. Some herbs might counteract the actions of anti-
hypertension drug preventing any improvement in the condition.  Others could increase 
the action of anti-hypertension drugs to the extent of causing life-threatening situations 
of hypotension.  Other traditional healers would tell their patients to take their traditional 
medicines and stop the Western drugs as they counteract each other’s mechanism of 
action.  If patients stop taking their anti-hypertension drugs, they risk incurring the 
potential complications of hypertension.   
Kazembe (2007:62) reported that there are five spirit mediums in Zimbabwe, ranked 
according to their power hierarchy. These are Gombwe, Sadunhu, Tateguru, N’anga 
and Shave. 
• Gombwe is first level of spiritual power that practices through prayer, dreams      
divination and sacrificial activities as well as the use of herbs. It is considered to 
be the most successful cleansing act. It relies more on spiritual power than 
herbs.  
• Sadunhu indicates the second level in spiritual power. Their power comes from 
the spirit of the original leaders of the clan (ancestors). They do not charge for 
their services. 
• Tategulu is third in the spirit hierarchy. They practice to discover peoples’ 
problems and solutions by working closely with sekulus (grandfathers) and 
ambuyas (grandmothers). The person with a problem is informed about the 
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diagnosis before it is presented to the Tategulu. They do spiritual cleansing 
producers for an illness that might have caused problems (Kazembe 2007:63).  
The family learns something from the experience of what they should do in 
future to avoid illnesses. After the cleansing the spirit disappears.  It involves 
large payments to the parties concerned.  
• N’anga implies the fourth level of spiritual power for diagnosis and for solving 
problems. They are the real herbal experts, and receive their powers from the 
maGombwe and maSadunhu. They rely on their divine gadgets to identify the 
problem and the type of medicine to prescribe for specific illnesses and 
problems. They receive some animals’ power from maShave. Under N’anga are 
herbalists, they are not spirit mediums. They are people who have learnt about 
different herbs through their association with the Gombwe, Sadunhu and 
Tategulu (Kazembe 2007:64). They charge fees for their services and the herbs. 
The N’anga who becomes greedy and dishonest will be punished, his or her 
powers will decline, practices will falter, and patients will stop consulting him/her. 
• Shave refers to the fifth level of spirits, associated with some animals and they 
behave likewise, as a baboon and a leopard. They do have bad spirits that 
include witching, theft and murder. They also have good spirits that include 
talent of healing diseases, recovering stolen property, or spirit of getting 
employment, to hunt and to lead others. A fee is charged for their services 
(Kazembe 2007:65).  
 
In SSA, over 80.0% of people have reported that they utilised the services of traditional 
healers before visiting Western health care services/providers (Sato 2012:1). 
Traditonal medicines are defined as herbs, herbal materials, herbal preparations, 
finished herbal products, parts of plants or plant materials, and animal parts (Kazembe 
2007:58; Robinson & Zhang 2011:2). To increase patients’ treatment adherence, 
health care providers need to understand their patients’ beliefs about medication 
taking.  Medication adherence prediction is based on a specific patients’ medication 
taking beliefs (Osterberg & Blaschke 2005:491).  It is a belief and a practice that 
patients who go to Western medical practices will also visit the N’anga, even for the 
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same illness at the same time. The bond between patient and herbalist lasts even long 
after the illness has disappeared. The spirit mediums concurred that people visit 
traditional medical practitioners even during the time they are consulting Western 
medical practitioners, trying both systems simultaneously. Cultural factors also 
influence treatment adherence and require cultural understanding, support and an 
environment conducive to treatment adherence. Globally, individuals have culturally 
been using, are using and will continue to use traditional medicines, such as herbs. In 
some developing countries 70-95% of the population rely on traditional medicine for 
primary health care (WHO 2011:3). 
 
A study at George Town University in Washington DC (Gatti, Jacobson, Gazmararian, 
Schmotze & Kripalani 2009:659) aimed at examining the relationship between beliefs 
about medications, health literacy and self-reported medication adherence. Two 
thousand participants were interviewed for 50 minutes.  A baseline self-reported 
medication adherence was measured using the Morisky 8-item Medication Adherence 
Scale. The results showed that 53.0% reported low adherence, 53.1%, reported that 
they sometimes forgot to take their medications and 35.0% reported that they 
sometimes forgot to take their medication with them when they travelled or left home. 
About 25.0% reported discontinuing treatment when they experienced side effects. 
Patients who reported low adherence were younger than those who reported high 
adherence levels. The multivariate analysis indicated that several factors were 
associated with low self-reported adherence including negative beliefs about 
medication, younger age and low medication self-efficacy.    
 
Health care system-related factors 
 
The health care system-related factors influencing adherence include: inaccessibility or 
limited access to health care, expenses incurred to attend an appointment, long waiting 
times at health care facilities, unfriendly staff, lack of confidentiality, poor 
communication and culturally insensitive staff members, using a restricted formulary, 
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non-availability of drugs, switching to a different formulary when the usual one is  
unavailable, non-involvement of the patient, using expensive drugs, long distance from 
home to the health facility, number and spacing of reviews, unable to be seen due to 
being late for appointment, physicians’ fees, diagnostic tests and the cost of the 
prescribed anti-hypertension drugs (Maghrabi 2013:120; Mazzaglia et al. 2009:1598;  
Mweene et al 2010:252; Osterberg & Blaschke 2005:487; Saleem et al 2011:836). 
Patients encountered difficulties to access the health care system because priority is 
given to those who are acutely sick (Turki & Sulaiman 2010:26). This is the reason why 
some patients just collapse and die from uncontrolled hypertension “the silent killer” 
(Osterberg & Blaschke 2005:497; Saleem et al, 2011:386).  
In their systematic review Maimaris, Party, Perel, Legido-Quigly, Bulabanova, Nieuwlaat 
and McKee (2013:100) aimed to identify the health system factors influencing 
hypertension awareness, treatment and control. The reviewed studies were from low, 
medium and high income parts in the USA and Mexico. The results showed that 
physical location of the facility could positively influence patients’ awareness, treatment 
and control when patients walked a short distance to reach the facility and the opposite  
happened when patients had to walk long distances to reach the facilities.  
 
A Zambian study (Mweene et al 2010:252) at the Lusaka University Teaching Hospital, 
aimed to determine the prevalence of patients’ drug adherence and factors associated 
with poor adherence to anti-hypertensive treatment. The focus was on patient and 
health care system-related factors. The design was quantitative, involving 237 patients 
aged 18 and older who filed self-reports and modified Hill-Bone adherence scales. The 
results showed an adherence rate of 70.0% using the modified Hill-Bone scale and 
83.0% by self-reports. Patients on three anti-hypertension drugs had lower adherence 
rates (OR 0.21; 95% 95% CI 0.06-0.79) than patients taking only one drug, 60.0%. As 
many as 83.0% of the patients reported that the prescribed drugs were unavailable at 
the hospital pharmacy but 79.0% were able to buy these drugs elsewhere.  
 
Health care provider-related factors  
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Patients with hypertension experience certain problems which are related to health 
care providers who interact with them. The factors are grouped as health care provider-
related factors which improve or pose barriers to patients’ adherence to their anti-
hypertension treatment regimens. These factors may be related to providers’ personal 
characteristics, attitudes practices and commitment problems (Edo 2009:62; Mazzaglia 
et al. 2009:1598; Osterberg & Blaschke 2005:487; Saleem et al 2011:836). The WHO 
guidelines on treatment regimens were developed based on treatment trial results. 
Therefore, the provider should follow the guidelines to increase adherence.  A case 
report-based survey was conducted in Sweden, to investigate provider-related factors 
that hindered patients’ adherence. Results obtained from 109 questionnaires 
completed by randomly selected general practitioners, indicated that they failed to 
adhere to guidelines for the treatment of hypertension. The results showed that general 
practitioners focused on the hypertension drugs without assessing the entire 
cardiovascular system profile. The reasons were related to lack of knowledge in 
assessing individual patients' cardiovascular disease.  Patients with the highest risk of 
cardiovascular disease were not treated appropriately. Furthermore, the blood 
pressure levels for initiating pharmacological treatment varied widely. Patients were 
either under or over treated in relation to current guidelines for the treatment of 
hypertension. The health care providers did not adhere to the treatment guidelines. 
The patients did not derive the maximum benefits from their anti-hypertension 
treatment because the general practitioners failed to apply the guidelines 
recommended for treating hypertension. Charges for a physicians’ fees, diagnostic 
tests and medicines as well as having to travel long distances to the hospital also 
influenced patients’ adherence levels adversely (Ekesbo, Midlov, Gerward, Persson, 
Nerbrand & Johansson 2012:34; Mweene et al 2010:252). In addition, the Maimaris et 
al (2013:100), systematic review, identified other influencing factors which were the 
providers’ qualifications and experiences.  In countries where patients were treated by 
specialists, their blood pressures were better controlled than in those countries where 
patients were treated by generalists. The delivery approach and governance of the 
services was also listed as a factor influencing patients’ awareness, treatment and 
control of hypertension.  
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Maghrabi (2013:121), explored the profile of anti-hypertensive agents prescribed by 
physicians, investigated the extent of adherence to the national guidelines and 
detected prescription errors in treating hypertension patients. The results showed many 
deviations from the guidelines, which could seriously affect the patients' health and 
which could make patients quit their treatment. Some physicians prescribed direct 
vasodilators for angina patients – sometimes even for minor cases - and they 
prescribed non-recommended drugs.  These drugs might not be tolerated by patients, 
who could eventually abandon their prescribed treatment. A study conducted on the 
Praslin Isalnd of Seychelles, indicated that provider-related factors contributed to 
patients’ non-adherence to anti-hypertension treatment. The health care providers’ 
characteristics included patients’ lack of confidence in their health care providers’ 
competence, providers’ lack of patience and listening skills, being respectful, not being 
calm, and not explaining the condition clearly (Brobeck, Odencrants, Bergh & Hildingh 
2013:374; Barnett, Vasileiou, Djemil, Brooks & Young 2011:342; Edo 2009:52). If the 
health care provider is patient,  is a good listener, respectful, calm, confident, clearly 
explains the condition to the patients, the these patients might trust and feel safe in the 
hands of such a health care provider and might adhere to the prescribed treatment 
regimen. Schroeder, Fahey and Ebrahims’ (2008:7) systematic review  showed that 
physicians introduced complicated dosing regimens, prescribed complex treatment 
protocols without consideration of patients’ lifestyles or the cost of treatment, 
maintained poor therapeutic relationship with their patients, were unaware of the 
various reasons that caused poor adherence, did not conduct interventions to address 
these factors, did not explain the condition, treatment, and/or benefits of treatment and 
complications to patients.  
 
Medication-related factors  
 
Hypertension is a condition that requires a patient to take drugs for a lifetime because 
they do not cure hypertension but regulate, inhibit or facilitate the body’s mechanisms 
to control blood pressure levels (Lewis et al 2011:88).  As patients take these drugs 
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they might experience many problems, referred to as medication-related factors. These 
problems include lifelong swallowing of drugs, large number of pills to swallow, side 
effects, disruption of activities of daily living, medication errors and the cost of drugs, 
taking three anti-hypertension drugs, the primary level of education and other diseases 
such as heart failure (Mweene et al 2010:253). For example patients who are taking 
one type of drug, once a day, monotherapy, tend to be more adherent than those who 
take multiple drugs per day. However, less than half of the patients will attain the 
recommended level of blood pressure targets using monotherapy as most people 
require at least two anti-hypertension drugs.  On the other hand, patients who achieve 
low blood pressure readings, could see the achievements as a benefit.  The benefits 
could further motivate them to be more adherent.  Ramli et al (2012:613) reported that 
adherence levels decreased with an increase in the number of pills to be swallowed 
daily and with more complicated dosing regimens.  
 
In, Heidelberg, Germany, a study aimed to evaluate patients’ self-reported attitudes 
towards medication-related factors, known to impair adherence in 110 primary care 
patients.  The results showed that tablets with a once-daily dosage and drugs taken in 
the morning and evening improved adherence, whereas drugs taken at 12 noon and 
drugs taken independently of meals were least preferred (Witticke, Seidling, Klimm & 
Haefeli 2012:679. That the number of tablets and when they needed to be swallowed 
has an influence on treatment adherence was also reported by Mweene et al 
(2010:253).  
 
Maimaris et al’s (2013:100) system review study showed that the health financing 
system was a factor that influenced adherence levels. Patients who were on health 
insurance had their blood pressures controlled more than those who were self- 
sponsored. In addition, in countries with adequate funding for health and available 
drugs, patients’ blood pressures were consistently better controlled than in countries 
where drug supplies were irregular. 
 
Disease-related factors 
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Some patients with hypertension do not experience any symptoms relating to the 
condition because it is asymptomatic (Holt et al 2010:481).  Therefore they might feel 
well and healthy they might not seek medical help due to the nature of the disease. 
Other diseases, such as, heart failure might necessitate treatment with Digoxin. This 
drug might cause weakness and lethargy to the extent that patient might not have the 
energy to swallow anti-hypertension drugs (Mweene et al 2010:253). These are 
referred to as disease-related factors (Turki & Sulaiman 2010:29) making it difficult to 
access a health facility. This is one of the possible reasons why patients with 
hypertension might collapse and die silently (Hussain et al 2011:9; Nelms et al 
2011:289).  
 
However, Hareri and Abebe (2013:5), at Tikur Hospital, Addis Ababa assessed 
patients’ adherence to their anti-hypertension medications and associated factors. The 
286 systematically sampled respondents completed structured interviews. An 
adherence rate of over 69.0% was reported. The report also indicated that 68.2% of 
those, regardless of gender, had a higher adherence rate of 50.7%. This could be 
attributed to the fact that married couples could remind each other about taking their 
drugs as scheduled. In addition, the current work status of the patients included 
government employment, unemployed persons, private business people, retirees and 
housewives. Of the 36.0% employed by government, 28.3% were adherent and 7.7% 
were non-adherent.   
 
Another factor that influenced adherence was the type of health facility attended. 
These were government, private hospital and clinic. Those who attended the 
government hospitals (63.2%) had their adherence levels increased in comparison with 
those attending other facilities.  Of these, 45.9% were adherent and 17.3% were non-
adherent. This could be attributed to the type of services offered in government 
facilities and to available equipment, staff and drugs. Similarly, the duration of 
treatment influenced patients’ adherence levels.  The durations listed were less than 2 
years, 2-4 years then five years and more. Of those who had been on treatment for five 
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years and more, 46.5% were adherent and 15.8% were non-adherent. The explanation 
could be that with time the patients had perceived the benefits of treatment.   
 
Services factors 
 
Patients who live with hypertension experience some problems related to the nature 
and availability of services. The factors are grouped according to the nature and 
availability of services factors that improve or decrease patients’ adherence levels to 
their anti-hypertension treatment regimens. 
 
The advantages of adequate adherence include the patients’ feelings of wellbeing as 
the symptoms are allayed and the risk of developing complications is reduced. The 
individual is able to do activities of living for personal and family development (Saleem 
et al 2011:836).  
 
To emphasise the importance of treatment adherence, the WHO published evidence-
based guidelines for clinicians, health care managers, and policy makers for countries 
to improve strategies for achieving medication adherence (Sabate 2003:1987).  
 
2.3.1  Cigarette smoking and hypertension 
 
A study was conducted by Li et al (2010:93) in China among the Mongolian population.  
The background to the study was that the relationship between smoking and 
hypertension was still not known. The study aimed to examine the effects of smoking 
on blood pressure. A total of 2 589 people aged 20 were recruited. Demographic data, 
lifestyle factors, family history of hypertension and physical examinations were 
recorded and analysed. The results showed that blood pressures among non-smokers 
was lower than among smokers.  
 
2.3.2     Stress and hypertension 
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Stress is defined as a response to environmental demands placed on one’s body and 
mind. Stress can also be caused by a wide variety of emotional and psychologic 
events. The adrenaline causes stimulation of the sympathetic nervous system activity 
which leads to increased cardiac output and increased heart rate, peripheral 
vasoconstriction and this raises the blood pressure. The mind influences every part of 
the body. Hence, stress has significant effects on one’s health and well-being. Stress is 
one of the leading factors of hypertension, cancer, suicide, accidents and deaths 
(Lewis et al 2011:742). A study, compared smokers with non-smokers in a population 
of employees of a large US institution.  Multivariate regression models were used to 
compare data by active or never-smoker status for preventive care services; and 
medication adherence for chronic conditions. Adherence to chronic medications for 
hypertension was significantly lower among smokers. While not statistically significant, 
smokers were consistently less adherent to all other medications than non-smokers 
(Sherman & Lynch 2014:447). 
 
2.4      TREATMENT ADHERENCE IN PATIENTS WITH HYPERTENSION 
 
Treatment adherence is reported to be higher among patients with acute conditions 
such as malaria, pneumonia and flu than among patients suffering from any chronic 
condition, requiring daily lifelong treatment.. The pain perceived by the patients from 
the symptoms of acute conditions, prompts them to take the medication to get rid of the 
symptoms and feel better.  The treatment for acute conditions is prescribed for a short 
period of time such as two, five, seven or fourteen days.  On the contrary, adherence is 
reported to be lower among patients with chronic conditions, such as hypertension.  
The reasons are  the assymptomatic nature of the chronic condition (Sulaiman et al 
2009:43 and the taking of anti-hypertension drugs for a lifetime. Reportedly, many 
patients  discontinue their medication within six months of commencing the treatment 
as they might experience swallowing of drugs to be tiresome (Osterberg & Blaschke 
2005:487).  In some trials there have been adherence rates of 43%-78% among 
patients who were receiving treatment for chronic conditions while adherence with 
lifestyle modifications was as low as 10% (Osterberg & Blaschke 2005:487).  Many 
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studies focused on adherence issues related to patients’ behaviours.  However, the 
difficulty to measure adherence accurately, is another challenge because adherence 
measurement tools are not accurate because they have advantages and 
disadvantages.  Some tools are expensive, such as collecting blood specimens, while 
others are cheap such as checking patient’s records. The individual is able to do 
activities of living for personal and family development. The disadvantage of non-
adherence is the persistent hypertension (Saleem et al 2011:836) with the risk of 
developing complications and consequencial death.  Esler, Schwarz and Alvarenga 
(2008:175) reported that mental stress is a cause of hypertension and other 
cardiovascular disease.  
 
The WHO (2003:107) defines non adherence as the extent to which a person’s 
behaviour of taking medication and following a diet and/or executing lifestyle changes 
does not correspond with the regimen prescribed by the health care provider.  The 
Seventh Joint National Committee guidelines reported that non-adherence to 
prescribed treatment is a major barrier to achieving adequate blood pressure control 
(Chobanian et al 2003:2560). Non-adherence compromises treatment effectiveness 
causing uncontrolled hypertension. In the United States of America the national health 
and nutrition examination survey revealed that non-adherence with non-
pharmacological and pharmacological therapy was the cause of the limited blood 
pressure control (Gerin et al 2007: 460). There are several forms of non-adherence 
behaviours.  These include ommisions or missed daily or weekly doses, delayed, early 
taking, halving doses, doubling doses and defaulting treatment (Osterberg & Blaschke 
2005:487). Non-adherence is a major factor of uncontrolled hypertension in more than 
two thirds of hypertensive individuals (Bastos-Barbosa, Ferriolli, Moriguti, Nogueira, 
Nobre, Ueta & Lima 2012:636; Rachel, Bastos & Nereida Kilza da Costa 2006:36). 
 
Globally 69.0% of the population on anti-hypertensive treatment have controlled blood 
pressures. Those with uncontrolled blood pressure have frequent hospital outpatient 
visits with symptoms (Saleem et al 2011:836).  The persistant symptoms lead to the 
development of complications, injury and failure of the vital organs such as the brain, 
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eyes, heart and the kidneys.  The failure of one organ leads to failure of other organs 
because they work in coordination under the autonomic nervous system (Lewis et al 
2011:743).  Organ injury increases the morbidity and mortality rates attributable to 
hypertension.  This has direct and indirect costs to the individual, family and health 
care system (Osterberg & Blaschke 2005:487).  
 
2.4.1    Patients’ perceived susceptibility to complications of hypertension and       
            their treatment adherence 
 
Understanding patients' perceptions of hypertension and its complications is important 
for effective management.  A study  was conducted in Delhi, India to elicit perceptions 
of the settled migrants by Kusuma (2009:267).  The results showed that migrants 
perceived hypertension as a common, symptomatic and serious health problem in the 
community.  They identified city life of pollution, stress, high fat diet coupled with 
physical inactivity and some attitudes as contributing factors to the development of 
hypertension.     
 
In the USA, a national health and nutrition examination survey found that 72.0% of 
patients with hypertension were being treated. Those who had their blood pressure 
well controlled below 140/90 mmHg were 69.0% of those being treated. The shortfall 
has been attributed to a lack of adherence to treatment regimens (Mazzaglia et al. 
2009:1598). In a systematic review of 25 studies, the results showed a lack of 
convincing empirical evidence to support the hypothesis that inadequate control of 
blood pressure was attributed to poor treatment adherence (Schroeder et al 2008:7). 
However in a study by Hassan, Hasanah, Foong, Naing and Awang (2006:24) in 
Malaysia, the results showed that about 56.0% of drugs which were prescribed by the 
physicians were not taken as prescribed. The consequence was that there were 
frequent hospital admissions among patients suffering from hypertensions.  Sulaiman 
et al (2006:38) reported that one third of patients with hypertension admitted to hospital 
had a history of poor adherence. Stafford, Jackson and Berk (2008:946) reported that 
poor adherence to medication was a factor contributing to hospital admissions.  On 
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assessment of adherence by the Morisky scale, there was a statistically significant 
result that showed a much higher level of hospitalisation among patients who had poor 
adherence levels (M=4.50, SD = 0.384) compared with patients who were adherent 
(M=2.82, SD =1.486) which meant less frequent hospitalisations were more likely 
among adherent patients.  Patients who maintained their adherence rate at 80-100% 
were less likely to be hospitalised as they had controlled blood pressures.   In Scotland 
the treatment adherence rate was 91.0% while Pakistan’s was 77.0% (Stafford, 
Jackson & Berk 2008:946). 
 
A study in the USA (Epstein, Sherwood, Smith, Craighead, Caccia, Lin, Babyak, 
Johnson, Hinderliter and Blumenthal (2012:1764) aimed to determine factors that could 
predict adherence to dietary approaches to reduce hypertension (DASH). The results 
showed ethnicity to be a predictor of adherence to DASH and there was an increase in 
adherence to the DASH among African Americans less likely to be adherent to eating 
plans compared with those of whites.  A dietary adherence of 95.0% showed a 
reduction in blood pressure. 
 
Perceived susceptibility refers to patients views of the risk of having a condition such 
as hypertension or its complications such as a heart attack, kidney failure, or strokes 
(Glanz et al 2002:48).  Hypertension is an asymptomatic condition and patients have to 
believe that they are susceptible to develop complications with or without experiencing 
symptoms. Such a perception can only be based on sound knowledge about the 
condition.  Patients with knowledge of the nature and course of hypertension, the 
possible risks associated with treatment non-adherence would be more likely to 
perceive themselves as being susceptible to complications.  According to the HBM,  
patients with hypertension who feel susceptible to complications would be more likely 
to adhere to treatment regimens than those who do not (Edo & De Villiers 2009:52; 
Glanz et al 2002: 48).   
 
The likelihood of hypertensive patients’ adherence to their treatment, depends on the 
degree to which they perceive themselves to be susceptible to complications. In 
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addition, their perceptions of the severity of the complications is weighed against the 
benefits expected from the adherence to the prescribed treatment regimen and the 
barriers they need to overcome. The HBM hypothesises that in a patient with 
hypertension, a high perceived threat; low perceived barriers and a high perceived 
benefit would result in the likelihood of exhibiting adherent behaviour. However, the 
final outcome of the decision would be determined by the patient’s analysis of various 
factors. 
 
Kusuma (2009:268) in New Delhi, India, aimed to understand perceptions of patients 
with hypertension among immigrants using a qualitative design. The results showed 
that the condition was perceived as being a condition that reduces physical activity. 
That it was a result of overweight and eventually it causes weakness and shortness of 
breath. The patients’ perceptions of the condition were based on symptoms. The 
migrants would resort to bed rest which would not be addressing the condition but only 
relieving the symptoms temporarily. Patients lacked knowledge about hypertension, 
and could not understand its potential complications. 
 
Kaplan’s (2005:13) study showed that the lack of knowledge about the susceptibility for 
developing severe complications from hypertension, the severity of the complications, 
benefits of adhering to the prescribed lifestyle modification and medicines, barriers to 
treatment adversely influenced patients' treatment adherence levels.  
  
2.4.2  Patients’ perceived severity of complications of hypertension and their 
treatment adherence 
 
Perceived severity refers to the extent to which persons judge a condition such as 
hypertension to be serious.  Perceived severity is the judgement of the ability of a 
condition to cause morbidity, disability and mortality (Glanz et al 2002:48).   
 
According to the HBM, patients who perceive the complications to be serious would be 
more adherent with medication and lifestyle modifications than those who do not hold 
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such perceptions. Under perceived severity, the patients were asked whether or not 
they perceived the complications of hypertension to be severe. 
 
Daugherty et al (2012:303) in Colorado, conducted a study to examine the association 
between treatment adherence, intensification, and control of hypertension.  These were 
patients who had uncontrolled hypertension.  
 
The results showed that among the patients who enrolled in the study, and who 
recieved increased treatment intensity had their blood pressures under control after 
one year. There was an association between perceived severity of uncontrolled 
hypertension and treatment intensification but non-adherence was significantly 
associated with the absence of blood pressure control.  
 
 
2.4.3 Patients’ perceived benefits of adhering to anti-hypertensive treatment 
 
Patients, who adhere to their prescribed antihypertension treatment regimens perceive 
more benefits of such adherence than those who do not hold such perceptions. 
Patient-related perceived benefits include the beliefs which hypertensive patients hold, 
that a proposed course of action would be effective in reducing the potential threats.  
Such perceptions are based on patients’ knowledge about hypertension and its 
potential complications.  Other benefits included relief from symptoms, enhanced 
wellbeing and an ability to do household chores. 
 
Holt et al (2010:484) examined the association between health-related quality of life 
and anti-hypertensive treatment adherence in older adults.  The MMAS-8 was used to 
assess anti-hypertensive treatment adherence. The results showed that the patients 
who scored high on the health-related quality of life had a higher adherence level to 
anti-hypertensive treatment. When a patient perceived a benefit, it motivated the 
patient to adhere to treatment; the greater the perceived benefit, the higher the 
adherence rate. 
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Akazawa and Fukuoka (2012:124) investigated the economic benefit of switching to 
fixed dose anti-hypertension combination (FDC) therapy among Japanese patients in 
Tokyo. This was a retrospective cost analysis study.  Data were collected from 64 
community pharmacies located in Tokyo that were used to identify hypertensive 
patients under continuous treatment with angiotensin-receptor blockers (ARBs).  
Patients  switching  to  FDC  between  December  2010  and  April  2011  were  
compared  to patients who did not switch treatment regimens (control group).  Changes 
in annual anti-hypertensive drug costs were compared.  Sub-population analyses were 
performed; pre-index treatment patterns and prescribers’ characteristics were 
considered. The results showed a significant difference in anti-hypertensive drug use 
patterns before the combination and after.  The switch to FDC was associated  with  an  
annual  saving  of  10 420  yen  (US$112.0)  in  anti-hypertensive drug  costs.  Patients 
found a benefit in using the fixed dose combination therapy, because it was cheaper, 
and this improved its usage and controlled their hypertension. Thus, the benefit of 
reduced cost promoted patients’ adherence behaviours. 
 
2.4.4  Patients’ perceived barriers to taking anti-hypertensive treatment and 
treatment  adherence 
 
Patients with hypertension might perceve barriers to taking treatment as being  related 
to obstacles standing in the way of executing the required health bebaviour. These 
perceived barriers relate to patients, physicians, disease, and medications (Ramli et al 
2012:614).  Patients who perceive more barriers, are expected  to be less likely to 
demonstrate adherence behaviour than those who perceive fewer barriers (Glanz et al 
2002:48).  
 
Patient-related barriers 
 
Patient-related barriers are a result of patients’ gender, beliefs, culture, religion and 
personal values, attitudes, feelings and economic status, educational level, occupation, 
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fear of pain or any discomfort. According to Osterberg and Blaschke (2005:491), when 
patients start treatment they tend to adhere during the first few weeks because they 
intend to get rid of the illness experiences of the hypertension, until they feel better. 
The good response patients get from treatment makes them feel “cured” and then they 
quit treatment without the doctor’s consent. In addition, some patients become 
complacent and they stop adhering to the treatment regimen.  In a study by Mweene et 
al (2010:252), the patients reported the following barriers to anti-hypertension 
treatment adherence: lifelong duration of therapy, symptomless nature of the condition, 
side effects of the drugs. The examples of side effects included headaches, heart 
palpitations, dizziness, drowsiness forgetfulness, complicated drug regimens, lack of 
understanding about hypertension management, non-availability of drugs, and distance 
to the health facility, forgetting, lack of knowledge and information, omission and 
having other priorities. In  studies (Ambaw et al 2012:282; Edo 2009:62; Munro, Lewin, 
Stewart & Volmink 2007:5; Mweene et al 2010:253) gender, distance from the hospital, 
number of co-morbidities, side effects of drugs, poverty, lack of resources and 
unemployment were reported as factors that barred patients from adhering to their 
treatment regimen.  
 
Hussain et al (2011:10) conducted a study to determine the prevalence, awareness, 
treatment and control of hypertension in India’s Rajshahi and in Bangladesh during 
2006-2007. The results showed these participants’ characteristics: 69.2% were males, 
32.5% had no education, 19.2% had primary education, 29.2% had secondary 
education and 19.0% had bachelor’s degrees. The majority (77.5%) were poor farmers.  
As many as 85.0% were non-adherent, 75.0% knew that uncontrolled hypertension 
could cause strokes and heart disease, 15.0% knew that it could cause retinopathy and 
peripheral vascular disease.  
 
The patient- related barriers to treatment included forgetfulness and missing drugs 
from one day to one week to the whole month. Meanwhile, one third, who were 
reportedly knowledgeable about hypertension perceived that it could lead to kidney 
injury; one third knew that exercises help to control blood pressure. However, such 
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knowledge and perceptions did not help them to improve their adherence levels. Two 
thirds reported family members as providing support in reminding them about re-
supplies, two thirds stated that they attended follow up clinics only when they felt 
symptoms of hypertension. Some patients (78.0%) never attended a follow up clinic. 
Reasons given for missing appointments included feeling well (37.0%), poverty 
(29.0%), visiting homeopaths (38.0%), and visiting traditional herbalists (25.0%). 
 
Physician-related barriers 
 
Patients might not go to see physicians because physicians might not be easy to 
reach, physicians might fail to explain the prescribed drugs actions, benefits and side 
effects to the patients (Hussain et al 2011: 10; Maghrabi,  2013:120; Osterberg & 
Blaschke 2005:489).  
 
 
Disease-related barriers 
 
Patients might  experience problems related to the treatment regimens prescribed for 
them. The study findings of Edo and De Villiers (2012:5) in the Seychelles, showed that 
the patients’ greatest disease-related barriers were the lack of discipline to stop 
smoking and to comply with the required dietary restrictions, lack of time to relax and 
sleeping problems, lack of motivation to continue swallowing drugs when they knew 
that the disease was incurable, the ineffectiveness of the medicine to stabilise the 
blood pressure, having no time to exercise and failure to see the value of exercise and 
hypertension control.  
 
Medication-related barriers 
 
The complexity of the treatment regimen, the number of tablets that need to be taken 
and the side-effects of the drugs might pose barriers to continuing treatment.  Complex 
dosing schedules, frequent changes of medications and high costs of drugs aggravate 
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any perceived barriers. Providers did not explain to the patients how the drugs control 
the hypertension, and that patients believed that hypertension could be cured with local 
herbs (Edo 2009:123). 
 
Health care systems, structures and process  
 
The financial standing of the facility to buy drugs, the distance to the facility, the 
complicated structure of the facility where patients have trouble locating the various 
rooms for consultation or pharmacy or physiotherapy. When the patients perceive 
barriers to out-weigh the perceived benefits, then patients will be less likely to adopt 
and maintain the behaviour of adhering to anti-hypertension treatment.  
 
The standard WHO regimen for treatment aims to achieve control of hypertension and 
it involves using a combination of drugs. The more pills that have to be swallowed, the 
greater the likelihood of non-adherence. However, perceived barriers imply that the 
patients who perceive that there are negative consequencie such as physical, 
psychological or financial costs, and that the costs out-weigh the expected benefits, 
might not adhere to the advised health actions. Osterberg and Blaschke (2005:490) 
identified the following barriers that influenced patients not to adhere to their anti-
hypertensive treatment: forgetfulness (30.0%), other priorities (16.0%), decisions to 
omit doses (11.0%), lack of information (9.0%) and emotions (7.0%). 
 
Health worker and family support 
   
Patients require support from their health workers and family members to adhere to 
their anti-hypertensive treatment regimens. The patients accept that the condition was 
theirs, but they regarded the management of hypertension to be a shared responsibility 
(Edo 2009:124). The health workers are responsible for explaining how the drugs work. 
They must explain how the prescribed diet and exercise can help to reduce blood 
pressure. 
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Other barriers to treatment adherence included missed doses of the prescribed drugs 
as the other family members did not remind them since some medications cause 
drowsiness, missed appointments due to lack of transport and lack of family 
accompaniment; living at a distance of more than 10 kilometres from the hospital and 
taking three anti-hypertension drugs, illiteracy and other diseases such as heart failure. 
In addition, some patients reported that when they felt better, they decided to quit the 
anti-hypertension treatment (Mweene et al 2010:253). 
 
Many patients with hypertension remain unaware of the condition and its complications 
in both developed and developing countries (Msyamboza et al 2011:4). In addition, 
some patients stop taking treatment because they say that, it makes them feel worse 
because of the side-effects, or their non-responsiveness/non-effectiveness to the 
prescribed treatment regimen. Some patients, reported mere carelessness with their 
lives by having negative attitudes towards life while other patients reported financial, 
cultural, and spiritual factors as well as poor patient-provider relationships (Edo 
2009:62; Mazzaglia et al. 2009:1598; Osterberg & Blaschke 2005:487;  Saleem et al 
2011:126) .    
 
Knowledge about hypertension and beliefs about medications might enhance or impair 
adherence to their treatment regimens. In addition culture, gender, age, health status 
and religion have been linked to adherence in health care settings. For example, 
cultural belief systems and religion of patients might support the use of traditional 
healers, thereby, causing conflict with Western medicine.  Some patients older than 45 
years of age might experience some altered mental states caused by hypo-perfusion 
and body weakness (Lewis et al 2011:743). This might also influence their adherence 
behaviour due to memory and energy loss. This is also true for patients who have heart 
disease as a complication of the hypertension.  
 
Therefore, there are many patient-related factors that could influence them not to 
adhere to their treatment regimen. These include the patients’ internal and external, 
emotional, attitudinal and demographic factors, such as, gender, age, educationan 
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level, occupation, religion and tribe or ethnic group. Osterberg and Blaschke 
(2005:487) reported that it is important for health care providers to involve patients with 
hypertension closely, in the management, to identify adherence barriers that patients 
might experience quickly and to  intervene appropriately. 
 
Kara, Caglar and Kilic (2007:243) correlated patients’ non-adherence with diet, fluid 
restrictions and the level of perceived social support in haemodialysis patients.  Data 
were obtained from 160 patients in three haemodialysis canters in Turkey between 
March and May 2006.  The results showed that barriers to treatment adherence in 
most patients were age, marital status, mostly among younger married patients, lack of 
family and friends’ support.  
 
The study in Nigeria by Chiazor and Oparah (2011:139) aimed to describe and 
compare the treatment pattern of patients with hypertension and assessed patients’ 
risk factors.  A validated 9-item instrument was used over a period of four months.  The 
results showed the following risk factors for hypertension patients, obesity (74.1%); 
stress (56.0%); overweight (37.5%); smoking (32.0%); salt intake (26.0%) and alcohol 
(24.0%).  More than half (53.5%) had blood pressure readings exceeding 160/100 mm 
Hg, showing a relationship between obesity and hypertension.  The hypertension 
readings provided an indication of the patients’ non-adherence behaviours. 
 
2.4.5   Patients’ cues to action for  adherence to anti-hypertension treatment 
 
According to Glanz et al (2002:48), cues to action refer to factors that could drive, 
motivate or prompt an individual to feel the need to take an action. These drivers could 
be internal or external. Internal factors might be the manifestation of the condition while 
external factors are  advice from friends, family members, books, media such as the 
radio and television.   
 
In a study conducted by Chen et al (2011:32) in Taiwan, guided by the HBM, aimed to 
understand the factors that influenced the caregivers to take their underfive children for 
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the childhood influenza immunisations. The results showed that the caregivers’ cues to 
action were the recommendations from the mass media, and also from nurses and 
doctors, which influenced them when they adhered to taking the chilren for influenza 
immunisations. 
 
2.4.6   Patients’ self efficacy and likelihood of adherence to their anti- 
hypertension  
          treatment regimens 
 
The HBM proposes that hypertensive patients with higher levels of perceived self-
efficacy might be more adherent to medications and lifestyle modifications than those 
with lower levels of self-efficacy. Many patients know the type of anti-hypertension 
actions they need to take, such as weght loss, smoking cessation, and participating in 
exercises.  However, knowledge only is insufficient to stimulate behaviour. Patients 
need to believe in their capability and have confidence to perform the expected 
behaviour. Health professionals might use verbal persuasion and expressive 
encouragement to stimulate self-efficacy in their patients (Glanz et al 2002:48).   
 
2.5 CONTEXTUALISING THE LITERATURE REVIEWED WITHIN THE HEALTH  
           BELIEF MODEL 
 
The studies reviewed have highlighted various factors that affect patients’ adherence. 
The main grouping of the factors were based on the six concepts of the HBM: patients’ 
perceived susceptibility to potential complications of hypertension, patients’ perceived 
severity of complications, preceived barriers to treatment adherence and cues to 
action. 
 
The reviewed literature has exposed some factors which could influence patients from 
being adherent to their anti-hypertensive treatment. These barriers were further 
grouped according to the adherence model factors which are related to the following 
aspects: patient/family, health care system, health care provider, medication, disease 
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and the nature and availability of services. The patient-family related aspects were 
internal, such as, awareness, understanding of the condition and treatment, ability to 
control own hypertension, age, marital status, family and friends’ support, being newly 
married, and the level of perceived social support (Kara et al 2007:213).  Health care 
provider-related, and physician-related factors, included a lack of patience, not 
listening, not being respectful, providing no explainations of the condition, lack of 
experience and lack of confidence (Osterberg & Blaschke 2005:490). The provider-
related factors included the expenses for physician’s fees, diagnostic tests and 
medicines (Saleem et al, 2011:386). 
 
Factors that barred patients from being adherent included health facility and family 
support, limited family income, low level of knowledge, conflict between cultural beliefs 
and Western medicines (Kazembe 2007:62; Gatti et al 2009:650). Understanding 
regarding the disease, its consequences, side effects of the drugs, benefits of 
controlling  blood pressure levels, someone to accompany the patient to the hospital, 
lack of patient education regarding complications influenced patients’ adherence 
behaviours adversely (Hussain, et al 2011:10). The other barriers listed in previous 
studies included patients’ forgetfulness, being too busy, travels, hospitalisation and/or 
sickness, the inability to to get to the pharmacy, and events that interfered with the 
patients’ daily routines. Some factors were related ot the clinic, physicians and nurses 
(Nair et al 2011:199).  
 
The results showed that health care provider-related factors contributed to patients’ 
non-adherence to their anti-hypertension treatment. The health care providers’ 
characteristics included patients’ lack of confidence in their health care providers’ 
competence, providers’ lack of patience and listening skills, being respectful, not being 
calm, and not explaining the condition clearly (Ambaw et al 2012:282; Barksdale 2009: 
57; Edo & De  Villiers  2009:52). If the health care provider is patient,  is a good 
listener, respectful, calm, confident, clearly explains the condition to the patient, these 
patients might trust and feel safe in the hands of such a health care provider and might 
adhere to the prescribed treatment regimen.  Schroeder et al’s review  (2008:7) 
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showed that physicians introduced complicated dosing regimens, prescribed complex 
treatment protocols without consideration of patients’ lifestyle and cost of treatment, 
maintained poor therapeutic relationships with their patients, were unaware of the 
various reasons that caused poor adherence, did not conduct interventions to address 
these factors, did not explain the condition, treatment, and/or benefits of treatment and 
complications to patients. The prescribers did not follow the standard treatment 
guidelines contributing to patients’ final abandonment of their treatment (Ekesbo et al 
2012:35).  
 
2.6    SUMMARY 
 
This chapter presented a review of previous studies done in the area of hypertension  
treatment adherence, related literature and the HBM. The literature was mostly from 
elsewhere as minimal research has been conducted in Malawi. Most of the studies 
reviewed looked at adherence and non-adherence, none looked at levels of 
adherence.  The literature review was contextualised within the major tenets of the 
HBM. 
 
The next chapter will present the research design: the study setting, study population, 
sample, sampling design, sampling frame, selection and calculation of sample size, 
sampling, sample selection procedure, research instrument, data collection procedure, 
pre-testing the research instrument, refinement of instrument, data collection 
technique, validity and reliability, data analysis and the methods of statistics that were 
used; dissemination of findings, ethical considerations and limitations of  the study. 
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CHAPTER 3 
RESEARCH DESIGN AND METHOD 
 
3.1       INTRODUCTION 
  
This chapter presents the methodology of the study, the strategy used by the 
researcher to collect, analyse and interpret data in the course of the study (Leedy & 
Ormrod 2010:182).  It covers the study design, setting, population, sample and 
calculation of the sample size, sampling design, sampling frame, selection and 
calculation of sample size, sampling method, sample selection and procedure, 
research instrument, data collection method, procedure, pre-test of instrument, 
recruitment of 10 research assistants, data collection technique, validity and reliability 
of the design, validity and reliability of the instrument, data analysis, dissemination of 
the findings, ethical considerations, study limitations and conclusion. 
 
3. 2 RESEARCH DESIGN 
 
According to Burns and Grove (2011:536) a research design is defined as, “a blueprint 
that is developed for conducting a study to answer a research problem".  The main aim 
of the research design is to maximise control over factors that could interfere with the 
validity of the study findings.  The researcher used a quantitative, descriptive design to 
quantify hypertension patients’ treatment adherence levels, using the Morisky 
Medication Adherence Scale.  
 
A quantitative research design is defined as a positivist scientific method that uses 
numerical data, a set of orderly, disciplined procedures to obtain information.  It 
maximises precision and validity by providing control mechanisms that eliminate or 
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minimise the researcher’s and respondents’ biases.  The data collection is systematic, 
formal and it uses structured tools to gather empirical evidence directly or indirectly.  
Statistical packages are used for data analysis and the design allows for deductive 
reasoning, so that the findings can be generalised to individuals other than those who 
participated in the study, provided that a random sampling method had been used.  In 
addition, it generates further topics for research.  In this study, the researcher chose a 
quantitative design because it best suited the study’s intention, which was to 
investigate the level of treatment adherence in patients with hypertension according to 
MMAS-8, quantify them as low, medium and high, identify and rank the factors that 
influence treatment adherence and describe these factors (Polit & Beck 2010:16; 
Gliner, Morgan & Leech 2009:7). 
 
A descriptive study, according to Polit and Beck (2010:552) is defined as research that 
aims to accurately present the characteristics and frequencies of occurrence of a 
phenomenon of a person, groups or situation.  In this study, the researcher chose a 
descriptive design because it best met the aim of the research which was to establish 
and describe, levels of adherence of patients to their anti-hypertensive treatment 
regimens, and rank their influencing factors. The design accurately described the 
characteristics of patients and factors that influenced their treatment adherence levels 
according to the MMAS-8, rank and describe the factors that influence adherence.  
 
3.2.1 Study setting 
 
Polit and Beck (2010:568) define the setting as,” the physical location and conditions in 
which data collection takes place in a study”.  In this study, the site was QECH 
hypertension clinic in Blantyre.  The clinic is located within the hospital's out-patient 
department.  This is the only established hypertension clinic in the southern region of 
Malawi (at the OECH referral hospital).  The clinic is managed by specialists from the 
College of Medicine who diagnose and treat patients with hypertension. These patients 
are referred from both urban and rural areas of the southern region of Malawi from 
government, CHAM and private hospitals for further management. The hypertension 
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clinic manages chronic and acute hypertension patients. The environment was not 
manipulated for the study. The researcher chose this site because the clients and 
potential respondents were patients with hypertension on treatment regimens.   
 
3.2.2  Study population 
 
Burns and Grove (2011:290) define a population as a particular group of individuals, 
which is the focus of the research.  In the current study, the population which the 
researcher was interested to study comprised patients suffering from hypertension. 
The population could be further sub-divided into the target population, to which the 
study’s findings could be generalised and the accessible population comprise those 
individuals who can be accessed to participate in the study.  In the current study the 
target population comprised hypertensive patients who attended the QECH 
hypertension clinic to whom the researcher could generalise the study findings. The 
accessible population comprised the patients attending the hypertension clinic at the 
QECH on the Fridays when 10 research assistants conducted interviews at this clinic. 
 
The hypertension clinic at the QECH was the only one in the southern part of Malawi 
(MDHS 2010), implying that patients were referred to this clinic from 18 hospitals and 
clinics throughout southern Malawi. The total population of patients served by all these 
clinics was unknown although the population of Blantyre was estimated to exceed 
1 000 100 during 2010 (MDHS 2010). 
 
The exact population of hypertensive patients being treated at this clinic was unknown, 
but it was estimated as follows: 
• 100 appointments are made for patients on Fridays 
• 400 patients receive treatment at the clinic per month 
• most patients receive anti-hypertensive treatment for three months 
• 1 200 (approximately) patients are therefore treated at the OECH hypertension 
clinic. 
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3.2.3  Sample 
 
A sample is defined as a group of people that is selected to represent the population 
(Burns & Grove 2011:290). 
 
3.2.3.1 Sampling design 
 
Sampling is defined as, a process which selects a representative portion of the entire 
population (Polit & Beck 2010:307).  In this study, the researcher used probability 
sampling, the simple random sampling design to get the representative sample.  
According to Polit and Beck (2010:313) simple random sampling is considered as the 
most basic probability sampling design and is the most effective, in selecting a 
representative sample. The researcher chose it because it gave all patients with 
hypertension a known chance of being included in the study (Polit & Beck 2010:313), 
therefore it was best suited for the quantitative; descriptive research. 
 
3.2.3.2 Sampling frame 
 
According to Polit and Beck (2010:308), in simple random sampling the researcher 
establishes a sampling frame, which is a technical name for a list of the population.  In 
this study, the practice at the QECH hypertension clinic was that 100 hypertensive 
patients were booked for the hypertensive clinic every Friday. This appointment 
booking list was used as a sampling frame fromh which the respondents were 
selected. 
 
3.2.3.3 Selection and calculation of sample size 
 
As a quantitative study, a large sample was required for representativeness and 80% 
power to detect the assured difference of 15% (Fox, Hunn & Mathers 2009:17) and to 
have a smaller sampling error (Polit & Beck 2010:316). The sample size was 
determined by using the EPI-Info version 3.5.1 and by using an estimation of the 
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educational level of patients with hypertension population. The researcher assumed 
that 75% of the hypertension population has primary education while 25% has 
secondary education, based on the information provided in the Malawi and 
Demographic Health Survey (2010).   
 
If 50% of the patients with hypertension who have primary education have poor 
adherence, and if 35% of those patients who have secondary education have poor 
adherence, then there would be 80% chance of detecting the difference in adherence 
between hypertension patients who have primary and those who have secondary 
education. 
 
Epi-Info version 3.5.1 calculated that 480 patients would be required for there to be 
80% power to detect the assured difference of 15% (Fox et al 2009:17). Given 
specified values of p1 and p2, the standardised difference was calculated as follows. 
              P1- P2 
 √  p(1- p) 
P1 =  0.5 
P2  = 0.35 
^ 
P = 0.425 
d S = Standardised difference  
d S  = 0.5 - 0.35 
         √ 0.425 x (1-0.425) 
      = 0.15 
         √ 0.244 
      = 0.303 
N = 340 for equal group sizes 
k = 3/1 =3 
N'  = N(1+k)2        = 112 x16   =   4 
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                 4k                  12             3 
The nomogram provided by Altman (1991:456) was used to find the sample size (N) 
assuming equal groups sizes.  The adjustment provided by Altman (1991:459,460) was 
used to find the numbers with unequal group sizes (see Annexure O). 
N = 480  
3.2.3.4    Sampling  
 
Sampling criteria imply a list of characteristics that the target population should 
possess to be included in the study (Burns & Grove 2011:548).  In this study, the 
inclusion and exclusion criteria for respondents were: 
 
Inclusion criteria 
 
An individual with a blood pressure reading of at least 140/90mmHg at the 
commencement of treatment, male or female aged 18-90 years, on treatment for a 
minimum of one year, attending the hypertension clinic, in possession of a health 
passbook, able to understand and speak Chichewa or English or both and consenting 
to participate in the study.  
 
Exclusion criteria 
 
Individuals who had not received hypertension treatment for at least one year at the 
participating clinic could not participate in this study because they might have been 
unable to evaluate the treatment they had received and their treatment adherence 
levels might have been influenced by the short duration of their treatment. Those who 
were younger than 18 years were excluded from this study as they could not legally 
sign consent for participating in the study in Malawi.  People older than 90 years of age 
were excluded because it might have been difficult to interview them. Patients without 
health passbooks were excluded because their blood pressure readings and weights 
would have been unavailable and this information was required during the data 
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analysis phase of the study. Only persons who could understand and speak Chichewa 
or English or both could be interviewed as the research assistants could only speak 
these two languages.  Any person who did not wish to sign consent to participate in the 
study was excluded as no one was coerced to participate in the study.  
 
3.2.3.5    Sample selection procedure 
 
Based on the health service delivery system at the QECH hypertension clinic, patients 
were consulted by appointment.  The clinic day was Friday and was managed by five 
clinicians, one registered nurse, two nurse technicians and two clerks.  The patients 
were given appointments by date and not by time.  Therefore, all the patients booked 
on a specific Friday, arrived at the clinic waiting room by six o'clock in the morning and 
were organised on a first-come first-served basis, using the numbers 001-100. The 
patients had a group health education session, followed by blood pressure and weight 
checking before consultation with the clinician.    
 
The researcher recruited and interviewed respondents at the hypertension clinic. The 
clinicians and the nurses were not involved in the recruitment of patients and data 
collection, to avoid bias.  The researcher made an announcement about the study to all 
hypertensive patients in the waiting room after the conclusion of the health education 
session and after their blood pressure and weight checks. The announcement included 
the: researcher's name, title and aim of study, study objectives, sample selection, data 
collection procedure and period, ethical considerations to be observed and how long 
the interview would last. This information was given to help the patients to make 
informed decisions as to whether or not to participate in the study. Voluntary 
participation was emphasised, and that they could withdraw from the study at any point 
without incurring any penalty. The researcher explained to the patients that those 
willing to participate in the study would be interviewed after the clinician's consultation 
but before they went to the pharmacy for treatment refills. This allowed the patients to 
attend to their core business of consultation with the clinician. Conducting the interview 
before the patient collected his/her medicines from the pharmacy was desirable 
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because pharmacists give instructions to the patients.  Interviewing patients 
immediately after receiving medicines and instructions from the pharmacy assistants 
could have influenced their responses on knowledge of drugs.   
 
After explaining the information about the study and responding to questions, a neutral 
person shook the container with 100 pieces of papers and blindly picked 50 pieces.  
The picked numbers represented the randomly selected respondents to be interviewed 
on that specific day. The selected patients were requested to meet the research 
assistant after their clinical consultations. This ensured that 50 respondents were 
interviewed on a specific Friday. 
 
The numbered piece of paper for any patient who declined to be interviewed, or who 
did not turn up for his/her clinic appointment on the designated date, was discarded 
and replaced by another number drawn randomly from the container until 50 
respondents agreed to be interviewed every Friday. This amounted to random 
sampling without replacement or simple random sampling.   
 
Thompson (2012:11) stated: “Simple random sampling or sampling without 
replacement is a sampling design in which n distinct units are selected from N units in 
the population in such a way that every possible combination of n units has an equal 
likelihood to be the sample selected… One may make a succession of independent 
selections from the whole population, each unit having an equal probability of selection 
at each step, discarding repeat selections until n distinct units are obtained”.  Similarly, 
the Statistical Counselling Group of the University of California, Los Angeles (2007) 
state: “In random sampling without replacement, each object in the data set has an 
equal chance to be selected, once selected it cannot be chosen again”.  According to 
Burns and Grove (2011:807) random sampling does not necessarily require that every 
unit in the population should have an equal chance to be selected, by stating: “Random 
sampling techniques [are those] in which each member (element) in the population 
should have a greater than zero opportunity to be selected for the sample..” 
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3.2.4 Research instrument 
 
Polit and Beck (2010:557) define an instrument as a, “device used to collect data such 
as a questionnaire, a test or an observation schedule”.  In this study, the researcher 
used a structured interview schedule to collect data. The structured interview schedule 
was chosen to allow the researcher to assess multiple variables with minimal risks of 
researcher and respondent bias. In addition, it allowed the researcher to employ 
various questioning styles during the face-to-face interviews. This personal contact led 
to a high response rate.  Furthermore, the presence of the researcher assisted with 
clarification of any misunderstood questions to the respondents, which enhanced 
completeness and correctness of data as the respondents chose their responses from 
predetermined response options or described their experiences in their own words.  
The mixture of various types of questioning styles provided an active interaction 
between the parties which ensured easiness of administration. Furthermore, the face-
to-face interview process provided an interaction that prevented boredom to the 
parties. The structured interview schedule also provided the researcher ease of data 
entry and analysis.   
 
3.2.4.1 The structured interview schedule  
     
The structured interview schedule, for this study was developed by the researcher 
based on the literature reviewed and on the concepts of the HBM. 
The instrument had several sections, each measuring different aspects of the 
phenomenon "adherence". The initial "check list" was followed by sections A-F with the 
following subheadings:  
• demographic data  
• knowledge about hypertension  
• knowledge about treatment of hypertension  
• medical, social cultural and reproductive health data  
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• the HBM concepts 
• Morisky Medication Adherence Scale (MMAS-8).  
 
The instrument comprised closed-ended questions and open-ended questions (see 
annexure D). The closed-ended questions required the interviewer to tick from the 
predetermined response options. Items with an option of yes/no and Likert scale items 
were also included.  For the open-ended questions the respondents were allowed to 
phrase their responses in their own words and the interviewers documented their 
responses verbatim. The instrument had the following sections:   
The check list: There were ten items eliciting the specific type of data to be obtained 
from the hypertensive patients' health pass books as previous clinical records (see 
annexure D). The clinical records of the respondents were used because previous 
records contain clinical data that could be used as a reference for comparison. The 
following hypertensive respondents’ clinical records from the health passbooks were 
elicited and recorded in the instrument: the current blood pressure reading, four 
previous blood pressure readings. It also elicited data on the names of prescribed 
medicines, their doses and frequencies. In addition, the appointment dates and drug 
refills, height, weight and body mass index were elicited. The year the hypertension 
was diagnosed and at what age, number of years the patient had been on 
hypertension treatment, year tested for HIV, year started on antiretroviral therapy 
(ART), and the names of the antiretroviral drugs the patient was taking (if applicable). 
Section A: Demographic data comprised 16 items, A1-A16, that elicited the following 
data: age, gender, marital status, ethnic background, religion, level of education, 
occupation, home district, marital status, number of children and referring health 
facility. 
Section B:  Knowledge about hypertension comprised 12 items, B.17-B.28. The 
items elicited data on the patients’ knowledge about hypertension, the signs and 
symptoms, the triggering factors, and what they thought triggered their hypertensive 
condition.  
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Section C: Knowledge about treatment of hypertension comprised 9 items, C29-
C36, and included an open ended question 36a. This section  elicited data on the 
patient's knowledge of the names of their prescribed drugs, doses, the side effects they 
experienced and lifestyle changes that were undertaken to reduce hypertension. 
Section D: Medical, social, cultural, internal and external factors, reproductive 
health history, lifestyle, treatment received comprised 38 items, D37-D74 that 
elicited data on medical, social, reproductive health history, lifestyle, treatment received 
for malaria, bilharzias, liver cirrhosis, cancer and tuberculosis as well as antiretroviral 
drugs. This was deemed essential as the use of over-the-counter drugs, religious, 
cultural and traditional medicines and practices related to hypertension, could influence 
hypertension treatment adherence and outcomes. In addition some drugs could have 
interactions with anti-hypertension drugs hindering their intended effects. 
Section E: The HBM’s concepts comprised 18 items that elicited data on the 
perceptions of hypertensive patients according to the HBMs concepts. These were: 
perceived susceptibility, 4 items; Esu.75-77 and an open-ended item, 77a; perceived 
severity, 4 items; Esev.78-80 and an open-ended item 80a; perceived benefits, 3 
items, Ebe.81-83; perceived barriers, 13 items; Eba.84-86 and  open-ended items 86a-
86j; cues to action, 4 items, Eca.87-90; and self-efficacy, 3 items, Esef.91-93.and 
open-ended questions 93a-93b. 
Section F: The Morisky Medication Assessment Scale (MMAS-8) comprised 8 
items that elicited data on treatment adherence. The items were numbered F94-F101 
for purposes of this study for ease of data entry, but all the original numbers with the 
three pages of the Morisky Scale were part of the structured interview schedule 
whenever it was used. The 8 items in the scale followed the rating scale 0-1 and 0-4 
(see annexure D). The MMAS-8 was originally developed to measure treatment 
adherence in hypertensive patients (Morisky, 2008:5).  But with time, it had been used 
in other chronic health conditions where adherence was an issue like in diabetes 
mellitus patients. The original MMAS-8 was a self-reported medication adherence 
scale.  It has eight items, which followed a rating of 0-1, and one item that follow a 5-
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point Likert format of 0-4 (Morisky 2008:5). The eight items assessed various 
psychosocial determinants of adherence, knowledge, social support, satisfaction with 
care and complexity of medication regimen. It had four pages, page 1 had the title and 
6 questions, page 2 had questions 7, 8 and the coding instructions, page 3 had the 
required citations and foot notes for the 8 item of the MMAS-8, page 4 had the 
copyright instructions, declaration and signature of the user of the scale.  
 
3.2.5 Data collection procedure 
 
As patients walked out of the doctors' rooms, those who had been randomly selected 
were requested by the clinic nurse to speak to a research assistant in a specific private 
room. In the private room, each patient was welcomed by a research assistant, 
introduced herself to the patient and requested to see the health passbook to verify the 
patient's eligibility to participate, based on the inclusion criteria.  If the patient was not 
eligible to participate in the study, the research assistant thanked the patient for coming 
and explained why he/she was not eligible for  being interviewed; and was offered a 
soft drink of choice, with a snack; after which, she/he was allowed to leave.  Such a 
patient’s random number was discarded and replaced by another randomly selected 
number. If the patient was eligible a signed consent form was obtained by the research 
assistant. Those participants who were unable to sign were assisted with an ink pad, to 
record a right thumb print. 
 
3.2.5.1 Pre-testing the research instrument 
 
Polit and Beck (2008:507) defined a pre-test as “the trial administration of a newly 
developed instrument to identify flaws and to assess time required”.  In the current 
study the pre-test was conducted during the training of the 10 research assistants.  The 
structured interview schedule (comprising the researcher-developed sections and the 
borrowed MMAS-8) was pre-tested at Ndirande Health Centre Out Patients 
Department with ten hypertensive patients.  The ten hypertensive patients who were 
selected had similar characteristics as those of the main study. Each research 
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assistant interviewed one patient.  Permission to use the Ndirande Health Centre Out-
Patients’ department was sought from Blantyre District Health Officer (see annexure 
M).  The data obtained from the pre-test was not used for the main study.  The facility 
was also excluded from data collection for the main study.  The interviews took 
approximately 45 minutes. 
 
3.2.5.2 Refinement of the research instrument 
 
After development of the instrument, it was reviewed by four content experts in the field 
of hypertension management (two clinical nurse specialists and two nursing education 
specialists), two language specialists and the statistician. Their feedback was used to 
refine the instrument. The nurse specialists indicated that the questions were clearly 
related to the purpose of the study and the statistician indicated that the quantitative 
data could be entered into the SPSS program relatively easily.  The two language 
experts suggested that a few simpler Chichewa words should be used in brackets to 
explain potentially difficult concepts.  All these recommendations were implemented. 
The refinement of the research instrument used feedback from the pre-test. The 
feedback from COMREC (College of Medicine Research Ethics Committee of Malawi) 
requested the researcher to include external factors in the items asked in the barriers 
section. These were depleted stocks of prescribed drugs at QECH and the distance 
patients had to travel to the QECH hypertension clinic.  The feedback from the pre-test 
included: 
• checking for HIV test in the passbook, it was found that patients usually have 
two passbooks, the one they use for other diseases is different from the one 
they use for HIV testing and for getting ARVs. It was agreed that the question 
should remain and see what data would be obtained;  
• another option “other, please specify......” was added;  
• similar items were combined; 
• on the HBM concepts, a 5-point Likert rating scale was implemented: Strongly 
agree=4, Moderately agree=3, Agree=2, Dont agree=1, Dont know=0. However, 
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with the respondents’ low level of literacy it was difficult to differentiate and 
suggested 3-point Likert scale wasused: Agree=3, Disagree=2, Don’t know=1.  
• A question on have you ever suffered from cancer? and a follow up one ,”have 
you received medicines for it, were combined as: “Were you treated for cancer 
during the last three months.  If yes, please specify?” 
• All questions were rephrased to start with “is it true” for example, “Is it true that 
hypertension runs in families?  
 
3.2.5.3 Recruitment and training of the research assistants 
 
The recruitment of 10 research assistants was done based on the desired nursing 
qualifications and field of experience in line with the subject area of the research study.  
The required characteristics included that each person had to be a team player, 
dependable, available full time, for the training and data collection period, able to speak 
Chichewa or English, humane, respectful and polite, physically fit, able to create 
rapport easily, and write legibly.  These characteristics were necessary for good 
practice and to add credibility to the study process.  Ten research assistants were 
recruited from staff members of the medical and surgical nursing department of KCN 
and from nursing staff of the medical wards of QECH, because these were experts in 
the subject area of study. 
 
The selected research assistants were trained during in a two day programme (see 
Annexure L), to empower the team of 10 research assistants, with the research 
protocols’ title, objectives, design, sample recruitment of participants, the QECH 
protocol of hypertension diagnosing and treating hypertension (see Annexure L), 
participant information sheet with the informed consent (see Annexures F & G), and 
the data collection instrument (see Annexures D & E).   
 
As indicated in Annexure M ethical aspects of research were addressed including 
aspects related to informed consent, voluntary participation, confidentiality, privacy, 
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anonymity and respect for people. Before conducting any interview, every research 
assistant signed a confidentiality agreement. 
 
During their training the research assistants were equipped with knowledge, skills and 
attitudes to ensure a successful data collection exercise that would produce good 
quality data.  The researcher selected experienced nurses from KCN faculty members 
and nurses in the medical wards of QECH as research assistants because of their 
expertise in the subject area of the current study.  The training was conducted by the 
researcher and an independent consultant with vast experience in field work and 
health-related studies.  The researcher was always available while the research 
assistants conducted interviews with the patients and could assist in case any 
interviewer required assistance or if any patient might have required medical care. No 
emergencies occurred during the data collection phase. 
 
3.2.5.4 Data collection technique 
 
If the patient was eligible to participate, the research assistant informed the patient 
about the study, the researcher’s name, title and aim of study, the objectives, data 
collection procedure and the interview.  The research assistant had to emphasise the 
nature of voluntary participation, and to indicate that even after volunteering any 
respondent could withdraw from the study without incurring any penalty whatsoever. 
Finally the research assistant had to ask the patient whether the explanations about 
the study had been understood and whether the patient wished to ask any questions.  
If the patient said all was understood, the researcher asked the patient to sign a 
consent form. Those unable to sign were assisted with an ink pad, to record a right 
thumb print. The researcher kept these consent forms locked up as proof of informed 
consent. The individual face-to-face structured interviews lasted approximately 45 
minutes. After the interview the respondent was thanked and offered a drink and a 
snack.  The researcher collected all the completed interview schedules and the signed 
consent forms from the 10 research assistants, verified the completeness and locked 
them up. This interview process was followed every Friday until the sample size of 480 
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had been achieved, during the period July to September 2013. Each of the ten 
research assistants conducted a maximum of five interviews on Fridays, amounting to 
a maximum total number of 50 interviews per Friday. 
 
3. 3 VALIDITY AND RELIABILITY 
 
Schmidt and Brown (2012:492) define validity as the degree that an instrument 
measures what it is supposed to measure. 
 
3.3.1  Validity of the research design and instrument 
 
According to Schmidt and Brown (2012:149) design validity is defined as, the ability to 
accept study results as logical, reasonable and justifiable according to the evidence 
provided. There are internal and external threats, forces that can change the results of 
studies; which have to be controlled for design validity to be achieved (Schmidt & 
Brown 2012:149). The researcher in the current study controlled the threats in the 
following ways: 
 
3.3.1.1 Validity of the structured interview schedule 
 
Validity of the instrument is defined as ‘the degree that an instrument measures what it 
is suposed to measure’ (Schmidt & Brown 2012:492). After development of the 
instrument, it was reviewed by four content experts in the field, two clinical nurse 
specialists and two nursing education specialists. The instrument was reviewed by two 
language specialists. The feedback from six reviewers was used to refine the 
instrument.  Furthermore, the instrument was pre-tested.  The feedback of the pretest 
further refined the instrument.   
 
3.3.1.2 Internal validity 
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Internal validity is defined as the degree to which one can conclude that the 
independent variables, not extraneous variables, produced changes in the dependant 
variable (Schmidt & Brown 2012:482).  In this study, the researcher used a simple 
random sampling technique which is an effective way of controlling extraneous 
variables therefore achieving validity.  In addition, the researcher used inclusion criteria 
which brought elements of the same characteristics into the study. The researcher 
conducted intense training of the research assistants, thus, consistency was 
maintained in sampling and data collection, to avoid instrumentation and testing 
biases. The study was conducted at one site; therefore, it was easier to control the 
environment. 
 
3.3.1.3 External validity 
 
External validity is defined as the degree to which the results can be generalised to 
other subjects, settings and times (Schmidt & Brown 2012:480).  In this study, results 
could be generalised to patients being treated for hypertension at the QECH because 
simple random sampling was used, a strong technique that allows generalisability.  
 
The instrument items were developed with consideration of the following: reading skill 
level of a twelve year old; use of simple terms which were not difficult or ambiguous, or 
double barrelled; the reading skill level or interpretability, the items used simple words 
with few syllables, and sentences with few words, short questions that asked for one 
variable (Steiner & Norman 2006:65).   
 
3.3.1.4 Face validity 
 
Polit and Beck (2008:753) describe face validity as “The extent to which a measuring 
instrument looks as thoug it is measuring what it purports to measure”. In a similar 
manner Burns and Grove (2005:798) maintain that face validity “verifies that the 
instrument looked like or gave the appearance of measuring the content”.  In this study, 
two language experts, and the researcher's supervisor, as well as a statistician, and 
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Professor Morisky verified the face validity (see annexures H and I) by confirming that 
all the items in the instrument appeared to be relevant to the major purposes of the 
study namely to identify patients anti-hypertension adherence levels and to identify 
factors that could influence these levels of adherence.  
 
3.3.1.5 Content validity 
 
Content validity reflects the extent to which a research instrument’s items “adequately 
represent the universe of content for the concept being measured” (Polit & Beck 
2008:750).  The items were developed by the researcher based on the title of the 
research, the aim, objectives, design, the concepts of the HBM and literature. Most 
items were derived from the (WHO-ISH 2003) protocol for treating hypertension. The 
items were reviewed by the two subject experts, the researcher's supervisor and 
Professor Morisky who verified the content validity (see annexures H & I). 
 
3.3.1.6 Construct validity 
 
Construct validity “examines the fit between conceptual and operational definitions of 
variables and determines whether the instrument actulally measures the theoretical 
construct that it purports to measure” (Burns & Grove 2005:793). The structured 
interview schedule items were reviewed by the researcher’s supervisor, two language 
experts and Professor Morisky who verified that the construct validity was acceptable 
because the operational definitions and concepts used in the study were relevant to the 
theoretical constructs  (see annexure H & I). The concepts of the Health Belief Model 
also guided the instrument development. 
 
3.3.1.7 Validity of the MMAS-8 
 
The MMAS-8 was validated in a sample of 1 367 hypertensive patients and had a 
Cronbach alpha coefficient of 0.83. Another study was done in Malaysia, the first to 
systematically translate and validate MMAS-8 into the Malaysian language.  A 
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significant association was found between the MMAS-8 scores and diabetic control 
represented by HbA1c (χ2 = 20.261; p ≥ 0.001), with sensitivity and specificity of 77.6% 
and 45.3%, respectively. This finding was accepted, as those patients with higher 
adherence had more awareness about the control of their diabetes and self-
management processes, and they were concerned that poor adherence might worsen 
their clinical condition.  
Other studies included the translation and validation of the Malaysian version used on 
diabetic patients and correlated hypertensive patients' self-reported medication 
adherence with their pharmacy refills (AlQazaz, Hassali, Shafie, Sundram & Morisky 
2010:217; Krousel-Wood, Islam, Webber & Morisky 2009:61).  Researchers assessed 
factors contributing to non-adherence to oral hypoglycaemic medications among 
ambulatory type 2 diabetic patients and the scale was reported to be a valid one (Adisa 
et al 2009:165). A study was conducted in Malaysia on the relationship between beliefs 
about medications and adherence levels (Gatti et al 2009:658).  In all these studies the 
Morisky Scale was used and was reported to be a valid scale. The Chichewa, Malawi 
version of MMAS-8 was sent to Prof. Morisky, for the content and construct validity 
which was acceptable and approval was granted on 3rd March, 2012 (see annexure G). 
 
3.3.1.8 Reliability of the MMAS-8. 
 
Reliability is defined as the ability of the instrument to obtain consistent measurements 
over time (Schmidt & Brown 2012:488). Reliability of the MMAS-8 was tested originally 
in a study, on a sample of patients with hypertension to test the validity and reliability of 
the tool. The results showed that the scale was reliable, with good predictive validity 
and sensitivity, and was published (Morisky 2008:5; Morisky, Ang, Krousel-Wood & 
Ward 2008:354; Sakthong, Chabunthom & Charoevisuthiwongs 2009:956).  The 
Cronbach alpha coefficient for internal consistency was 0.675 for the eight items in 
MMAS-8.  The test-retest reliability of the MMAS-8 items indicated excellent reliability 
and stability of the instrument with Spearman’s rank correlation coefficient of 0.816 (p< 
0.001).  Reliability tests showed a positive correlation between the MMAS-8 and the 
original four item MMAS scale (r =0.792, p< 0.01).  
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3.3.1.9 Inter-rater reliability 
 
This is defined as the measure of association and examining the effect of different 
observers on scores (Munro et al 2005:48; Streiner & Norman 2006:137).  In this study, 
there were ten research assistants who collected data. To ensure that the collected 
data would be reliable, the research assistants were trained for two days. This included 
classroom training and field experience. Classroom sessions concentrated on 
familiarising the research assistants with the research topic, aim, objectives, and the 
101 items of the structured interview schedule (see annexure D). Role plays were also 
done to demonstrate the correct way of using the structured interview schedule when 
the research assistants interviewed each other.  The field experience was the pre-test 
of the structured interview schedule when every research assistant conducted one 
interview with one patient. An inter-rater reliability coefficient could not be determined 
because 10 research assistants could not interview the same patient to obtain data for 
such a calculation. However, the interview schedules completed during the pre-test 
were compared and no major discrepancies occurred.  The researcher was always 
available during the data collection phase and could be consulted whenever deemed 
necessary by the research assistants.  The researcher also tried to scan every 
completed interview schedule as soon after the completion of every interview as 
possible.  
 
Permission to use and translate the Morisky scale to Chichewa 
 
The researcher sought written permission from Professor Morisky to use and translate 
the MMAS-8 to Chichewa and for the researcher and research assistants to conduct 
face-to-face interviews instead of patients self-reports. This was to ensure 
completeness of data considering the low literacy levels in Malawi (MDHS, 2005:8). 
The process of formalising the copyright instructions with the publisher and author 
started in July 2011.  Permission to use the scale was granted by Professor Morisky on 
5th January 2012 (see annexure F). Written approval of the backward and forward 
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translation of the MMAS-8 Chichewa version was granted on 3rd March, 2012 (see 
annexure H) with a specific validity limited to the current research study only, up to the 
time of submission of the research results to the university and to the College of 
Medicine Research Ethics Committee. It is a copyright requirement that a report of the 
study be submitted to Professor Morisky.  
 
 
The copyright procedure MMAS-8 translation 
 
Through the literature review, several adherence tools were identified.  The researcher 
chose the MMAS-8 because of its characteristics that were relevant to the study 
objectives. The author sent the tool with copyright instructions to the researcher. The 
researcher followed the MMAS-8 copyright instructions to translate the scale as 
follows:   
Forward translation of the original scale was done from English to Chichewa to 
produce a version that was semantically and conceptually as close as possible to the 
original one. There were two groups of language experts from the language 
departments in the University of Malawi, at Chancellor College and at Kamuzu College 
of Nursing. They undertook the translation process of the MMAS-8 into the Chichewa 
language using the standard “forward–backward” procedure (Morisky 2008:8; Wild et al 
2005:8). Each group of translators produced a forward translation of the original 
structured interview schedule into the target language without mutual consultation. One 
Malawian researcher reviewed the two primary versions and compared them with the 
original version.    
Reverse translation was done by another translator, from Chichewa to English after 
repeated discussions between the translators and Malawian researchers. 
Inconsistencies were resolved in a consensus meeting and a final version was 
generated. The translated scale was distributed to 20 Chichewa speaking individuals 
who completed the structured interview schedule and commented on the questions. 
The comments were discussed by the researchers.  
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Subsequently, six master’s students who were experts in the field judged the face and 
content validity of the scale. The final version of the Chichewa MMAS-8 was sent back 
to Professor Morisky for validation after which approval was granted to the researcher 
to use it. Permission to use the scale was granted only for the duration of the current 
study (see annexure F) and would expired after completion of the study report  
 
 
 
Scientific honesty and integrity  
         
         Polit and Beck (2010:568) define scientific merit as the degree to which a study is 
methodologically sound. In this study the main goal was to generate sound scientific 
knowledge through honest methods and to reach conclusions, generalise findings, 
and suggest further studies to improve the hypertension patients’ treatment adherence 
levels.  Scientific dishonesty involves fabrication or falsification of research steps and 
results, plagiarism and manipulating results to obtain financial benefits or honour. 
Research must be conducted and reported with honesty and integrity and it must be in 
line with established national, institutional and professional codes of practice (Schmidt 
& Brown 2012:480). The researcher followed the principles of scientific honesty and 
integrity in research.  The required process of data collection was followed as guided 
by the supervisor. An independent statistician performed the statistical analysis of data 
and no attempts were made to manipulate or fabricate raw data or falsify research 
findings. All quoted or paraphrased sources of information used in this study were 
acknowledged and a complete list of references is included so that any reader of the 
thesis can access the sources consulted. 
 
3.3.1.10 Reliability of the instrument 
 
Schmidt and Brown (2012:492) define reliability of the instrument as the atainment of 
consistent measurements over time.  In this study the pre-test corrections were used to 
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improve the reliability of the tool. For the MMAS-8, several studies had used it over 
time, it yielded consistent measurements (Fongwa, Evangelista, Hays, Martins, 
Elashoff,  Cowan & Morisky 2008:157; Krousel-Wood et al 2004:358; Morisky et al 
2008:52; Sakthong et al 2009:102).  
 
3.4    DATA ANALYSIS 
 
Data analysis is defined as the systematic organisation and synthesis of research data, 
the testing of a research hypothesis using the acquired data (Polit & Beck 2010:758). 
In this study, quantitative data were entered and analysed using the SPSS program 
version 19.0. Descriptive statistics were computed for the demographic data and 
presented as frequencies. The results are presented in tables, figures and graphs.  To 
generate the outcome variable of adherence, scores for each respondent were 
generated which formed the basis for categorisation into three adherence levels 
namely low (score of <6), moderate (score of 6 to <8) and high (score of 8) (Morisky 
2008:3; Morisky et al 2008:350). In order to estimate levels of adherence, one-way 
tabulation of the adherence variable was done in order to obtain frequencies for each 
category. The adherence variable was analysed as an ordinal outcome variable with 
the three categories described above. 
 
To investigate factors associated with levels of adherence, a number of statistical 
methods were employed. For categorical variables, Pearson Chi-square or Fisher’s 
Exact tests were used to assess whether a significant association existed between a 
specific factor and the patient’s adherence level. Analysis of variance (ANOVA) was 
used to investigate associations between continuous variables (factors) and 
adherence. In order to compute odds ratios (ORs) and p-values for each variable, 
simple ordinal logistic regression models for each factor were fitted.  
 
To compute data distributions for the measures of the specific objectives, one way 
tabulation was used to obtain frequencies related to the objectives as specified in 
section 1.3.2 of this thesis. The accepted level of significance was 5%.  
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3.5 DISSEMINATION OF RESEARCH FINDINGS                                                                                                                                                                           
 
The results will be disseminated locally, nationally, regionally, and globally.  Locally, a 
meeting will be organised for hypertensive patients and staff of QECH to provide 
feedback about the findings. The study reports will be submitted to the College of 
Medicine Research Ethics Committee (COMREC) of Malawi, to Professor Morisky in 
California, and to the Kamuzu College of Nursing in Blantyre, Malawi.  A copy of the 
thesis will be submitted to University of South Africa and to the Library at the Kamuzu 
College of Nursing. A paper will be presented at an annual scientific research 
conference at the College of Medicine of Malawi, and at other conferences.  A paper 
will be submitted for publication in an academic accredited journal. 
  
3.6 ETHICAL CONSIDERATIONS  
 
Ethical considerations in research imply “a system of moral values that is concerned 
with the degree to which research procedures adhere to professional, legal and social 
obligations to the study participants” (Polit & Beck 2008:753).  Basically research ethics 
imply that the rights of all participants/respondents and all institutions should be 
respected at all times and that the researchers should maintain scientific integrity by 
adhering to “… the principles of respect for persons, beneficence, and justice relevant 
to the conduct of research” (Burns & Grove 2005:797). 
 
The researcher obtained ethical approval from the Higher Degrees Committee of the 
Department of Health Studies at the University of South Africa. The committee granted 
an ethics clearance certificate number HSHDC/2012, dated 29th August 2012 (see 
annexure A). Permission was also granted by the Kamuzu College of Nursing's 
Research and Publications Committee (see Annexure J).  Permission to conduct the 
study at the QECH, Hypertension Clinic, in Blantyre was granted by the Hospital 
Director (see annexure K). The University of Malawi’s Research and Ethics Committee 
(COMREC) of the College of Medicine in Malawi granted an ethics clearance, under 
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certificate number P.03/13/1370 dated 16th May 2013 (see annexure M). The Blantyre 
District Health Officer granted permission to conduct a pre-test of the study instrument 
at Ndirande Health Centre (see annexure N). 
The researcher respected the respondents’ autonomy, and adhered to the ethical 
principles of beneficence, non-maleficence and justice, as explained in the following 
paragraphs. 
Autonomy refers to self-rule and self-determination to have the ability to make one’s 
own decisions regarding one's own life (Schmidt & Brown 2011:482). In this study the 
researcher upheld this principle, by respecting the respondents who were fully 
informed about the study, including the study’s title, purpose, site, population, duration 
and the researcher’s particulars. This allowed respondents to make informed decisions 
as to whether or not to participate in the study.  Informed consent was obtained as an 
indication of voluntary participation by the respondent (see annexures F and G). Those 
who could not sign provided a right thumb print. Respondents were informed about 
their right to withdraw from the study, if they felt so at any point in time, without 
incurring any penalty whatsoever.  
 
The principle of beneficence refers to the concept of doing ‘good’ and maximising 
benefits for the respondents (Schmidt & Brown 2011:475).  During data collection, 
private rooms were used to maintain privacy and confidentiality. In addition, 
respondents were guaranteed that their information would be kept in the strictest 
confidence throughout the study, and would be locked up and used only for research 
purposes and be accessible only to the researcher, supervisors and the statistician. 
The structured interview schedules had codes and not names to maintain anonymity. 
After data analysis and report writing, the completed interview schedules would be 
destroyed after three years. Respondents were given the researcher's contact details 
to talk to her if they had any queries about the study. 
 
The principle of non-maleficence refers to the obligation of the researcher to 
minimise harm.  In the current study there was no risk of physical harm to the 
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respondents. However, some might have experienced emotional upsets when thinking 
about painful experiences, in which case the interview would be stopped and the 
respondent would be referred to a psychologist or relevant health care professional. 
 
The principle of justice is an ethical principle of equity and fairness in the distribution 
of benefit and opportunities and giving equal treatment to equal people (Schmidt & 
Brown 2011:482).  In this study the respondents were randomly selected using 
selection criteria.  Both males and females were equally assessed by the same 
eligibility criteria to be recruited in the study and were accorded similar respect during 
data collection.  The simple random sampling process allowed the respondents a 
known chance of participating in the study.  The researcher and all assistants gave 
respondents with hypertension equal and fair treatment at the hypertension clinic.   
 
3. 7 LIMITATIONS OF THE STUDY 
 
The study was conducted at one site only; multiple sites could have enriched the 
research findings.  A structured interview schedule was used, but individual in-depth 
interviews might have yielded richer data. These limitations resulted from the time and 
financial constraints of the researcher as the study was a requirement for the fulfilment 
of the degree of doctor of philosophy in health studies; and as such the researcher had 
to complete the study with limited financial resources.   
 
3.8    SUMMARY 
 
This quantitative descriptive study employed structured interviews (including a 
checklist) to collect data. The research design, sampling method, ethical issues related 
to sampling, population sample, data collection and data analysis were explained.  The 
internal and external validity of the study were discussed.  Various measures were 
applied to enhance the study’s validity and reliability and to uphold the ethical 
principles of research.  The findings will be presented and discussed in chapter 4. 
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CHAPTER 4 
DATA ANALYSIS AND DISCUSSION 
 
 
4.1   INTRODUCTION 
 
This chapter presents the results of a quantitative descriptive study conducted to 
investigate levels of patients’ adherence to anti-hypertensive treatment 
regimens and factors influencing adherence at QECH hypertension clinic in 
Blantyre, Malawi. Data were collected from 480 randomly selected hypertension 
patients using structured interviews and the adherence levels were measured by 
using the MMAS-8 instrument. The questions that needed to be answered were:  
• What are hypertension patients’ treatment adherence levels?  
• What are the factors that influence hypertension patients’ treatment 
adherence at QECH hypertension clinic? 
  
The specific objectives of the study, phrased in terms of the major concepts of 
the HBM, were to: 
• establish hypertensive patients’ levels of adherence to their treatment 
regimens; 
• identify hypertensive patients’ knowledge of high blood pressure, non-
pharmacological and pharmacological management of high blood 
pressure;  
• identify hypertensive patients' perceived susceptibility to potential 
complications attributable to high blood pressure;  
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• identify hypertensive patients’ perceptions of severity of high blood 
pressure complications;  
• determine hypertensive patients’ perceived benefits of treatment 
adherence;  
• describe hypertensive patients’ perceived barriers to treatment 
adherence;  
• describe hypertensive patients’ cues to action and self-efficacy for 
treatment adherence. 
 
4.2 DATA ANALYSIS 
 
The quantitative data were entered using the SPSS program version 19.0. 
Descriptive statistics, including univariate and multivariate analyses, were 
computed using Stata software version13.0. The level of significance was set at 
5%.  
 
To generate the outcome variable of adherence, scores for each respondent 
were generated which formed the basis for categorisation into three adherence 
levels based on the MMAS scores of low (<6), moderate (7<8), and high (=8) 
adherence (Morisky et al 2008:350). In order to estimate respondents’ levels of 
adherence, one-way tabulation of the adherence variable was done in order to 
obtain frequencies for each category. The adherence variables were analysed as 
ordinal outcomes with three categories described according to the MMAS-8 
coding instruction (Morisky et al 2008:352). 
 
To investigate factors associated with levels of adherence, a number of statistical 
methods were employed. For categorical variables, Pearson Chi-squares or 
Fisher’s Exact Tests (for cell values less than 5 in contingency tables) were used 
to assess whether a significant association between the factor and adherence 
levels existed. Analysis of variance (ANOVA) was used to investigate 
associations between continuous variables and adherence.  In order to compute 
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odds ratios (ORs) and probability values (p-values) for each variable, simple 
ordered logistic regression models were calculated for each variable. Likelihood 
ratio tests were used to compare models in order to build the most parsimonious 
model. To compute data distributions for the measures of the specific objectives, 
one way tabulation was used to obtain frequencies. The following conventions 
have been used for the discussion of the research findings in this chapter: 
• N = total sample 
• n = total of sub variables or topics 
• f  = frequency within N or n. 
 
4.3 RESPONDENTS’ DEMOGRAPHIC CHARACTERISTICS 
 
This section presents information about respondents’ demographic 
characteristics obtained through questions in the demographic section of the 
interview schedule. These included respondents’ gender, age, religion, tribe, 
marital status, educational level occupational status. A total of 480 respondents, 
being treated at QECH hypertension clinic, participated in the study. Their 
demographic and socio-economic characteristics are presented in sections 4.3.1- 
4.3.7. 
 
4.3.1  Gender  
 
More females (78.0%; f=370) than males (22.0%; f=105) participated in this study 
(see table 4.1).  
 
Table 4.1 Respondents’ gender (n=475)  
____________________________________ 
Gender   (f)  (%)_ 
    
Males    105  22.1 
Females    370  77.9 
Total    475          100.0 
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These findings are similar to those reported by Chibwana, Mathanga, 
Chinkhumba and Campbell (2009:221) in Malawi, indicating that men were 
reluctant to use health facilities, even when they were ill. Holt et al’s (2010:481-
483) study on health–related quality of life, and anti-hypertensive medication 
adherence levels among adults with a mean age of 75 years, revealed that 
58.0% of the patients suffering from high blood pressure were females in New 
Orleans (USA).  Ramli et al (2012:613) assessed medication adherence, among 
hypertensive patients treated in PHC clinics in Malaysia. Females comprised 
62.8% of the sample of hypertensive patients.  Similarly, Ambaw et al 
(2012:282) assessed treatment adherence among hypertensive patients in 
Ethiopia’s Gondar health facility. The findings showed that 63.0% of patients 
with hypertension were females. Msyamboza et al (2011:3) assessed the 
burden of selected chronic non-communicable diseases and their risk factors in 
a nationwide STEPS Survey in Malawi. These findings showed that 68.0% of 
the patients with hypertension were females. 
 
In Malawi women face many challenges. For example, when a husband, a child 
or a relative is sick, the key person responsible for providing care is the 
woman/wife/mother/daughter. Malawian women also cultivate land and sell 
produce at the roadside.  Stress is reported to be a risk factor for hypertension 
through the sympathetic nervous system’s stress reactions, as discussed in 
chapter 1 of this thesis. Gianaros et al (2007:134) reported that when an 
individual experiences stress and/or worries continuously; there is a release of 
adrenaline from the adrenergic fibres of the adrenal glands, the stress hormone. 
This is a stimulant and a vasoconstrictor, which increases peripheral resistance 
resulting in raised blood pressure.   
 
However, Roeters van Lennep, Westerveld, Erkelens and Van der Wall’s 
(2002:541) article on risk factors for coronary heart disease, reported that 
hypertension results from a loss of arterial elasticity which increases with age in 
both males and females. It was not reported how women or men responded to 
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hypertension treatment and prevention, as this review article addressed the role 
of cardiovascular risk factors focusing on the differential impact they might have 
on men and women (Roeters et al 2002:541). 
 
4.3.2   Respondents’ ages 
 
The ages of the respondents ranged from 30 to 85 with a mean of 58 years.  
However, the majority of respondents were within the age range of 51-60 years 
but as many as 79.0% (f=380) of the respondents fell within the 31-70 year age 
group (see figure 4.1 and table 4.2).   
 
Hypertension is a physiological process which can occur at any age, but it 
occurs mostly at or after middle age and among older adults (McCance et al 
2010:1155). It is a response to alterations in the blood pressure controlling 
factors in old age that slows down a person’s activity levels. Activity is important 
for burning of the fats in the body. In the same manner the metabolic processes 
in the body also slow down. This leads to the accumulation of fats in the body 
including the blood vessels, narrowing of the lumen which eventually disturbs 
the normal flow of the blood, leading to an accumulation of blood in the vessels 
and causing hypertension (because of the increased pressure of the increased 
volume of blood against the blood vessels’ walls). This increases the peripheral 
resistance causing hypertension in older persons. Older adults refer to persons 
in the age range of 30-70 years according to Lewis et al (2011:742) although 
different authors have different age brackets for ‘older adults’. 
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Figure 4.1:   Age of respondents (n=479) 
 
This age range is the productive age group, busy and stressful as they try to 
earn a living while raising their families.  The stress, in turn, has some negative 
effects on their bodies (Gianaros et al 2007:134).  Similar findings were reported 
at Tikur hospital, Addis Ababa (Hareri & Abebe 2013:2). While assessing 286 
patients’ adherence to their anti-hypertension medications and associated 
factors, results showed that this sample’s mean age was 52.  A systematically 
selected sample of 286 patients was interviewed (Hareri & Abebe 2013:2).  
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Table 4.2:   Respondents’ ages (n=479) 
             Age range (f) (%) 
             30 & below 
             31  -  40 
             41  -  50  
             51  -  60 
             61  -  70 
             71  -  80 
             81  -  90 
             Total 
 13 
 49 
121 
152 
107 
 32 
   5 
479    
2.7 
    10.2 
    25.3 
    31.7 
    22.3 
      6.7 
      1.0     
    99.9   
 
The respondents mean age was 54.9 years (standard deviation [SD] 11.6). The 
average age at high blood pressure diagnosis was 50.4 years (SD 12.1 years).  
Age in years was normally distributed (see figure 4.1), and was analysed as a 
continuous variable.  The average age of this study’s respondents is in line with 
the age findings of Ambaw et al (2012:284) in Ethiopia at Gondar Hospital 
where the hypertension patients’ mean age was 57 years. Other studies, 
conducted on patients with hypertension, have described similar age groups for 
hypertension patients, 36-45 years (Turki & Sulaiman 2010:27), 40-50 years 
(Sulaiman et al 2009:41), and 32-84 years with a mean of 57.84 years (Ramli et 
al 2012:616).Thus the 475 respondents’ mean age of 58 in this study seems to 
correlate with the mean age of hypertensive patients reported by various studies 
from different parts of the world. 
 
4.3.3 Religion of the respondents 
 
Out of 480 respondents, 27.7% (f=133) belonged to the Presbyterian Church, 
26.2 % (f=126) were Roman Catholics and 11.2% (f=54) belonged to Seventh 
Day Adventist Church. It was important to know respondents’ religious 
affiliations because some religions might prohibit their members from taking 
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Western medicines thereby causing non-adherence in patients. There were also 
some Muslims 8.1% (f=39). The other respondents belonged to religions such 
as the Anglican, Pentecostal, Church of Christ, Calvary and Assemblies of God 
(see table 4.3). 
 
Table 4.3: Respondents’ religious affiliations of (N=480) 
____________________________________ 
Religion________________(f)________(%)_ 
Roman Catholic  126  26.3 
Presbyterian   133  27.7 
SDA      54  11.3 
Muslims      39    8.1 
Pentecostal     29    6.0 
Others      99  20.6 
TOTAL   480              100.0 
 
Similar religious groupings, although with different percentages of followers, 
were reported by the MDHS (2010:26).  This report indicates that in Malawi, 
Presbyterians represent 33.4% and Roman Catholics 42.9% of the population. 
 
Religion has been found to be significantly correlated with treatment adherence 
(Gatti et al 2009:657; Kazembe 2007:45, 58; Robinson & Zhang 2011:2; Sato 
2012:1; WHO 2011:358) because of the spiritual support that religion could 
provide to people. However, patients’ treatment adherence levels could also be 
adversely influenced if their church maintains that people who have been prayed 
for, do not need to take medicines to get cured of their illnesses (Holt et al 
2010:483).  
 
Gatti et al (2009:657) examined the relationship between beliefs about 
medications, health literacy, and self-reported medication adherence of 275 
African-Americans.  These researchers used the “Beliefs about Medicines 
Questionnaire” and the MMAS-8, at an inner city hospital in Washington DC in 
the USA. Their results showed that 52.7% of the participants reported low 
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medication adherence levels of <2. Multivariate analysis indicated several 
factors that were associated with low adherence levels including negative beliefs 
about medications, younger age, low medication self-efficacy and 
hyperlipidaemia. Health literacy was not independently associated with beliefs or 
adherence. Patients who had negative beliefs about medications, who were 
younger than 65 or who had low medication self-efficacy, reported low 
medication adherence. When patients face tasks such as taking hypertension 
medication every single day for the rest of their lives, it is not an easy issue. 
They weigh many factors, including their beliefs about the necessity of the 
medications against their concerns such as side effects, the inconvenience of 
swallowing pills, and the cost of obtaining the medications. The patients’ 
analyses of all the factors, could influence their decisions whether or not to 
adhere to the prescribed treatment regimen (Gatti et al 2009:658). 
 
4.3.4 Respondents’ tribal affiliations 
 
Respondents belonged to the following tribes: Chewas, 15.6% (f=75), Ngonis 
23.3% (f=112), Lomwes 24.0% (f=115); and Yaos 16.9% (f=81). It was important 
to know respondents’ tribes because some tribal customs might prohibit their 
members from taking Western medicines thereby causing non-adherence by 
patients to their anti-hypertensive medications. There were other tribes as well 
(refer to table 4.4 and figure 4.2).  
 
Table 4.4:   Respondents’ tribal affiliations (n=478) 
Tribe of respondent     (f)      (%) 
Chewa 75 15.7 
Ngoni 111 23.2 
Tumbuka 29 6.1 
Lomwe 115 24.1 
Yao 82 17.2 
Other 66 13.8 
Total 478 100.1 
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Figure 4.2: Tribal affiliations of respondents (n=478) 
 
 
The MDHS (2010:26) reported the following tribal affiliations of Malawian 
citizens for the entire country: Lomwes 34.1%, Chewas 67.4%, Ngoni 25.8% 
and Yaos 26.3%. However, Blantyre city, bordered by the districts of Chiradzulu, 
Mulanje, Thyolo and Zomba, is a cosmopolitan city which has industries, 
companies, governmental and non-governmental organisations and 
international shopping malls and Asian shops.  People from all these 
neighbouring districts come to Blantyre to seek employment and patients are 
referred to QECH from many areas and districts. It has Lomwe and Chewa and  
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Ngoni as key tribes (MDHS 2011:26) and most of this study’s respondents 
belonged to these three key tribes (see figure 4.4 and table 4.2).  Tribal 
affiliations could influence patients’ adherence behaviours because tribe shapes 
peoples beliefs, attitudes and practices (Kazembe 2007:54). Therefore tribal 
influences could affect peoples’ treatment adherence based on their perceptions 
of the disease, treatment and adherence. 
 
Epstein et al (2012:1764) in America randomly assigned participants to three 
groups: DASH diet only, DASH diet plus weight management and usual diet 
controls. The primary outcomes of the study were adherence to DASH diet and 
level of blood pressure. They found that the two groups, DASH diet only, DASH 
diet plus weight reduction, showed significant reduction in blood pressure in 
comparison with the usual diet controls. A dietary adherence of 95% showed a 
reduction in blood pressure (Epstein et al 2012:1764; Kastarinen, Puska, 
Korhonen, Mustonen, Salomaa, Sundvall, Tuomilehto, Uusitupa & Nissinen 
2002:2505). 
 
4.3.5 Marital status of respondents  
 
Out of 476 respondents, 67.6% (f=322) were married; 24.4% (f=116) were 
widows. The single, divorced/separated respondents were 8.0% (f=38) (see 
table 4.5). 
 
Table 4.5 Respondents’ marital status (n=476) 
____________________________________ 
Variable                 ____     (f)_________(%)_ 
Married     322  67.6 
Widowed   116  24.4 
Divorced/separated    38    8.0  
Total    476          100.0   
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According to the MDHS (2010:26), 58.7% of Malawians are married. Malawi, as 
a country, supports marriage as an institute of love and support in wellness and 
in disease and in the upbringing of children. Marriage is included in the 
Constitution of Malawi, referred to as: “The African Marriage Registration Act, 
Caption 25 section 02”.  In Malawi, marriage is encouraged and supported by 
religions, tribes and government (Constitution of Malawi 2004:18). This explains 
why 67.6% (f=322) of the respondents were married. If one member of the 
couple has hypertension, the other one could provide support through 
encouragement in terms of reminders to take the medicines for the day.  
 
Therefore, marital status as a demographic characteristic could influence 
treatment adherence. In this study, out of the 67.6% (f=322) married 
respondents, only 50.6% (f=163) were adherent.  Consequently, this study’s 
findings did not indicate that married people were significantly more adherent to 
their hypertension treatment than those who were not married. Similarly, 
Kulkarni, Alexander, Lytle, Heiss, and Petersen (2006:490) did not find a 
relationship between marital status and adherence. However, Caldwel, Theisen, 
Kaunisto, Reddy, Smythe and Smith as reported by Trivedi, Ayotte, Edelman 
and Bosworth (2008:490), indicated that marital status played an important role, 
as part of the patient’s social network, and it was associated with improved 
adherence (r=.19; p<.001).  
   
4.3.6   Respondents’ educational levels 
 
The results showed that out of 479 respondents, 55.7% (f=267) attained primary 
school education, and 24.8% (f=119) had secondary school education.  There 
were a few of the respondents who had reached college 3.5% (f=17) and 1.7% 
(f=5) had university education. However, 14.8% (f=71) of the respondents had 
never attended school (see figure 4.3). 
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Table 4.6:   Respondents’ educational levels (n=479) 
Education level    (f)     (%) 
None 71 14.8 
Primary School 267 55.7 
Secondary School 119 24.8 
College (Deg/Dip/Cert) 17 3.5 
University (Deg/Dip/Cert) 5 1.0 
Total 
 
 
479 99.8 
 
 
 
Figure 4.3: Respondents’ level of education (n=479) 
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The significance of knowing the level of education of the respondents was that 
people with higher education levels should be able to acquire the knowledge of 
hypertension required to understand the consequences of treatment adherence 
and non-adherence. Such insight is essential to be able to make informed 
decisions and to adhere to the prescribed treatment regimens.  According to 
Glanz (2002:42) the six concepts of the HBM require that an individual should 
have a base of knowledge, upon which health education knowledge could be 
grounded, before an individual can make an informed health-related decision 
and perform the required actions. 
 
This is supported by a nurse-led intervention study conducted at the QECH 
hypertension clinic (Starichi et al 2011:22), that involved providing health 
education regarding hypertension, its treatment, importance of adherence to 
treatment, and the dangers that might arise as a result of non-adherence. Thirty 
seven hypertension patients attended a mean of 3.5 individual counselling 
session on a one-to-one basis, over a mean of 118.5 days.  The results showed 
that the education intervention increased the patients’ adherence to treatment 
and the patients’ blood pressure readings were reduced. This supports the 
argument that health education interventions can benefit hypertension patients’ 
medication adherence levels (Aminoff & Kjellgren 2001:582; Chang, Fritschi & 
Kim 2012:119; DeCola, Benton, Peterson & Matebeni 2012:322; Drevenhorn, 
Bengtson & Kjellgren 2007:47; Drevenhorn, Bengtson & Kjellgren 2009:350; 
Ericksson & Nilsson 2008:2353; Epstein et al 2012:1764; Ham & Bong 
2011:1246; Kastarinen, Puska, Korhonen, Mustonen, Salomaa, Sundvall, 
Tuomilehto, Uusitupa & Nissinen 2002:2506). 
 
Hacihasanoglu and Gozum (2011:696), in Turkey, assessed the effect of anti-
hypertensive patient-oriened education and in-home monitoring of medication 
adherence, hypertension management, healthy life style, and body mass index 
in a PHC setting by providing education about medication adherence and 
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healthy lifestyles. The 120 hypertensive patients were divided into groups A and 
B. Structured education sessions on medication adherence and healthy lifestyle 
behaviours were provided to Group B for six weeks. These results showed that 
healthy lifestyle behaviours and perceptions of self efficacy, regarding 
medication adherence, improved after education sessions.  Benefits of such 
education sessions also included decreased blood pressure readings, healthier 
life styles, with increased perceptions of self-efficacy regarding blood pressure 
control and its benefits.  However, behaviour changes take time.   
 
Among African-Americans, Middleton (2009:12) found that the factors related to 
uncontrolled hypertension were not knowledge nor access to health care 
services. This was because their knowledge scores on hypertension tests were 
high and they had access to health care because they had health insurance.  It 
is thus important to consider all possible factors that could influence medication 
adherence (Barksdale 2009:54; Kalogianni 2011:157; Mazzaglia et al 
2009:1601), in addition to patients’ knowledge levels and access to health care 
services. 
 
4.3.7   Occupations of respondents 
 
Table 4.7 represents the respondents’ occupations. Recording the respondents’ 
occupations in the current study was important as it could indicate the 
hypertensive patients’ financial ability to travel to the clinic for appointments.  In 
addition, they would manage to buy drugs from private suppliers if these were 
out of stock at the public clinic’s pharmacy and they would be able to afford to 
follow the prescribed diet for hypertension. 
 
The occupations of respondents included those of housewives (36.3%; f=166). 
Out of the 457 respondents 22.8% (f=104) engaged in private small businesses 
and others (18.8%; f=86) were retired (see table 4.7). 
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Table 4.7:  Respondents’ occupational status (n=457) 
__________________________________________ 
_Variable____________________(f)________(%)_ 
Housewives                           166   36.3 
Small-scale business                     104                22.8 
Retired        86                18.8 
Farmer, tailor                           38                  8.3 
Supervisor, teacher, secretary        30                 6.6 
Others      33                  7.2 
Total        457              100.0 
 
 
Similar findings were recorded by Hareri and Abebe (2013:4) who assessed 
adherence to anti-hypertension medications among patients at Tikur Hospital, in 
Addis Ababa, Ethiopia. The participants’ occupations were housewives (7.3%; 
f=35), traders (6.7%; f=32) and retirees (0.6%; f=3).   
 
4.3.8   Correlations between biographic factors and adherence to anti- 
            hypertensive treatment 
 
In summary the findings of the current study indicated no significant association 
between anti-hypertension medication adherence and gender, age, tribe, 
religion, education or occupation, as shown in table 4.8. From One-Way 
Analysis of Variance (ANOVA), there was no significant association between 
gender, age and education level with blood pressure.  
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Table 4.8: Two-way associations between biographic characteristics and 
anti-hypertensive treatment adherence 
Factor Chi-square/F   df  P-value    F 
Gender    0.525 2 0.769 476 
Age (years)†  1.34 2 0.264 480 
Tribe of respondent 14.54 16 0.558 478 
Education level   3.40 2 0.691 479 
Marital status  1.25 6 0.975 475 
Number of children        10.84 6 0.094 460 
Suffered BP in previous pregnancy   0.81 2 0.667 351 
Number of live children 33.53 26 0.147 460 
Number of children who had died 25.44 18 0.113 436 
Currently pregnant   0.36 2 0.836 370 
†P-value from Analysis of variance (ANOVA).     
‡ From Pearson Chi-square or Fisher's Exact test     
*df: degrees of freedom     
 
Table 4.9: Two-way associations between demographic factors and blood 
pressure 
 
Factor Chi-square df P-value N 
Gender 2.59 4 0.628 465 
Age (years)* 1.48 4 0.208 469 
Education level 16.56 16 0.415 468 
From one-way analysis of variance (ANOVA) 
df: degrees of freedom 
 
  
 
4.3.9    Health facilities that referred patients to the QECH hypertension  
             clinic 
 
The health facilities which referred patients to QECH hypertension clinic were 
QECH outpatients/accident and emergency trauma departments (67.4%; f=323); 
health centres such as Limbe (8.6%; f=41); Ndirande (7.9%; f=38); Zingwangwa 
(5.8%; f=28); Chilomoni (4.0%; f=19).  In addition, there were some patients who 
were referred from other districts 6.3% (f=30), including Chikwawa, Chiladzulu, 
Dedza, Lilongwe, Mulanje, Nsanje, Ntcheu, Zomba, Thyolo and Zomba (see 
table 4.10) 
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Table 4.10:   Health facilities that referred patients to QECH hypertension  
                      clinic (n=479) 
 
             Age range (f) (%) 
             QECH 
             Limbe 
             Ndirande 
             Zingwangwa 
             Chilomoni 
             Other districts 
             Total 
 323 
    41 
    38 
    28 
    19 
     30 
  479    
  67.4 
        8.6 
        7.9 
        5.8 
        4.0 
        6.3 
    100.0 
 
        
 
 Figure 4.8: Health facilities which referred patients to the QECH  
                     hypertension clinic (n=479) 
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These patients had QECH as their nearest health facility where they were seen 
with their initial health complaints. Therefore, when hypertension was diagnosed 
at the QECH facility, they were referred to the hypertension clinic, a unit within 
the QECH outpatient department run by medical specialists. The significance of 
this is that the majority of the respondents travelled a short distance to get 
treatment. However, some patients came from other districts outside Blantyre, 
travelled long distances from Chikwawa, Chiladzulu, Dedza, Lilongwe, Mulanje, 
Nsanje, Ntcheu, Thyolo and Zomba.  
 
Having to travel long distances to the QECH facility could influence patients’ 
treatment adherence negatively. For instance, if the patient lives in another 
district, such as Mulanje, did not have transport money to travel to QECH to get 
the medication refilled, he/she would be unable to adhere to the prescribed anti-
hypertensive regime. This would mean that treatment would be missed for a 
period of time, lack of transport money being a barrier to adherence. These 
findings are supported by Ambaw et al (2012:283), who indicated that time 
taken to reach the hospital had an influence on  patients’ medication adherence 
levels. For those who took 30 minutes to reach the hospital, 29.2% were 
adherent and 20.1% were non-adherent.  Of those who took more than 30 
minutes to reach the hospital, 35.4% were adherent while 25.3% were non-
adherent. In normal circumstances, the understanding would be that,  those who 
took a short time to the hospital would be more adherent than those who took a 
long time to do so.  
 
However,  Ambaw et al (2012:283) found that the patients who travelled for a 
longer time, implying that they lived far from the clinic, were the ones who 
adhered in large numbers. Those who travelled for a shorter time, because they 
lived near the clinic, adhered in small numbers. The possible explanation for 
these findings could be that those who travelled from far made a greater effort 
on time and transport money which is a sign of motivation towards their 
treatment. Therefore when they collected the medications, which costed them 
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dearly in terms of money and time, they felt motivated to swallow the pills as 
prescribed.  Likewise the others who lived near to the clinic and spent less time 
and money to get their medications, became complacent, were less motivated 
and did not swallow their medicines regularly. These findings on low motivation 
in patients were supported by Hareri and Abebe (2013:5) who showed that 
patients who lacked awareness of the risks of non-adherence, had low 
motivation levels which led to low levels of adherence. These findings show that 
whether near or far from the clinic, some hypertensive patients would adhere to 
their prescribed anti-hypertensive medications regimens and others would not. 
This  also confirms how complex the issue of anti-hypertension treatment 
adherence is.  
 
4.3.10  Respondents’ clinical manifestations and adherence levels  
 
In this section possible correlations between patients’ clinics signs and symptoms  
and their treatment adherence levels will be addressed. 
 
4.3.10.1   Blood pressure levels of respondents 
 
In the current study out of the 469 respondents: 
• 6.6% (f= 31) were controlled  
• 21.1% (f=99) had pre-hypertension 
• 36.9% (f=173) had hypertension stage 1 
• 19.8% (f=93) had hypertension stage 2 
• 5.6% (f=73) had a hypertensive emergency.  
 
The WHO (2003:1986) classifies blood pressure as: 
• normal at 120/80mm Hg 
• pre-hypertension at 129/85 mm Hg 
• hypertension stage 1 at 130/90mm Hg 
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• hypertension stage 2 at 140/95mm Hg 
• hypertensive emergency (crisis) at 150/110mmHg and higher.  
 
These WHO blood pressure classifications were used in the data analysis of the 
current study.  
 
 
Table 4.11 Blood pressure levels of respondents (n=469) 
___________________________________ 
Blood pressure levels*     (f)      (%) 
Controlled 31 6.6 
Pre-hypertension 99 21.1 
Stage 1 Hypertension 173 36.9 
Stage 2 Hypertension 93 19.8 
Hypertensive Emergency 73 15.6 
Total 469 100.0 
 
   
In the current study, the respondents’ recent blood pressure levels, documented 
by the clinic nurse in the health passbook on the day of data collection was 
recorded, by the research assistants from each respondent. Therefore from the 
blood pressure readings, adherence and blood pressure control could be 
identified. Medications do work for those people who take them the way they 
should take them and their blood pressures do get controlled (Osterberg & 
Blaschke 2005:448; Gerin et al 2007:460). 
 
Many patients  discontinue their medications within six months of commencing 
the treatment as they might experience swallowing of drugs to be tiresome 
(Osterberg & Blaschke 2005:487; Weber, Schiffrin, White, Mann, Lindholm,  
Kenerson, Flack, Carter, Materson, Ram, Cohen, Cadet, Jean-Charles, Taler, Kountz,  
Townsend, Chalmers, Ramirez, Bakris, Wang, Schutte, Bisognano, Touyz, Sica, Harrap 
2014).  The Seventh Joint National Committee Guidelines reported that non-
adherence to prescribed treatment is a major barrier to achieving and 
maintaining adequate blood pressure control (Chobanian et al 2003:2560). Non-
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adherence compromises treatment effectiveness causing uncontrolled 
hypertension. In the USA the national health and nutrition examination survey 
revealed that non-adherence with non-pharmacological and pharmacological 
therapy was the cause of the limited blood pressure control (Gerin et al 2007: 
460). There are several forms of non-adherence behaviours. These include 
ommisions or missed daily or weekly doses, delayed, early taking, halving 
doses, doubling doses and defaulting treatment (Osterberg & Blaschke 
2005:487). It has been reported that two thirds of the people with hypertension 
have uncontrolled blood pressures (Bastos-Barbosa, Ferriolli, Moriguti, 
Nogueira, Nobre, Ueta & Lima 2012:636; Rachel et al 2006:36). 
 
The greatest challenge in public health is to get patients to adhere to treatment.  
However, in the adherence model there is more than the patient. Gascon, 
Sanchez-Ortuno Llor Skidmore and Saturno (2004:125) investigated why 
hypertensive patients did not adhere to their treatment, using qualitative 
methodology. They found that a complex web of factors caused non-adherence, 
including patients’ fears and negative imaginations of anti-hypertensive drugs. 
There was a lack of basic background knowledge about hypertension; the 
clinical processes were viewed as unsatisfactory because it took long, few 
explanations were supplied by the providers, low levels physician-patient 
interaction, and a disregard for patients’ options and preferences. From the 
patients’ point of view, there were more problems to be sorted out by the 
providers than the patients. Although Osterberg and Blaschke (2005:490) 
suggested that adherence factors require the patient to do more work to improve 
the situation because many factors centre on patients Barksdale (2009:54) 
suggested that provider-related factors affect treatment adherence in 
hypertension patients, and providers have to be culturally competent and 
sensitive.  All the dimensions of the adherence model should guide efforts to 
attain and maintain adherence to anti-hypertensive treatment. In the current 
study, out of 480 hypertensive patients, only 10.8% (f=52) achieved blood 
pressure control because they were adherent. This is also supported by the 
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findings of Starichi et al (2011:26) whose results indicated that nurse-led 
interventions at the QECH hypertension clinic, managed to achieve reduced 
blood pressure levels and increased adherence levels in hypertension patients 
and Bosworth (2008:338) reported similar results. 
. 
4.3.10.2 Adherence levels of respondents 
 
Table 4.10 presents the adherence levels of the respondents. This was 
essential for good adherence is important for blood pressure control and for the 
prevention of hypertension complications.  Adherence levels of respondents 
were measured using the MMAS-8 which categorises adherence into three 
different levels. These are low, if the score is less than 6, or moderate, if the 
score is 7 <8 and high, if the score is 8. 
 
At the QECH hypertension clinic from the 480 respondents, 50.6% (f=243) had 
low adherence levels, 32.1% (f=154) had medium adherence, and 17.3% (f=83) 
had high adherence. The results indicated that out of 480 respondents, only 
6.6% (f=31) had their blood pressures controlled, a benefit of high adherence 
levels.  The majority, had low and medium adherence (82.3%; f=395) and these 
were at high risk of incurring potential complications due to their uncontrolled 
blood pressure levels (see table 4.12). Bastos-Barbosa et al (2012:637) found 
similar results. 
 
Table 4.12: Adherence levels of respondents (N=480) 
________________________________________ 
Adherence level  (f)     (%) 
Low adherence (<6)                   243 50.6 
Moderate (7< 8) 154 32.1 
High (=8) 83 17.3 
Total 480 100.0 
 
 
  
 
According to the WHO (2003:1983) the recommended adherence rate is 80.0% 
to 95.0% for the control of hypertension and for the prevention of potential 
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complications. In SSA, adherence rates in the range of 47.0%-50.0% have been 
reported (Osterberg & Blaschke 2005:488) which are below the WHO’s 
recommended adherence rate to control hypertension and prevent 
complications from occurring. 
 
These findings at QECH hypertension clinic indicate low anti-hypertension 
treatment adherence levels. Computing the average of the three levels of 
adherence gives a rate of 33.3%. These findings are supported by Holt et al 
(2010:483) in the USA.  They used two instruments, the 36-item tool, assessing 
health-related quality of life, and MMAS-8 assessing adherence levels in older 
hypertensive adults. Out of those 2 180 participants, 48.3% had low adherence 
and 51.7% had high adherence levels. Low adherence rates have also been 
reported in other countries such as 74.0% in Egypt (Mweene et al 2010:259), 
49.0% in Malaysia (Sulaiman et al 2009:38), 77.0% in Pakistan (Hashmi, Afridi, 
Abbas, Sajwani, Saleheen, Frossard, Ishaq, Ambreen & Ahmad 2007:1315), 
69.2% in Addis Ababa in Ethiopia, 75.0% in Nigeria, 73.0% in India,  72.0% in 
Turkey (Hareri & Abebe 2013:5), 46.0% in the Seychelles (Edo & De Villiers 
2012:4), and 76.0% in Lusaka, Zambia (Mweene et al 2010:259). These 
reported rates of adherence in most of these countries are inadequate to control 
the  blood pressure effectively and prevent potential complications (Osterberg & 
Blaschke 2005:488 WHO 2003:1983).  
 
The differences in the adherence rates in countries might be attributed to 
various factors according to the adherence model. In the developing countries, 
the reported adherence rates were lower than in developed countries.  The 
higher rates in the developed countries might be as a result of better access to 
the health facilities, which were well stocked with medicines, and patients had 
high literacy levels and could read about anti-hypertensive medications on their 
own, understand and follow the prescriptions easily enhancing their treatment 
adherence levels. The similarities in low adherence rates in developing 
countries might be explained by a lack of access to treatment, as well as 
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practices and attitudes, low literacy levels and limited financial capacities. In 
developed countries health services are paid for by health insurances but in 
developing countries very few people can afford health insurance.  Many 
patients have to depend on government hospitals where the medicines are out 
of stock sometimes.   
 
Lack of knowledge is not the only factor that affects patients’ adherence levels 
to their anti-hypertensive treatments. In the Ethiopian Gondar study, the 
respondents’ knowledge about hypertension and treatment was high, at 76.8% 
but the adherence rate was only 64.6% (Gatti et al 2009:659).   
 
There appears to be a need for better health education for patients to know that 
if anti-hypertension treatment adherence is jeopardised or discontinued, they 
might be susceptible to potential health problems as complications of 
uncontrolled hypertension including cardio-vascular, renal and ocular 
consequences.  There is a need for a certain level of education to get exposed 
to cues that might motivate an individual to live a healthy behaviour and sustain 
it for a lifetime.  There is a need for sustainable cues to achieve sustainable 
health behaviour. After a while, an individual might perceive a benefit. The 
perceived benefit becomes the tangible cue to continue living according to the 
expected health behaviour (Chang et al 2012:118; DeCola et al 2012: 321; Gatti et 
al 2009:657; Glanz et al 2002:42; Kusuma 2009:280) . 
 
Adherence to treatment is a behaviour issue that requires to be addressed 
socially and psychologically. Behaviour takes long to be learned. Similarly, 
adherence to anti-hypertension treatment requires time to address all the 
adherence model’s elements such as the patient, disease, medications, 
healthcare workers, health care facility as a system, and the processes that take 
place within the health care facility (Mazzaglia et al 2009:1601). There is a 
positive association between patients’ adherence behaviour and their perception 
of disease severity and medication beliefs are also predictive of adherence 
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(Drevenhorn et al 2007:46; Drevenhorn et al 2009:349; Edo & De Villiers 2012:3; Gatti 
et al 2009:657). 
 
Table 4.13: The association of social, cultural and religious factors with 
anti-hypertension treatment adherence 
Factor Chi-square df P-value  f 
Being prayed for 0.46 2 0.794 477 
Ever suffered from malaria 3.91 2 0.142 476 
Used medicines against worms in last 3 
months 
2.83 4 0.587 231 
Treated for cancer in last 3 months 1.11 2 0.574 473 
On TB treatment 2.21 2 0.331 476 
Treated for yellow fever in last 3 months 7.43 2 0.024 451 
Had bilharzia parasites in last 3 months 0.71 2 0.702 474 
Had either malaria, cancer, yellow fever  
or bilharzia:                                                            
4.22 2 0.121 480 
Smoking status               8.43 4 0.077 454 
Alcohol drinking status 1.32 4 0.859 477 
Extra salt added to food 1.20 4 0.879 477 
Mother alive 4.31 2 0.116 461 
Mother on BP medicines 2.75 2 0.253 133 
Father alive 1.73 2 0.420 465 
Father on BP medicines 6.31 2 0.043 79 
Combines herbal and prescribed 
medicines 
10.78 2 0.005 366 
Used any herbs for BP for last 3 months 16.56 2 <0.001 474 
‡ From Pearson Chi-square or Fisher's Exact test  
*df: degrees of freedom     
 
Concerning their knowledge of hypertension, 55.2% (f=255) of the respondents 
in the current study knew that hypertension is a lifelong condition and that it is 
not curable.  In addition, 91.7% (f=440) of these respondents knew that 
hypertension could be controlled if the patient adheres to the medicines.  
Knowledge of the condition is not related to practice.  This is reflected in table 
4.12 where 45% (f=220) of the respondents reported that they forgot to take the 
medicine the previous day. There low and medium adherers in the current study 
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amount to 82.7% (f=395) out of 480 respondents. These patients were being 
treated at the clinic, but their blood pressures were not controlled. Therefore, 
with uncontrolled blood pressure, they were at high risk of developing potential 
complications of hypertension. Respondents were questioned about their social, 
cultural, religious practices to see whether those factors influenced their 
adherence behaviour. Statistically, all these aspects had no significant 
association with adherence except when the father was on anti-hypertension 
treatment which he combined with herbal treatment (see table 4.13).  
 
4.3.10.3   Factors influencing non-adherence to anti-hypertension  
                Treatment 
 
Patients have multifaceted reasons patients have for being non-adherent to their 
anti-hypertension treatment. The current study used MMAS-8 to measure levels 
of adherence in the patients as it was originally developed to measure non-
adherence to anti-hypertensive drugs. The theory underlying the MMAS-8 
suggests that non-adherence might be due to forgetfulness, carelessness, 
stopping the drug when feeling worse, or stopping the drug when feeling better 
and the eight items of the MMAS are centred on these four possibilities. The 
eight questions are: 
 
1. Do you sometimes forget to take your anti-hypertension pills? 
2. People sometimes miss taking their medications for reasons other than  
forgetting. Thinking over the past two weeks, were there any days when you 
did not take your hypertension medicine? 
3. Have you ever cut back or stopped taking your medication without telling  
      your doctor, because you felt worse when you took it? 
4. When you travel or leave home, do you sometimes forget to bring along your  
      anti-hypertension medication? 
5. Did you take your anti-hypertension medicine yesterday? 
6. When you feel like your hypertension is under control, do you sometimes  
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     stop taking your anti-hypertension medicine? 
7. Taking medication every day is a real inconvenience for some people. Do you  
     ever feel hassled about sticking to your anti-hypertension treatment plan? 
8. How often do you have difficulty remembering to take all your anti-hyper-    
    tension medications? (Please circle the correct number). 
 
       Never/Rarely……………………….4 
 
   Once in a while…………………….3 
   Sometimes………………………….2 
   Usually………………………………1 
   All the time…………………………..0 
The factors for non-adherence that were listed by respondents at QECH 
hypertension clinic included: forgetting, feeling better, feeling worse, and 
carelessness. 
 
Forgetting 
 
When the respondents were asked whether they had taken their anti-
hypertension medicine the day prior to the interview, 45.8% (f=220) said “no” 
and 54.2% (f=260) said “yes”. 
 
Table 4.14    Factors influencing anti-hypertension treatment non-
adherence (N=480) 
____________________________________ 
Factor___________ (f)     ____________(%)_ 
Forgetting  220   45.8     
Skipping  207   43.1    
Leave behind  141   29.4  
Troubled   105   21.9 
Feeling better 116   24.2 
Feeling worse 105   21.9 
Carelessness 103   21.5 
Difficult   212   44.1 
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These findings concur with what was reported that in many studies forgetfulness 
was found to be prominent (Osterberg & Blaschke 2005:490) in patients’ 
responses as a cause of non-adherence.  In addition, Sulaiman et al (2009:42) 
in Malaysia also found that 51.3% of their respondents were taking their 
medicine irregularly. This irregularity could be described as forgetfulness, which 
could be an intentional and non-intentional non-adherence, forgetting when you 
are mentally well. The difference between the two is that non-intentional non-
adherence is forgetfulness or difficulties keeping track of treatment associated 
with mental impairment.  
 
Feeling better 
 
Of the 480 respondents 78.5 % (f=377), reported that sometimes they stopped 
taking medications for a week or two, while 21.5%, (f=103) reported that they did 
not do so. These findings are similar to what was reported by (Osterberg & 
Blaschke 2005:487) who found that, about one third of patients stop taking 
drugs after feeling better, three months after beginning treatment. When they 
stopped the symptoms started again.  
 
Never stopping the drug when feeling better should be emphasised among 
hypertensive patients. It is quite common and is a behaviour that is a sign of 
lack of knowledge about the condition and its potential complications that with 
long term drugs adherence declines significantly overtime. This often happens 
when patients have no symptoms. It is the absence of symptoms that poses a 
barrier for people to take their medication. 
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Table 4.15: Univariate and adjusted correlations with adherence to anti-
hypertensive medications 
  Univariate†  P- Adjusted†#  
Characteristic f OR 95% CI value OR 95% CI P-
valu  
Having malaria 476 0.70 0.47, 1.04 0.077 ‡   
Had cancer in the last 3 months‡ 473 0.54 0.11, 2.51 0.429 ‡   
Had yellow fever in last 3 months 451 0.17 0.04, 0.75 0.019 ‡   
Had either malaria, cancer or yellow 
fever 
480 0.66 0.43, 0.99 0.046 0.89 0.52, 
1.52 
0.67  
Mother alive 461 1.33 0.91, 1.96 0.143 ‡   
Father alive 465 0.67 0.42, 1.08 0.099 ‡   
Have either parent alive 463 1.05 0.73, 1.50 0.803 0.96 0.63, 
1.47 
0.86  
Mother on htn drugs 133 2.09 1.02, 4.26 0.044 ‡   
Father on htn drugs 79 4.58 1.45, 
14.48 
0.010 ‡   
Either parent on htn drugs¶ 168 2.76 1.45, 5.26 0.002 2.36 1.19, 
4.67 
0.01  
Mixed herbs and drugs 366 1.99 1.31, 3.02 0.001 ‡   
Taking herbs in the last 3 months 474 0.48 0.34, 0.69 <0.00
1 
0.53 0.34, 
0.81 
0.00  
Long waiting times put me off  473 0.49 0.33, 0.72 <0.00
1 
0.62 0.38, 
1.03 
0.06  
Affected by long distance to clinic 455 0.61 0.42, 0.89 0.011 0.84 0.50, 
1.39 
0.49  
Htn drugs make me feel sleepy 429 0.70 0.49, 1.01 0.055 ‡   
Htn drugs make me feel weak 426 0.75 0.49, 1.15 0.190 ‡   
Htn drugs make me feel tired 425 0.74 0.48, 1.15 0.177 ‡   
Htn drugs make me feel sicker 396 0.51 0.31, 0.84 0.008 ‡   
Htn drugs caused side effects* 438 0.58 0.40, 0.84 0.004 0.88 0.55, 
1.41 
0.59  
Had any other problems 451 1.41 0.92, 2.16 0.118 0.74 0.45, 
1.23 
0.81  
Increasing level of htn knowledge** 446 1.43 1.15, 1.78 0.001 1.40 1.08, 
1.81 
0.01  
*Side effects: sleepy, weak, tired, sick        
**1=low, 2=moderate, 3=high defined using principal components (PCA) analysis and Cronbach's 
alpha 
† From ordered logistic regression models. ‡Not included in the adjusted final model due to multico-
linearity or p>0.2 
¶Adjusted for taking herbs in the last 3 months, htn knowledge level and long waiting times at clinic 
(f=154) 
#Adjusted for all other variables except either parent on BP drugs (f=358)   
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Feeling worse 
 
Some studies (Barksdale, 2009:55; Kazembe 2007:60; Lee, Grace & Tailor 
2006:622; Sattar, Shakeel, Majeed & Petty 2004:622) have reported patients 
who stopped treatment because of feeling worse from the side effects. Non-
adherence from side effects could be attributed to patients’ lack of knowledge 
about these side-effects.  
 
Health professionals should monitor the side effects and reassure the patients 
that with time the side effects could disappear or if necessary the treatment 
could be changed before non-adherence occurs (Osterberg & Blaschke 
2005:492). 
 
4.3.10.4   Cross tabulation: gender, adherence level and blood pressure  
 
In this section attempts will be made to cross tabulate the respondents’ gender 
with their anti-hypertension medication adherence levels and their blood 
pressure readings. 
 
• Gender 
 
On cross tabulation, gender of respondents and levels of blood pressure, more 
female respondents had severe hypertension 152 female versus 50 males. For 
moderate hypertension there were 136 females and 34 males. On cross 
tabulation of age of respondents and levels of blood pressure, the results 
showed that the older the age the lower the adherence, and the more the blood 
pressure increases from normal to mild, to moderate and to severe.  In addition, 
of the respondents falling within the age range 41-50 years, the majority (f=119) 
experienced severe hypertension, and the number increased as the age range 
increased, 81-90 years (f=204). In the age range 41-50, some respondents 
maintained their blood pressures under control (f=17) and even the age range 
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51-60 which was ten years older, but some respondents maintained their blood 
pressures under control (f=18), and at age range 81-90, some respondents 
maintained their blood pressure under control  (f=52) (see tables 4.16 and 4.17). 
 
Table 4.16: Cross tabulation of gender and level of blood pressure  
(N=480) 
  controlled mild moderate severe total 
 
Male  11  10   34    50  105 
Female 41  41 136  152  370 
Total  52  51 172  205  480 
 
These findings show that many patients (42.7%; f=205) at the QECH 
hypertension clinic had severe hypertension despite receiving treatment. 
 
• Age 
 
Table 4.17: Cross tabulation, age range and level of blood pressure  
                     (N=480) 
Level of blood pressure   
Age range  Normal Mild   ModerateSevere_ 
 
00-30     2    0    3     6 
31-40     5    5  15    15 
41-50   17  12  54  119 
51-60   18  17  59    60 
61-70     6  13  48    46 
71-80     3    3    8    21  
81-90   52  51 172  204 
 
 
• Education 
 
The levels of education of respondents and levels of blood pressure/adherence 
were cross tabulated. The results indicated that the respondents were mostly in 
two levels of education, primary school and secondary school. More than half of 
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the respondents (f=266) had primary school education, while 117 obtained some 
secondary school education.  The lower the education level the lower the ability 
of an individual to manage hypertension the lower the adherence and the lower 
the control of hypertension (see table 4.18) 
 
 
Table 4.18  Cross tabulation, level of education and level of blood pressure  
                    (N=480) 
 
Level of blood pressure 
_____________________________________________________________ 
Level of education  Controlled Mild Moderate SevereTotal_ 
None                6  4 28    33   72 
Primary school  27          39 91  109 266 
Secondary school  16  7 46    48 117 
College     0  1   7    12   19 
University     3  0   0      3     6 
Total    52          51       172  205 480 
 
4.3.11    Respondents’ knowledge about hypertension 
 
Respondents showed that they had some knowledge about hypertension 
because 55.2% (f=246) said hypertension runs in families and 55.2% (f=265) 
also mentioned that hypertension is a lifelong condition which can be controlled 
with adherence 91.7% (f=440).  As many as 91.7% (f=388) of the respondents 
identified some risk factors that could contribute to hypertension, and some of 
the factors were external 64.2% (f=308), while others mentioned diet (47%; 
f=226) and stress (83.8%; f=402).  
 
Out of 480 respondents, 74.7% (f=355) reported that they had received health 
education from the nurse about hypertension on the day of diagnosis and every 
day of review before consultation with the doctor. This showed that people had 
some knowledge about hypertension (see table 4.18). 
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Table 4.19: Respondents’ knowledge of hypertension (n=424) 
___________________________________________________________ 
          Yes (f)  (%) no (%)    don’t    (%) 
_______________________________________________ know _____ 
       
Runs in families   246 51.2 143 29.8 91 18.9 
Lifelong condition   265 55.2 143 29.8 72 15.0 
Controlled with adherence  440 91.6   18   3.3 22   4.6 
Has risk factors   388 80.8   43   9.0 49 10.2 
______________________________________________ 
Contributing factors________________  (f)________(%)_ 
   
Stress  402  83.8 
External  308  64.2 
    Diet  226  47.0 
    Salt  118  24.6 
    Alcohol   38    7.9  
    Cigarette   26    5.4    
_______________________________________________ 
Diagnosis      (f)      ______(%)_ 
 
            Hospital  424  88.3  
   Antenatal              42    8.8 
   Family planning   14    2.9 
_______________________________________________  
Complaints     (f)        (%)_ 
 
   Dizziness  109  22.7 
   Headaches   101  21.0 
   Heart palpitations 100  20.8  
   Tiredness   160   33.3 
    Painful eyes              10    2.2 
________________________________________________ 
Complications    (f)  (%)__ 
 
   Sudden death 139  28.9 
   Stroke   305  63.5 
   Kidney failure   20    4.3 
 Heart failure    16    3.3  
________________________________________________ 
Education received                                    (f)                (%)  
    
Agree   355  74.7 
   Disagree  125  25.3 
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4.3.11.1 Respondents’ knowledge about the management of hypertension   
 
Table 4.20 displays the management strategies adopted by patients suffering 
from hypertension.  
 
Table 4.20: Respondents’ knowledge about hypertension management  
                     (n=468)    
Variable      f    % 
Cigarette smoking  influences htn Yes  60 12.5 
 No 420 87.5 
Drinking alcohol influences to htn Yes   63 13.1 
 No 417 86.9 
Stress influences to htn Yes 355 74.0 
 No 125 26.0 
Hypertension influences to strokes Yes 335 70.2 
 No 142 29.8 
Heart attacks can occur as htn complications Yes   95 20.0 
 No 381 80.0 
Hypertension runs in families Yes 246 51.5 
 No 232 48.5 
Hypertension is a lifelong condition Yes 265 57.0 
 No 200 43.0 
External factors influence htn Yes 308 65.0 
 No 166 35.0 
Htn contributes to eye problems if untreated Yes 404 85.2 
 No  70 14.8 
Htn puts me at risk of heart conditions Yes 436 92.0 
 No   38   8.0 
Htn might cause strokes if untreated Yes 451 95.1 
 No   23   4.9 
Htn-triggered strokes can cause  death  Yes 468 98.5 
 No     7 1.5 
Complications of htn can endanger life Yes 467 98.5 
 No     7 1.5 
Friend/relative’s motivated me to take pills Yes 402 85.0 
 No 71 15.0 
Regular exercises help prevent htn Yes 434 91.7 
 No 39 8.3 
Medicines help reduce htn Yes 407 85.9 
 No 67 14.1 
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Almost all (98.8%; f=474) of the respondents knew the names of the drugs they 
were taking and these drugs were hydrochlorothiazide commonly called HCT 
and Propranolol. In addition some patients (41.7%; f=200) took other medicines 
such as Aspirin and Panadol for headaches or at bed time, while others (58.3%; 
f=280) said they did not do so. 
 
4.4 THE CONCEPTS OF THE HEALTH BELIEF MODEL 
 
The researcher assessed the patients’ perceptions of hypertension 
complications and their severity, treatment and treatment adherence with its 
benefits using the concepts of the HBM. There were 18 items that elicited data 
on the perceptions of hypertensive patients according to the HBMs concepts.   
 
Structured statements were read to the patients who were asked to rate the 
statement given using a 3-point Likert scale: Agree=3, Disagree=2, Don’t 
know=1. These were: perceived susceptibility, 4 items and an open-ended item,  
perceived severity, 4 items; and an open-ended item; perceived benefits, 3 
items, perceived barriers, 13 items and open-ended items; cues to action, 4 
items; and self-efficacy, 3 items and open-ended questions. 
 
4.4.1  PERCEIVED SUSCEPTIBILITY TO HYPERTENSION COMPLICATIONS    
 
The patients attending the QECH hypertension clinic demonstrated that they 
perceived that they were susceptible to potential complications of hypertension.  
The majority (86%; f= 410) reported that just by having hypertension they felt 
that they were at risk of developing potential complications. However, 8% (f=38) 
of the respondents did not perceive that they were susceptible to any 
complications. In addition, 6% (f=32) of them did not know whether they were 
susceptible to complications attributable to hypertension. Those who perceived 
themselves to be susceptible to complications listed potential complications 
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such as eye problems (84.2%; f=404), heart conditions (90.8%; f=436) and 
strokes (94.0%; f=451) as shown in table 4.21. 
 
Table 4.21: Perceived susceptibility to hypertension complications (N=480)     
__________________________________________           
Perceived susceptibility     opinion (f) (%)__ 
 
  
Develop eye problem agree  404 84.2    
    disagree   38   8.0    
    don’t know   38   8.0 
Develop heart conditions agree  436 90.8    
    disagree   24   5.0    
    don’t know   14   2.9 
Develop stroke  agree  451 94.0    
    disagree   16   3.3    
    don’t know     7   1.5  
 
These findings are in contradiction with those of Hareri and Abebe (2013:3)  in 
Tikur Hospital, Addis Ababa, where they assessed adherence and associated 
factors of adherence to medications among hypertensive patients attending a 
renal unit. Most of their respondents (82.2%; f=235) had a low level of 
perception of risks of developing hypertension complications.  
 
Kusuma (2009:268) in New Delhi, India, investigated the perceptions of patients 
with hypertension among the Indian immigrants using a qualitative design. The 
results showed that hypertension was perceived as a condition that reduces 
physical activity and causes tiredness, it was a result of being overweight and 
eventually it causes weakness and shortness of breath. These patients’ 
perceptions of hypertension were based on symptoms.  
 
The respondents were further asked to explain why they felt that they were 
susceptible to develop potential complications.  Some patients (58.3%; f=280) 
explained that the fact that their blood pressure was high made them 
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susceptible to strokes because they had heard that it is a common complication 
and they had seen many stroke patients in their communities (see table 4.22). 
 
Table 4.22:  Respondents’ explanations of their perceived susceptibility to 
complications attributable to hypertension (N=480) 
_______________________________________________________________ 
Explanation        (f) (%)_ 
 
I know people who have stroke, it can happen to me too 280  58.3 
Drugs are sometimes out of stock      100 20.8 
My blood pressure is always high despite taking medicines     43   9.0 
Condition is incurable, I lack discipline to stop drinking              26      5.4 
I lack discipline to follow the advice given by the doctor    25   5.2 
I live with stress from my family, and lack of support       6      1.3 
 
 
The major findings were that some respondents (58.4%; (f=280) in the current 
study were aware that uncontrolled hypertension could cause strokes, eye 
problems or heart attacks. This was possibly the case because they had 
received health education at the hypertension clinic where this study was 
conducted. 
 
4.4.2    PERCEIVED SEVERITY OF HYPERTENSION COMPLICATIONS 
 
The findings of the current study showed that most respondents (97.5%; f=468) 
at QECH hypertension clinic perceived the complications of hypertension to be 
severe. Only 1.7% (f=8) of the respondents did not perceive the complications of 
hypertension to be severe.  In addition, 0.8% (f=4) of the respondents did not 
know if complications of hypertension were severe. Of the 480 respondents, 
97.3% (f=467) reported that complications of hypertension could be very 
dangerous to life.  As many as 83.8% (f=402) reported that a relative’s death 
motivated them to take their anti-hypertension pills correctly for fear of death. 
Those who perceived the severity of the complications were requested to 
explain further how severe or dangerous the complications were. Out of 480 
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respondents, 34.8% (f=167) mentioned that complications could be heart 
attacks, 30.6% (f=147) said it could lead to sudden death, 4.2% (f=404) 
mentioned eye problems, while the majority (90.8%; f=436) mentioned heart 
conditions and strokes (94.0%; f=451) as shown in table 4.23. 
 
Table 4.23: Perceived severity of hypertension complications (N=480) 
_______________________________________________________________ 
Perceived severity              opinion   (f) (%) 
Someone can have a stroke but unaware of condition Agree  468 97.5 
Disagree     8   1.7 
        Don’t know     4   0.8 
Complications of hypertension are dangerous             Agree 467 97.3 
        Disagree   11   2.3 
        Don’t know      2   0.4 
A relative’s death motivated me to take pills correctly Agree  402 83.8 
        Disagree   67 13.9 
        Don’t know    11   2.3 
 
 
4.4.3 Perceived benefits of adhering to anti-hypertensive treatment  
          
These findings showed that the respondents had realistic perceptions of the 
severity of hypertension complications. This could be attributed to the health 
education that the nurses gave to the patients at the hypertension clinic. This 
education is given to a group of patients, and then followed by individual health 
education sessions. Health education is given every clinic day to the patients 
before consultation with a doctor. The health education, received at the 
hypertension clinic, enabled them to obtain high knowledge scores. They even 
explained the severity and gave examples to show that they knew what they 
were talking about (see table 4.24). 
 
These findings were similar to those found by Hareri and Abebe (2013:3).  In 
that study, the respondents (67.8%; f=194) had high perceptions of the severity 
of hypertension. Patel and Taylor (2002:43) conducted a study at Michigan   
Medical Centre’s hypertension clinic that aimed to determine if there was a 
relationship between illness perception, illness control and adherence to anti-
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hypertensive treatment. This was a prospective, cross-sectional survey of 
hypertension patients. The results showed that almost 68.0% of those patients, 
who perceived that they had hypertension and that hypertension causes 
complications, were adherent to treatment.   
 
Table 4.24: Respondents’ perceived benefits of anti-hypertension 
treatment adherence (N=480) 
________________________________________________________________ 
Item on perceived benefits    opinion   (f)   (%) 
Exercise and weight reduction  
Prevents complications    Agree  441 91.9 
    Disagree    21   4.4 
    Don’t know    18   3.8 
Medicine stop symptoms and I feel good   Agree   413 86.0
    Disagree    61 12.7
    Don’t know      6   1.3  
Salt reduction has reduced my heart palpitations Agree  465 96.8 
    Disagree    11   4.4  
 
Almost all respondents (91.9%; f=441) interviewed during the current study, 
reported perceived benefits of adhering to regular exercises and weight 
reduction which had helped them to prevent hypertension complications; 90.8% 
(f=436) of the respondents reported a reduction in heart palpitations as a result 
of reducing salt in their food; 86.0% (f=413) indicated that their anti-hypertensive 
medicines made them feel good, without hypertension symptoms. This meant 
that they had a feeling of well-being, and were able to do household chores 
which they were unable to do previously before they started treatment.  The 
expression was that before their treatment they could not manage to do their 
household chores due to breathlessness. But when they started attending the 
hypertension clinic, they received health education about diets, exercises, stress 
management and anti-hypertensive medications. These health education 
sessions were given by the clinic nurses on day of diagnosis and repeated at 
every subsequent clinic visit. Patients reported that they received health 
education about the names of drugs, doses and how the drugs worked. The 
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patients were able to mention the drugs’ names which they were taking, and 
could explain how many tablets they had to take how often. 
 
4.4.4 Perceived barriers to adhering to anti-hypertensive treatment  
            
 
The respondents perceived barriers impacting on their adherence to their 
treatment regimens as long waiting times for consultations with their clinicians 
(28.9%; f=139); shortages of drugs at the clinic’s pharmacy (69%; f=327); 
having to travel long distances to clinic (33.4%; f=160) (see table 4.25). 
Table 4.25: Respondents’ perceived barriers to adhering to anti-
hypertensive treatment regimens (N=480) 
_____________________________________________________ 
Barrier______________________________________(f)____(%)_ 
Long waiting time    Agree  333 69.3 
      Disagree 140 29.2  
      Don’t know      7   1.5 
 
Side effect-sleepy    Agree    95 19.8 
      Disagree 369 76.9 
      Don’t Know   17   3.3   
 
Side effect -weak     Agree    79 16.5 
      Disagree 397 82.7 
      Don’t know     4   0.8 
 
Side effect -tired    Agree    48 17.1 
      Disagree 399 82.1 
      Don’t know    24      5.0 
 
Side effect-Sicker    Agree     48 10.0 
      Disagree 339 85.1 
                                                                 Don’t know93 19.4 
 
Long distance to clinic   Agree  160 33.4 
      Disagree 317 69.2 
      Don’t know     3   0.6 
 
Drug stock out at the clinic   Agree  327 69.0 
      Disagree 153 31.0 
      Dont know     0 0 
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At the QECH hypertension clinic, 100 patients are booked every Friday. This 
makes the clinic full. QECH is the only central hospital that has a hypertension 
clinic and this is the reason why many patients are booked and so they have to 
wait in queues. Appointments are given by dates and not by time which means 
every patient arrives at 6:00am so that they are in front of the queue but they 
wait half the day before they get treatment. Patients experience long waiting 
hours but they still come because there is no other hypertension clinic except 
OECH. 
 
These findings are supported by Gascona et al’s (2004:125) qualitative study in 
which they investigated the factors why hypertensive patients did not adhere to 
their treatment.  The patients viewed the encounter and the process as being 
unsatisfactory because of the long waiting times.  Mweene et al (2010:252) in 
Lusaka, Zambia, interviewed 237 adult hypertensive patients and identified 
factors associated with poor medication adherence.  The majority of these 
patients (83.0%; f=195) reported that their barriers were prescribed drugs which 
were unavailable at the hospital pharmacy.  This could influence a patient’s 
adherence if he/she has to arrive at the clinic by 6:00 am and wait for many 
hours to be seen by a doctor only to get a prescription which the pharmacy 
cannot supply and which the patient cannot afford to buy elsewhere. 
 
4.4.5  Respondents’ cues to action 
 
     Out of the 480 respondents, 95.2% (f=457) said that health education about 
hypertension, which they received at the hypertension clinic, helped them to get 
motivated to follow their treatment regimens. It is the practice at the QECH 
hypertension clinic that when patients are referred for diagnosis and 
management they are given health education on hypertension as a condition, 
the causes, risk factors and the management. This is to equip the patients with 
basic knowledge to help them understand their condition. This also helps them 
to accept the condition, own it and take personal responsibility and active 
involvement in its control (Dreyer 2011:1-2). There is group education as well as 
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individual education. At the clinic there is a protocol for the management of 
hypertension (QECH, Protocol on diagnosing and treating hypertension 2011). 
The clinic nurse is a registered nurse who is in charge of the education 
programme of the patients and of running of the clinic.  During the structured 
interviews, the respondents frequently referred to the health education they 
received at the hypertension clinic. 
 
Table 4.26: Respondents’ perceived cues to action for adhering to their 
                   treatment regimens (N=480) 
 
_____________________________________________________ 
Item on cues     opinion (n) (%) 
____________________________________________________ 
 
Health education motivates adherence Agree  457 95.2 
      Disagree     5   1.0 
      Don’t know   18   3.8 
Family and friends’ advice motivates me Agree  429 89.4 
      Disagree   38   7.9 
      Don’t know   13   2.7 
Fear of kidney failure motivates me Agree  423 88.1 
      Disagree   24   5.0 
      Don’t know   33   6.9 
Fear of heart attack and stroke   Agree  440 91.7 
      Disagree   21   4.4 
      Don’t know   19   3.9 
____________________________________________________ 
 
 
These findings are supported by those of Kalogianni (2011:157) who found that 
provider-patient positive relationship fosters motivation, reinforcement and 
encouragement of adherence behaviours. Some of the patients (89.4%; f=429) 
said that they were motivated to adhere to treatment by their family members 
and friends through their advice. Family and friends are a support system of 
patients. In Malawi the severity of hypertension’s potential complications have 
been publisised (Mahawish & Heikinheimo 2010:25; Msyamboza et al 2010:88; 
Msyamboza et al 2011:4; Starichi 2011:24, QECH 2008:13; QECH 2010:15).    
Therefore family members and friends discuss this condition and warn each 
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other about the dangers of not adhering to treatment thereby motivating the 
patient to adopt adherence behaviours.  Kalogianni (2011:158) also found that 
lack of motivation was associated with poor medication adherence. Hence, the 
importance for health professionals to assess their patients and follow protocols 
that will motivate patients to increase their medication adherence.  
 
These findings were in contradiction to those found by Hareri and Abebe 
(2013:3) where 52.4% of their respondents were not motivated to adhere to anti-
hypertensive medication. This was explained, that some patients, especially 
men, were burdened by the outdoor activities which kept them busy causing 
them to lose focus, resulting in a lack of motivation to adhere to the anti-
hypertensive medications.  Alcohol consumption, a common practice by many 
males, could also destroy their motivation towards medication (Hareri & Abebe 
2013:5).    
 
In the current study there was another group of patients (88.1%; f= 423) who 
said that the fear of a heart attack and kidney failure motivated them to become 
more adherent. They had seen some patients who were bed ridden because of 
these complications of hypertension.  Some actually saw how others lost their 
lives due to strokes, kidney failure and heart attacks. This negative impact of the 
complications of hypertension on some patients was a positive motivator to be 
adherent because of the fear of potential hypertension complications and 
sudden death.  This is supported by the HBM which hypothesises that in a 
patient with hypertension, a high perceived threat; low perceived barriers and a 
high perceived benefit would result in the likelihood of exhibiting adherent 
behaviour (Glanz et al 2002:42).  
 
4.5   OVERVIEW OF RESEARCH FINDINGS 
 
The research findings have addressed demographic characteristics, socio-
economic aspects, knowledge, age, gender, religion, tribe, marital status, 
occupational status, health facility-related issues and blood pressure.   
153 
 
Table   4.27: Two-way associations between HBM concepts and adherence 
to anti-hypertensive treatment regimens 
  
Factor Chi-square df P- value‡
BP puts me at risk of eye problems 5.83 2 0.054
BP puts me at risk of heart conditions 3.95 2 0.139
BP might cause stroke 3.06 2 0.216
BP may lead to stroke-related death 0.39 2 0.825
BP complications are dangerous 1.43 2 0.490
Death of relative/friend motivates me 2.63 2 0.269
Excercise reduces BP complications 2.67 2 0.264
BP medicines relive me of BP 2.82 2 0.245
Reducing salt reduces palpitations 2.00 2 0.878
Long waiting times  put me off 14.75 2 0.001
Affected by long distance to clinic 8.80 2 0.012
Any adverse event from BP drugs 10.19 2 0.006
Any headaches 2.00 2 0.369
Experienced any stock outs 2.06 2 0.357
Health education motivates me 2.13 2 0.345
Family's/friends' advice motivates me 1.96 2 0.375
Fear of kidney failure motivates me 0.23 2 0.893
Fear of a heart attack motivates me 1.31 2 0.520
Able to manage own BP 4.74 2 0.093
Capable of managing own BP 4.72 2 0.095
‡ From Pearson Chi-square or Fisher's Exact test 
*df: degrees of freedom
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Cross tabulations were done of age, blood pressure range, and level of 
education. It has also presented respondents’ knowledge about hypertension 
management, of blood pressure, perceived severity of hypertension, perceived 
susceptibility to hypertension complications, perceived benefits, perceived 
barriers of adhering to anti-hypertensive treatment, and respondents’ cues to 
action. All these aspects are summarised in table 4.27. 
 
4.6 SUMMARY 
 
This chapter has presented the analysis and discussion of the study’s findings. 
The next chapter will present the study’s conclusions, limitations and 
recommendations. The synthesis of the research findings in relation to the 
research problem and objectives, the HBM, limitations of the study, 
recommendations and suggestions for future studies will also be addressed in 
the final (next) chapter of this thesis. 
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CHAPTER 5 
CONCLUSIONS, LIMITATIONS AND 
RECOMMENDATIONS 
 
 
5.1  INTRODUCTION 
 
The chapter presents the synthesis of the research findings in relation to the 
research problem and objectives, the HBM, limitations of the study, 
recommendations and suggestions for future studies. 
 
5.2  RESEARCH DESIGN AND METHOD 
 
In this study, the researcher used a quantitative, descriptive design because it 
best met the aim of the research which was to establish and describe, levels of 
adherence of patients to their anti-hypertensive treatment regimens factors. The 
design accurately described the characteristics of patients and factors that 
influenced their treatment adherence according to the MMAS-8.  
 
5.3    CONCLUSIONS 
 
The conclusions will be presented according to the objectives of the study, as 
stated in section 1.3.2 of this thesis. 
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5.3.1    Respondents’ levels of adherence to anti-hypertension treatment 
 
The first objective of the study was to establish patients’ levels of adherence, 
measured by the MMAS-8. There were 42.7% (f=205) patients with low 
adherence, 39.6% (f=190) patients with medium adherence and 17.7 %( f=85) 
with high adherence. Computation of average of the three levels is 33.3%. 
Therefore treatment adherence at QECH hypertension clinic is 33.3%.  
 
The positive findings of the study are that there are 17.7% (f=85) of high 
adherers at QECH hypertension clinic. But the majority of patients are living with 
uncontrolled blood pressures despite receiving treatment from the participating 
hypertension clinic. 
 
5.3.2     Respondents’ knowledge about hypertension 
 
The major findings indicated that most patients were knowledgeable about 
hypertension. However, there was a gap between what the patients knew and 
their actual behaviours. The knowledge was not translated into practice. For 
example, in the current study, out of 480 respondents 51.2% (f=246) said 
hypertension runs in families, while 55.2% (f=265) said hypertension is a lifelong 
condition, 91.7% (f=440) said it can be controlled with adherence, 80.8% (f=388) 
said it has risk factors.  However, from the same 480 respondents, 45.8% 
(f=220) stopped taking their anti-hypertensive medicines when they felt better 
and 43.1% (f=207) skipped some medication doses. This is a demonstration of 
knowledge that is not applied and it is as good as not knowing, because this 
knowledge did not benefit the individuals concerned.  
 
Regarding the factors influencing hypertension 83.8% (f=402) said stress, 
64.2% (f=308) external factors, others 47% (f=226) mentioned diet and 24.6% 
(f=118) mentioned salt intake. When asked about the complications of 
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hypertensions, 28.9% (f=139) said sudden death and 63.5% (f=305) mentioned 
strokes. 
 
5.3.3   Respondents’ perceived susceptibility to potential complications  
           attributable to hypertension 
 
The findings showed that respondents perceived themselves to be susceptible 
to complications because 94.0% (f=451) mentioned strokes as complications of 
hypertension.   
 
5.3.4 Respondents’ perceived severity of potential complications  
           attributable to hypertension 
 
The findings on perceived severity which were listed by the respondents were 
that someone can have a stroke but be unaware of his/her hypertension (97.5%; 
f=468) and complications are dangerous (97.3%; f=467). 
 
5.3.5 Respondents’ understanding of the benefits of treatment adherence 
 
The findings on perceived benefits which were listed by respondents included 
exercise and weight reduction to prevent complications (91.9%; f=441), anti-
hypertensive medicines stop symptoms (86.0% f=413), and salt reduction 
reduced heart palpitations (96.8%; f=465). 
 
5.3.6     Barriers impacting negatively on respondents’ adherence levels 
 
Respondents perceived barriers to adhering to treatment regimens included 
long waiting times at clinics (69.3%; f=333), medicines’ side effects (19.8%; 
f=95), the unavailability of prescribed drugs from the clinic’s pharmacy (69.0%; 
f=327) while 76.9% (f=369) said they encountered no barriers. 
 
158 
 
5.3.7   Respondents’ cues to action and self-efficacy for treatment  
           adherence 
 
The findings on perceived cues that were listed by respondents which motivated 
their adherent behaviour included the health education that they received 
(95.2%; f=457), advice from their families and friends (89.4%; f=429), fear of 
kidney failure (88.1% f=423), fear of heart attacks and strokes (91.7%; f=440).  
 
5.4  RECOMMENDATIONS 
 
The recommendations will be provided in relation to the conclusions (presented 
in terms of the study’s objectives).   
 
5.4.1   Enhancing patients’ adherence levels to anti-hypertension treatment 
 
An average adherence rate of 33.3% among patients attending the participating 
hypertension clinic must be improved, because this implies that 66.4% of these 
patients are non-adherent and do not benefit from their anti-hypertensive 
treatment.  Ongoing adherence studies should be conducted and quarterly 
audits of patients’ adherence levels should be conducted and published within 
the clinic.   
 
5.4.2   Enhancing the translation of patients’ knowledge into actions and 
behaviours 
 
Health education on hypertension, treatment, importance of treatment 
adherence, complications and the dangers of hypertension should attempt to 
enable patients to apply their knowledge to enhance their anti-hypertension 
adherence rates.  The clinic does provide effective health education for 
providing knowledge to patients, but means and ways should be found to help 
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patients to put their knowledge into action to enhance their adherence rates and 
reduce their risks of enduring complications from uncontrolled hypertension. 
 
Strategies should be put in place to help patients change behaviour and sustain 
them. Adherence to treatment is a behaviour issue that requires to be 
addressed socially and psychologically including culturally and attitudinally. 
Similarly, adherence to treatment in hypertension requires time allowed to 
address all the adherence model elements such as the patient, disease, 
medications, healthcare workers, health care facility as a system, and the 
processes that take place within the health care facility. All the elements or 
factors of the model should be involved each one taking their roles and 
responsibilities to improve adherence. 
 
5.4.3      Addressing respondents’ perceived susceptibility to potential  
              complications attributable to hypertension 
 
Health education efforts should emphasise that hypertension patients’ 
susceptibility to complications such as cardio-vascular incidents and strokes can 
be substantially reduced by adhering to their anti-hypertension treatment 
regimens.  Patients who have experienced such complications, or who have 
witnessed other patients who suffered from such complications, should be 
invited to participate in health education sessions.   
 
5.4.4      Respondents’ perceived severity of potential complications  
              attributable to hypertension 
 
The fact that more than 90.0% of the respondents knew that hypertension could 
pose life-threatening complications, did not enable 66.7% of them to adhere 
optimally to their anti-hypertension treatment.  The hypertension clinic should 
address this apparent discrepancy by conducting individual interviews with both 
adherent and non-adherent patients.  In this way some differences between 
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adherers and non-adherers could be identified and addressed to improve the 
average anti-hypertension treatment adherence level from the 33.3% 
documented during the current study. 
 
5.4.5      Respondents’ understanding of the benefits of treatment  
              adherence 
 
Ideally patients who have benefitted from anti-hypertensive treatment should 
join the nurses during health education sessions to inform other patients about 
their positive experiences and enhanced sense of wellbeing since they are using 
the drugs correctly and consistently.  Other aspects such as weight reduction 
and increased levels of physical activity and reduced intake of salt should also 
be addressed in similar ways. 
 
5.4.6     Barriers impacting negatively on respondents’ adherence levels 
 
Two major service-related barriers were identified during the current study.  Both 
these barriers could impact negatively on specific patients’ anti-hypertensive 
treatment adherence levels. 
 
The first barrier was posed by the long queues at the clinics that resulted from 
the clinic appointments being made for specific days without times.  This 
necessitated patients to spend many hours and even entire days at the clinic, 
making it almost impossible for working patients to attend the clinic regularly.  
Means and ways should be investigated into the possibility of making 
appointments for specific times and for adhering to these scheduled 
appointments.  This could enable a person to spend one hour at the clinic 
instead of six or more hours.  Having to spend less time at the clinic, could 
enhance patients’ adherence to clinic appointments, drug renewals and 
treatment efficacy. 
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The second major identified barrier was that the clinic’s pharmacy could not 
always supply the prescribed anti-hypertensive medicines and the respondents 
were unable to pay for these medicines at private pharmacies.  This 
shortcoming must be addressed as a matter of the greatest urgency because it 
defeats all efforts to ensure that patients’ hypertension levels are controlled.  
Shortages of medicines nullify all health education attempts.  The unavailability 
of relevant anti-hypertension medications must be investigated, addressed, 
audited and reported to the MoH on a monthly basis.  Without medications, the 
hypertension clinic with its nurses and doctors and pharmacists actually fail to 
provide hypertension services and its very right to existence should be 
questioned.  
 
Patients who waited in queues for six or more hours, listened to health 
education talks, and got prescriptions for unavailable medicines, wasted their 
time and might be demotivated to adhere to their future clinic appointments 
because it is impossible to adhere to unavailable medicines.   
 
One specific person should be assigned to monitor the unavailability of 
medicines at the clinic’s pharmacy.  Every identified challenge must be reported 
at clinic meetings and joint solutions should be sought to avoid this problem 
from wasting patients’ time and causing patients’ deaths due to uncontrolled 
hypertension because the clinic could not supply the necessary pills. 
 
5.4.7   Respondents’ cues to action and self-efficacy for treatment  
           Adherence 
 
Although the respondents in this study had the knowledge and support systems 
to adhere to their anti-hypertension treatment regimens, research should be 
sustained to enhance these abilities of the patients attending the hypertension 
clinic. 
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5.5  CONTRIBUTIONS OF THE STUDY 
 
The adherence levels for the QECH hypertension clinic patients are known: 
42.7% (f=205) have low adherence, 39.6% (f=190) had medium adherence and 
17.7% f=85 had high adherence. The adherence rate of patients to treatment at 
QECH hypertension clinic is known, 33%. There is a small number of patients 
with hypertension that are high treatment adherers. This is the small group of 
patients whose hypertension is controlled. This is the group that is protected 
from the potential complications of hypertension.  
 
Many hypertension patients are low and medium adherers 82.3% (f=395). 
These are the patients whose blood pressures are not controlled. Therefore, 
they are at high risk for developing potential complications of hypertension 
despite receiving treatment for hypertension at the clinic.  
 
These findings could provide useful inputs towards the finalisation of the            
national policy formulation in Malawi.  The results could be used as a guide to 
set bench marks for anti-hypertensive treatment adherence outcomes. 
  
5.6  LIMITATIONS OF THESTUDY 
 
The study was conducted at one site only; multiple sites could have enriched the 
research findings and enabled generalisation of the findings. Only structured 
interviews were conducted with 480 hypertension patients.  Individual in-depth 
interviews might have yielded richer data. These limitations resulted from time 
and financial constraints of the researcher as the study was a requirement for 
the fulfilment of the degree of doctor of literature and philosophy in health 
studies. As such the study had to be completed with limited financial resources. 
 
5.7  CONCLUDING REMARKS 
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This adherence study has provided awareness to the QECH hypertension clinic, 
the hospital management, the college of medicine, the college of nursing and 
the patients with scientific and current information on treatment adherence 
among hypertensive patients at the participating hypertension clinic 
 
The immediate action is to develop an intervention which will scale up the 
patients’ adherence levels to their anti-hypertension treatment (Starichi et al 
2011:28), using an adherence model with proven results. It is time to act against 
non-adherence. It is necessary to stress the type of condition, the importance of 
treatment, the dangers of not taking treatment, and the complications of 
hypertension.  
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Table 4.15: Univariate and adjusted correlations with adherence to anti-hypertensive 
medications 
  Univariate†  P- Adjusted†#  
Characteristic f OR 95% CI value OR 95% CI P-
value 
Having malaria 4f6 0.70 0.47, 1.04 0.077 ‡   
Had cancer in the last 3 months‡ 473 0.54 0.11, 2.51 0.429 ‡   
Had yellow fever in last 3 months 451 0.17 0.04, 0.75 0.019 ‡   
Had either malaria, cancer or yellow 
fever 
480 0.66 0.43, 0.99 0.046 0.89 0.52, 
1.52 
0.672 
Mother alive 461 1.33 0.91, 1.96 0.143 ‡   
Father alive 465 0.67 0.42, 1.08 0.099 ‡   
Have either parent alive 463 1.05 0.73, 1.50 0.803 0.96 0.63, 
1.47 
0.867 
Mother on htn drugs 133 2.09 1.02, 4.26 0.044 ‡   
Father on htn drugs 79 4.58 1.45, 
14.48 
0.010 ‡   
Either parent on htn drugs¶ 168 2.76 1.45, 5.26 0.002 2.36 1.19, 
4.67 
0.014 
Mixed herbs and drugs 366 1.99 1.31, 3.02 0.001 ‡   
Taking herbs in the last 3 months 474 0.48 0.34, 0.69 <0.00
1 
0.53 0.34, 
0.81 
0.004 
Long waiting times put me off  473 0.49 0.33, 0.72 <0.00
1 
0.62 0.38, 
1.03 
0.063 
Affected by long distance to clinic 455 0.61 0.42, 0.89 0.011 0.84 0.50, 
1.39 
0.492 
Htn drugs make me feel sleepy 429 0.70 0.49, 1.01 0.055 ‡   
Htn drugs make me feel weak 426 0.75 0.49, 1.15 0.190 ‡   
Htn drugs make me feel tired 425 0.74 0.48, 1.15 0.177 ‡   
Htn drugs make me feel sicker 396 0.51 0.31, 0.84 0.008 ‡   
Felt htn drugs made them feel side 
effects* 
438 0.58 0.40, 0.84 0.004 0.88 0.55, 
1.41 
0.591 
Had any other problems 451 1.41 0.92, 2.16 0.118 0.74 0.45, 
1.23 
0.810 
Increasing level of htn knowledge** 446 1.43 1.15, 1.78 0.001 1.40 1.08, 
1.81 
0.012 
*Side effects: sleepy, weak, tired, sick        
**1=low, 2=moderate, 3=high defined using principal components (PCA) analysis and Cronbach's 
alpha 
† From ordered logistic regression models. ‡Not included in the adjusted final model due to multico-
linearity or p>0.2 
¶Adjusted for taking herbs in the last 3 months, htn knowledge level and long waiting times at clinic 
(f=154) 
#Adjusted for all other variables except either parent on BP drugs (f=358)   
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Annexure D: Structured interview schedule English version 
Research title: Factors influencing treatment adherence amongst hypertensive patients at 
Queen Elizabeth Central Hospital, Blantyre, Malawi. 
Date______ Researchers’/Assistants’ name________________            Code___________     
Check list: Instruction: Enter the following from the patient’s health passbook:                                       
Time B/P Weight,  
height 
BMI                   Drug’s 
Name      Dose/tabs  Frequency 
1. Current     
2. Previous  1st     
3.    ,,          2nd     
4.    ,,          3rd     
5.    ,,          4th     
6. Year high blood pressure diagnosed___Age___   
7. Number of years patient has had high blood 
pressure and on treatment  
 
8. Year tested HIV ______________________           
9. Year started ART_____________________ 
10. List all prescribed ARVs_______________            
 
 
 
A. Demographic data  
Q Questions Possible  responses Code Skip 
A.1. Gender  Male …………… 
Female …………                         
    1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
 
A.2. How old are you? 
 
_____________      
    1 
A.3. What is your tribe? Chewa ………….. 
Ngoni …………… 
Tumbuka ……… 
Lomwe ………… 
Yao…………....... 
Other (specify)..... 
 
 
    1 
    2 
    3 
    4 
    5  
    6 
A.4. 
 
 
 
 
 
 
What is your religion? 
 
 
 
 
What is your highest level of 
education that you have 
Roman Catholic..... 
Presbyterian......... 
Anglican................ 
Pentecostal.......... 
Muslim................. 
Other (specify)...... 
 
    1 
    2 
    3 
    4 
    5 
    6 
 
185 
 
A.5. achieved a certificate? 
 
None……...…........ 
Primary school....... 
Secondary school... 
College (Deg, Dip, Cert 
University (Deg,Dip,Cert . 
   1 Skips 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If 
none 
Skip 
A.15,  
 
 
 
If 
male 
skip 
A.16. 
   2 
   3  
   4 
   5 
    
A.6. 
 
What is your occupation?     _______ 
 
   1 
 
A.7. 
 
What is your home district?     _______ 
 
   1 
 
A.8. 
 
Which health facility has referred 
you to QECH high blood 
pressure clinic? 
    _______ 
 
 
   1 
 
 
A.9. What is your marital status?      _______    1 
 
A.10.  
 
How many children have you 
had? 
     _______    1 
    
A.11. Did you encounter any of the 
following signs and symptoms 
during pregnancy 
 
Fits....................... 
Oedema............. 
Headache........... 
Blurred vision........ 
None……………. 
Other (specify)...... 
 
   1 
   2 
   3 
   4 
   5 
   6 
A12. Did you ever suffer from high 
blood pressure in your previous 
pregnancy?  
Yes................... 
No..................... 
   1 
   2 
A.13.   
 
How many children are alive? ______    1 
A.14.  
 
How many children have died? ______     1 
A.15.   What were the causes of deaths 
of the children? 
                          
____________________  
____________________ 
 
Don’t know……. 
   1 
    
2 
A.16. Are you currently pregnant? Yes………………….. 
No…………………… 
   1 
   2 
 
 
 
  
                                                                                                                             
 
B. Knowledge about high blood pressure/ Kudziwa za nthenda-Bipii 
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B.17. Is it true that high blood pressure 
runs in families? 
Yes........... 
No............. 
Don't know......... 
  1    
   2   3 
B.18. Is it true that high blood pressure 
is a life-long condition, not 
curable?  
Yes…………. 
No…………… 
Don’t know...... 
  1 
  2 
  3 
B.19. 
 
 
Is it true that high blood pressure 
can be controlled if patients 
accept it and adhere to their 
treatment? 
Yes.................. 
No................... 
Don’t know....... 
  1 
  2 
  3 
B.20. What complications can occur if 
high blood pressure is 
uncontrolled?  
(Tick all that patient mentions) 
Stroke................... 
Heart attack............ 
Blurred vision.......... 
Kidney failure.......... 
Sudden death......... 
  1 
  2  
  3 
  4 
  5 
B.21. Is it true that the reason why 
people get high blood pressure is 
not known but there are risk 
factors that contribute to it? 
Yes.....................  
No...................... 
 
Don’t know......... 
  1 
  2 
  
 3 
 
B.22. 
 
 
 
 
 
 
 
 
What factors do you think 
contribute to high blood 
pressure? 
. 
 
 
 
 
 
 
Cigarette smoking… 
Alcohol drinking…… 
Stress……………… 
Obesity……………. 
Lack of exercise….. 
Eating- salted foods 
(dried salted fish and 
meat). 
,,   too much salt....                
,,   too much sugar. 
Other (specify)...... 
 
 
  1 
  2 
  3 
  4 
  5 
  6 
   
  7 
  8 
  9 
B.23. Is it true that there are also 
external factors that contribute to 
high blood pressure? 
Yes..................... 
No........................ 
Don't know........... 
  1 
  2 
  3 
 
B.24. 
 
 
 
What external factors do you 
think contribute to high blood 
pressure? 
(Tick all that patient mentions) 
 
Diet……………..... 
Physical exertion... 
Strange environment 
Stress....................... 
   
  1 
  2 
  3 
  4 
 
 
B.25. What factors (risks and external) Cigarette smoking...   1    
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do you think contributed to your 
high blood pressure? 
(Tick all the patient mentions) 
Alcohol drinking.... 
Stress…………….. 
Obesity…………….. 
Lack of exercise..... 
Eating- salted foods. 
,,     too much salt...      
,,   too much sugar.. 
Diet........................ 
Physical exertion... 
Strange environment 
Other (specify)..... 
 
 
  2   Skips 
  3 
  4 
  5 
  6 
  7 
  8 
  9 
 10 
 11 
 12 
B.26. How was your high blood 
pressure diagnosed 
 
Checked my B/P at 
Hospital outpatients. 
Antenatal clinic....... 
Job appointment..... 
Blood donation day. 
Buying insurance.... 
Other (specify)........ 
 
 
 
   1 
   2 
   3 
   4 
   5 
   6 
B.27. 
 
What were your complaints when 
your high blood pressure was 
diagnosed? 
(Tick all that patient mentions). 
 
 
Dizziness………..... 
Severe headaches. 
Bells in ears........... 
Heart palpitations... 
Fainting attacks...... 
Other (specify)....... 
 
 
   1  
   2 
   3 
   4 
   5 
   6 
B.28. Have you ever received health 
education about high blood 
pressure? 
Yes…………….. 
No…………........ 
 
  1 
  2 
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C  Knowledge about treatment  of high blood pressure 
 
C.29. 
 
What high blood 
pressure medicines are 
you currently taking 
      a, name  
      b, dose 
      c, frequency? 
 
(Tick all that patient 
mentions) 
. 
 
 
 
Name Dose  Freq. 
Hydrochloro 
thiazide (HCT) 
  
Frusemide   
Propranorol   
Atenoral   
Nifedipine   
Aldomet   
Other (specify) 
Description of 
pills: small 
round pink 
white pills 
  
 
Code  
 
1a,b,c  
  
  
2a,b,c    
3a,b,c  
4a,b,c  
5a,b,c  
6a,b,c  
7a,b,c  
   
C.30. What other medicines 
are you currently taking 
in addition to your high 
blood pressure pills/ ndi  
a, name 
b, dose 
c, frequency? 
(Tick all that patient 
mentions) 
Panadol   
Indocid   
Diclofenac   
Aspirin   
Herbs   
Nutrition 
supplements 
  
Other (specify) 
 
  
 
1a,b,c 
 2a,b,c 
 3a,b,c 
 4a,b,c 
 5a,b.c  
  
 6a,b,c  
 8a,b,c 
  
C.31. 
 
 
 
Do you take your high 
blood pressure pills with 
other medicine/pills at 
the same time? 
Yes……………… 
No……………… 
  
 
      1 
      2 
 
 
C.32. What did you eat 
yesterday morning? 
 
 ________________________ 
 
       
     1 
 
C.33. What did you eat 
yesterday midday? 
(Probe for fats and salt 
content) 
 
 _________________________ 
 
 
     1 
 
C.34. What did you eat 
yesterday evening? 
Probe ! 
 
_________________________ 
 
      1 
C.35. 
 
What were you advised 
to eat in relation to 
hypertension? 
None……………………... 
Less salt............................. 
Less fats….......................... 
      1 
      2 
      3 
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(Circle all mentioned)  Less spices......................... 
Fewer carbohydrates............ 
Green vegetables............... 
Bananas............................. 
Other (specify).................... 
 
 
      4 
      5 
      6 
      7 
      8 
 
C.36. 
 
What were you advised 
not to take or do? 
 
(Tick all that patient 
mentions ) 
 
Excess salt…........................ 
Fatty Meat …………........... 
Spiced foods............................. 
Excess carbohydrates.............. 
Alcohol...................................... 
Cigarettes................................. 
Other (specify)…….................. 
 
 
      
      1  
      2 
      3  
      4 
      5 
      6 
      7 
36 a. Tell me about the type of food that your family eats most frequently for 
 Breakfast: __________     ____________   ___________  _______________   1           
Lunch    : ____________   ____________   __________  _________________  2 
Supper   : __________   ____________   __________  ___________________ 3       
 
D.37. Has someone prayed for your healing from high 
blood pressure? 
Yes…….............. 
No……............... 
       1  If no skip  
D. 38        2 
D.38. If yes, did you get better from high blood 
pressure after the pastors prayers ? 
Yes……............. 
No………........... 
       1  
       2  
D.39. Have you ever suffered from malaria? Yes………......... 
No………........... 
       1 If no skip 
40-41 
 
 
 
 
 
 
 
 
if no 
Skip 
43, 44 
 
 
       2 
D.40. 
 
 
If yes, when (in years) was the last malaria 
attacks?  
 
_____________ 
        
      1 
        
D.41. How many courses of malaria medicines have 
you had in the last three months?  
None………………. 
One..........................  
Two.......................... 
Three....................... 
 
       1 
       2 
       3 
       4 
D.42. Have you ever suffered from internal worms, if 
yes, how often? 
None..................... 
Once....................... 
Other (specify).......... 
       1 
       2 
       3 
D. Medical, social , cultural and reproductive health data 
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D.43. Were you treated for internal worms in the last 
three months? 
 
_____________ 
         
       1 
 
 
 
D.44. 
 
 
Have you used medicines against 
worms during the last three months? If 
yes what medicines? 
 
 
Yes........................... 
 
 
No............................. 
  
____________ 
   
 
     1 
 
 
 
       2 
        
 
       3 
D.45. Were you treated for cancer during the 
last three months? 
If yes, what treatment did you receive? 
Yes.......................... 
No............................ 
 
 
_______________ 
       1   
        2 
        
        
       3 
       
D.46. Are you on (tuberculosis) TB treatment? Yes…………………. 
No………………….. 
      1 
      2 
D.47.          
 
Have you been treated for yellow eyes 
(liver disease) in the last three months/ 
? 
Yes....................... 
No........................ 
      1 
      2 
D.48. Have you had bilharzias parasites in 
your bladder in the last three months? 
Yes…………………. 
No…………………… 
Don’t know 
      1 If no 
skip 
D.49.  
      2 
      3 
D.49. How many times have you had 
medicines for bilharzias?  
1 time………………… 
3 times……………… 
6 times……………… 
N/A........................... 
      1   
 
 
 
 
 
 
 
 
 
      2 
      3 
      4 
D.50. How many cigarettes do you smoke per 
day/ ?    
  _____________    
  
      1           
       
D.51. How much alcohol do you drink per 
week? (Probe for measure: bottles, 
packets, sachets or glasses)   
      
      ___________ 
 
      1 
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D.52. 
 
How much extra salt do you add to your 
food when eating?   
 
Nothing...………… 
Small pinch............ 
Half teaspoon............ 
Teaspoonful.........…... 
       
      1        
 
 
 
 
 
If no 
skip 
 
54-57 
 
 
 
 
 
      2 
      3 
      4 
D.53. Is your mother alive? Yes............................ 
No............................. 
      1 
      2 
D.54 How old is she?     __________ years       1 
 
D.55. Has she been taking high blood 
pressure medicines? 
Yes............................. 
No.............................. 
      1 
      2 
D.56. 
 
Has she ever suffered from a stroke? Yes........................... 
No............................ 
      1 
      2 
D.57. Has she ever suffered from a heart 
attack? 
Yes............................ 
No.............................                            
      1 
      2 
D.58.  If not alive what was the 
cause of death,  
Stroke........................ 
 heart condition.......... 
Other (Specify........... 
      1 
      2 
      3 
 
 
If  long r alive, what was the caus  
death? 
Stroke .................. 
Heart condition.......... 
Don’t know…………. 
Other (specify).......... 
 
     1  
 
 
 
      2 
      3 
      4 
D.59 How old was she when she died?  
__________years 
       
      1 
D.60. Is your father alive?  Yes………………… 
No……................... 
      1    If no, 
skip 
D.62-64 
      2 
D.61. How old is he?  
___________years 
       
      1 
D.62. Has he been taking high blood pressure 
medicines? 
Yes............................ 
No.............................. 
      1 
      2 
D.63. 
 
Has he ever suffered a stroke? 
 
Yes........................... 
No............................. 
      1 
      2 
       
D.64. Has he ever suffered a heart attack? Yes............................ 
No............................. 
      1 
      2 
D.65. If no longer alive, what was the cause of 
his death? 
Stroke....................... 
Heart attack.......... 
Don’t know………… 
Other (specify).......... 
      1 
      2 
      3 
D.66.  At what age did he die? _________ 
Don’t know 
      1  
 
D.67. Have any of your sisters died/? Yes………………… 
No………………….. 
      1 If no 
skip 68       2 
 
D.68. 
 
a) At what age did the sisters die? 
b) What high blood pressure medicines 
  
 
Ag
 
 
On 
 
 
Cause of 
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was she taking?  
c) What was the cause of  
     her death? 
(Fill in appropriate boxes). 
e? B/P 
drugs? 
death?  
 
 
 
 
 
 
 
1st            
1a,b,c 
2nd       
2a,b,c 
3rd     3a,b,c 
Other 
(speci
fy) 
    4a,b,c 
D.69. Have any of your brothers? Yes...............................
..................... 
No................................
...................... 
1    
 
 
 2                                                                
D.70. a) At what age did your brother die?  
b) What high blood pressure medicines 
was he taking?  
c) What was the cause of his death? 
(Fill in appropriate boxes). 
1st           
1a,b,c 
 
2nd     
2a,b,c 
3 rd     
3a,b,c 
Other 
(specif
y 
    
4a,b,c 
D.71. Have you used any herbs for high blood 
pressure during the last three months? 
Yes………………….... 
No…………………...... 
N/A………………….... 
      1  
       2 
      3 
D.72. Did you feel better when you used 
these herbs? 
Yes…………………. 
No…………………… 
N/A 
      1 
      2 
      3 
 
D.72a.  Please tell me how you took your prescribed high blood pressure pills during  
           the last three days/?___________________________________________ 
      ________________________________________________________________ 
D.73. Do you combine herbal and prescribed 
high blood pressure medicines? 
Yes………………….. 
No…………………… 
N/A…………………... 
     1 
      2 
      3 
D.74. What is your source of herbal 
medicine? 
(Tick all the patient mentions) 
Parents…………….. 
Friend……………… 
Neighbour ………….. 
Herbalist…………… 
Spouse……………… 
      1 
      2 
      3 
      4 
      5  
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Self………………… 
N/A………………… 
Other (specify)…… 
 
      6 
      7 
      8 
 
         E. The Health Belief Model Concepts 
Perceived susceptibility  
                 Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Esu.75-77a             
                Rating scale:  Agree = 3          Disagree = 2          Don’t know = 1             3 2 1   Code                                                                                            
No. Item      
Esu.75. Having high blood pressure puts me at risk of developing 
problems with my eyes if I do not take my prescribed high 
blood pressure medicines. 
    
1 
 
Esu.76. High blood pressure puts me at risk for developing heart 
conditions if I do not take my prescribed high blood pressure 
medicines.  
    
1 
 
Esu.77. High blood pressure might cause a stroke if I do not take my 
prescribed high blood pressure medicines. 
    
1 
 
77a.   Please, explain whether you feel that you are at risk of developing complications as    
           a result of your high blood pressure?. _____________________________________ 
          _________________________________________________________ 
 Perceived severity 
  Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Esev.78-80a             
Rating scale:  Agree = 3             Disagree = 2               Don’t know = 1    3   2  1 Code 
No. Item       
Esev.78. Some people can suffer from strokes and die without knowing 
that they had high blood pressure. 
     1  
Esev.79. The complications of high blood pressure are dangerous in life.      1  
Esev.80. The death of a relative or friend from a stroke motivated me 
never to miss taking my high blood pressure pills. 
     1  
80a.    Explain how dangerous you think complications of high blood pressure are? 
__________________________________________________________________ 
 __________________________________________________________________  
__________________________________________________________________  
Perceived benefits   
   Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Ebe 81- 83          
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                Rating scale:  Agree = 3         Disagree = 2           Don’t know = 1               3  2  1  Code                                                                                                  
Ebe.81. Regular exercises and weight reduction have helped me to 
prevent high blood pressure complications. 
   1  
Ebe.82. The medicines that I am taking make me feel good and without 
high blood pressure symptoms. 
   1  
Ebe.83. Reducing salt in my food helps to reduce my heart palpitations.    1  
   
Perceived barriers 
Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Eba.84-86, 86.1-86.10             
                Rating scale:  Agree = 3                Disagree = 2              Don’t know = 1        3 2 1 Code                                                                                                         
Eba.84. Long waiting times at the clinic put me off medication refills.      1  
Eba.85.  
       85a. 
       85b. 
       85c. 
       85d. 
High blood pressure pills make me:  sleepy ……….  ...............  
 weak                                                                                 
Tired......................................................................................... 
 Sicker……………………………………….................................. 
 Other/ (specify) ……………………….........................................                                                                                                                       
 
     1 
  2 
  3 
  4 
5
 
Eba.86.   The long distance to the high blood pressure clinic makes me 
miss my appointment when I have no bus fair. 
     1  
86.1 What unpleasant experience have you encountered after taking your high blood 
pressure pills during the last three months?________________________________ 
86.2 Have you had any headaches during the last three months? 
___________________________________________________________ 
86.3 At what time of the day did you have 
headaches?__________________________________________________________  
86.4 What steps did you take to relieve your 
headache?_________________________________________________________________
_________________________________________________________________   
86.5 Have you informed the high blood pressure clinic nurse/doctor about  
       your headaches?___________________________________________________ 
86.6 What remedy did the doctor suggest?__________________________________ 
86.7 Has the remedy worked for you?______________________________________ 
86.8 Do you experience any other problems when you take your blood pressure pills? 
___________________________________________________________________ 
195 
 
86.9 Do you experience drug stock outs at the hypertension clinic?_______________  
86.10   What happens when drugs are not there?_____________________________ 
 
Cues to action 
                Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Eca.87-90             
                Rating scale:  Agree = 3         Disagree = 2        Don’t know = 1                 3 2 1 code                                                                                                    
Eca.87. Health education about high blood pressure motivates me to 
adhere to treatment.  
     
Eca.88. My family's and friends' advice motivates me to take my high blood 
pressure treatment regularly. 
     
Eca.89. Fear of kidney failure as a complication motivates me to take my 
high blood pressure pills. 
     
Eca.90. Fear of a heart attack motivates me to take my high blood 
pressure pills as prescribed. 
     
 
 
Self-efficacy 
                 Instruction: Read the following statements to patient and allow to rate according to own 
opinion and fill in the provided column for Esef.91- 93, 93a-93b            
                Rating scale:  Agree = 3          Disagree = 2           Don’t know = 1             3 2 1 code                                                                                              
Esef.91. I have the ability to manage my high blood pressure     
1 
 
Esef.92. I understand the importance of taking my high blood pressure 
treatment regularly and correctly to control my blood pressure. 
    
1 
 
Esef.93 I am capable of keeping my blood pressure under control.     
1 
 
93a.What gives you confidence to adhere to your high blood pressure treatment? 
____________________________________________________________________ 
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93b.What physical activities have you done during the last one week? 
 ____________________________________________________________________ 
 
8. How often do you have difficulty, remembering to take all your medications?                
 (Please tick the correct number) 
     
               Never/rarely...................................................…........4 
               Once in a while..........................................................3 
       Sometimes................................................................2 
       Usually......................................................................1 
F. Morisky Medication Adherence Scale MMAS-8:  F94-101. 
©Morisky Medication Adherence Scale (MMAS-8-Item). This is a generic adherence scale and the name of 
the health concern can be substituted in each question item.  You have said that you are taking 
medications for high blood pressure. Individual people have given several issues concerning their 
medication–taking behavior and we are interested in your experience. There is no right or wrong 
answer.  Please answer each question according to your  personal experience with your high blood 
pressure medication 
                                                                 (Please tick the correct number)                                     
                                                                                                                                                            No-1     Yes-0 
1. Do you sometimes forget to take your high blood pressure pills?   
2. Sometimes individual persons skip their medication due to reasons other than forgetting. 
In the past two weeks were there any days when you did not take your high blood 
pressure medicine? 
 
 
 
 
3.  Have you ever reduced, or stopped taking your medicine, without informing your  
 doctor, because you felt worse when you took it? 
  
4. When you travel or leave home, do you sometimes forget to take with you your high 
blood pressure medicine? 
  
      5. Did you take your high blood pressure medicine yesterday?   
6. When you feel that your high blood pressure is controlled, do you sometimes stop taking 
your medicine? 
  
7. Taking medication every day is a real disturbance for some people. Do you feel 
troubled about following your high blood pressure treatment plan? 
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       All the time ....……....………………..........................0  
Coding Instructions for the ©Morisky Medication Adherence Scale (8-Item) 
You will need to reverse the code response in a positive direction for item number 5 and 
standardize the code for item 8 (0-4), resulting in a scale from low adherence to high 
adherence.  Item 8 is divided by 4 when calculating a summated score. This procedure 
standardizes the 5-point Likert scale.  The total scale has a range of 0 to 8.0.  The eight-item 
compliance scale had an alpha reliability of 0.83 (n= 1367) among patients diagnosed with 
essential hypertension attending an outpatient clinic of a large teaching hospital.  We have 
used a 75% completion criterion for establishing eligibility.  The median value of all missing 
items would be substituted for the missing item for individuals meeting the eligibility criterion.   
Re-codes: 
If Item5 = 0 Item5r =  1   (high adherence) 
If Item8=4 Item8r =    1  (highest adherence) 
If Item8=3 Item8r = .75  (high adherence) 
If Item8=2 Item8r = .50 (moderate adherence) 
If Item8=1 Item8r = .25 (low adherence) 
If Item8=0 Item8r =  0   (lowest adherence) 
Adherence Level Percent 
  
Low Adherence (< 6)                                                    32.1 
Medium Adherence (6 to <8)                                        52.0 
High Adherence (= 8)                                                    15.9 
Required citation and footnote for the 8-item MMAS are as follows: 
 
Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication Adherence 
Measure for Hypertension Control. Journal of Clinical Hypertension 2008; 10(5):348-354. 
 
This footnote is required on all tables or figures which present the ©MMAS-8. 
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. 
A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, 
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Department of Community Health Sciences, UCLA School of Public Health, 650 
Charles E. Young Drive South, Los Angeles, CA 90095-1772. 
Additional citation you may use to document criterion-related validity with pharmacy 
fills 
Krousel-Wood MA, Islam T, Webber LS, Morisky DE, Muntner P. Concordance of Self-
Reported Medication Adherence by Pharmacy Fill in Patients with Hypertension. Am J 
Managed Care 2009; 15(1):59-66. 
 
Al-Qazaz HK, Hassali MA, Shafie AA, Sundram S, Morisky DE. The Eight-Item Morisky 
Medication Adherence Scale (MMAS-08):Translation and Validation of the Malaysian 
version. Diabetes Research and Clinical Practice 2010; 90:216-221. 
COPYRIGHT-and Waiver of Licensure Fee for the Morisky Medication Adherence 
Scale, 8-Items 
 
All translations, adaptations, computer programs, and scoring algorithms, and any other 
related documents of the Morisky Medication Adherence Scale (MMAS 8- item version), or 
Morisky Adherence Questionnaire (MAQ 8-item version) are owned and copyrighted by, and 
the intellectual property of, Donald E. Morisky, ScD, ScM, MSPH. Professor of Community 
Health Sciences, UCLA School of Public Health, Los Angeles, CA 90095-1772.  Copyright 
protection is also extended to electronic versions of all Morisky Scale documents and 
products.  
 
Permission to use the scale is granted through a licensure agreement between the owner 
and licensee.   
 
1) No changes to the wording or phrasing of any Morisky Scale document can occur 
without written permission. If any changes are made to the wording or phrasing of any 
MMAS item without permission, the document cannot be considered the MMAS, and 
subsequent analyses and/or comparisons to other MMAS data will not be considered 
appropriate. 2) The specific coding and scoring criteria of the MMAS-8 cannot be divulged 
in any publication or external report without prior permission from the owner; 3) 
Permission to use the name "MORISKY SCALE" or MMAS will not be granted for any 
unauthorized use or translations of the MORISKY SCALE or MORISKY SCALE items. 
Any analyses or publications of unauthorized changes or translated versions may not use 
the MORISKY SCALE name. Any unauthorized translation will be considered a violation 
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of copyright protection.  If you are interested in translating this scale, please notify me and 
I will advise you regarding the requirements for translation 4) The MORISKY SCALE 
copyright information provided on these documents must be included on every page of a 
MORISKY SCALE questionnaire in study documents, and in any reproductions for 
manuscript or other publication purposes. 5) If there are issues of scientific or copyright 
misconduct in using the MORISKY SCALE system of questionnaires, Dr. Morisky 
reserves the right to withdraw permission for use and seek damages to the full extent 
provided by international copyright law. 
I understand that the licensure fee for use of the copyrighted MMAS-8 will be waived, 
as I am an academic researcher conducting adherence research. The license 
agreement is in effect for a one-year period or the duration of the study, whichever is 
shorter.  I agree with the specification outlined above regarding the use of the Morisky 
Medication Adherence Scale, 8-Items, MMAS-8 and will abide with its requirements. I 
agree to provide results of my research to Professor Morisky upon completion of the 
study.  Please fax or scan and email to : Donald E. Morisky, ScD, ScM, MSPH, 
Professor, Department of Community Health Sciences, UCLA School of Public Health, 
650 Charles E. Young Drive South, Los Angeles, CA 90095-1772,  fax 310-794-1805 
Name and contact information of Licensee: Mary Kachingwe-Sisya, Student # 3251-854- 
4,  email: marymbeba@kcn.unima.mw or mmbeba@yahoo.co; Promoter: Prof E Potgieter, 
Department of Health Studies, University of South Africa. 
 
Title of Research: Treatment Adherence amongst Hypertensive Patients at Queen Elizabeth 
Central Hospital Blantyre, Malawi. 
Date: 29th December, 2012. 
Signature of researcher : MMM. 
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Annexure E: Structured interview schedule Chichewa version. 
Chikalata cha mafunso 
Mutu wa kafukufuku: Zinthu zomwe zimaapangitsa kulondoloza mankhwala anthu odwala Biipi 
ku kiliniki ya Biipi pa Queen Elizabeth Central Hospital, Blantyre, Malawi. 
Tsiku______________            Dzina la ofufuza________            kodi namba____________ 
Zoyenela kucita:  Kuchokera mu buku la umoyo, lowetsani izi pa chikalata cha mafunso 
molondola.                                        
Nthawi Bii
pi 
sikelo BMI                   Mankhwala 
Dzina      Mulingo        Kangati 
1. Yalero     
2.Yakale yoyamba -     
3. Yakale yachiwiri                
4. Yakale yachitatu               
5. Yakale yachinayi             
6. Chaka anaidziwa Bipii ___    Age___   
7. Zaka zomwe amwa mankwala a Bipii_____    
8. Chaka ayezetsa HIV ________           
9. Chaka anayamba ART______ 
10 Lembani ma ARV____            
 
 
 
 
A.  Mbiri ya oyankha 
Q Mmafunso Mayankho Kodi Mojo
wa 
A.1.  munthu wanji Male …………… 
Female …………                         
    1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
 
A.2. Muli ndi zaka zingati? _____________     1 
A.3. Ndinu Mtundu wanji? Chewa ………….. 
Ngoni …………… 
Tumbuka ……… 
Lomwe ………… 
Yao…………....... 
Zina (nenani)..... 
 
 
    1 
    2 
    3 
    4 
    5  
    6 
A.4. 
 
 
 
 
Ndinu a mpingo wanji? 
 
 
 
 
Roman Catholic..... 
Presbyterian......... 
Anglican................ 
Pentecostal.......... 
Muslim................. 
    1 
    2 
    3 
    4 
    5 
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A.5. 
 
 
Ndi sukulu yiti yomwe 
munapambana? 
 
Zina (nenani)...... 
 
Ayi……...…........ 
Primary school....... 
Secondary school... 
College (Deg, Dip, Cert 
University (Deg,Dip,Cert . 
    6 
 
   1 
 
 
 
Mojo
wa 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.15,  
 
 
 
If 
male 
skip 
A.16. 
   2 
   3  
   4 
   5 
    
A.6. 
 
Mumagwira nchito yanji?     _______ 
 
   1 
 
A.7. 
 
Boma la kwanu ndi liti?     _______ 
 
   1 
 
A.8. 
 
Mwatumizidwa ndi/ mwachokera 
chipatala citi? 
    _______ 
 
 
   1 
 
 
A.9. Muli pa banja?      _______    1 
 
A.10.  
 
Muli ndi ana angati?      _______    1 
    
A.11. Nthawi ya mimba yanu 
munawonako izi? 
 
Kukomoka....................... 
Kutupa............. 
Mutu........... 
Osawona bwino........ 
palibe……………. 
Zina (nenani)...... 
 
   1 
   2 
   3 
   4 
   5 
   6 
A12. Nanga Bipii?  Eya.................. 
Ayi..................... 
   1 
   2 
A.13.   
 
Ana anu amoyo ndi angati? ______    1 
A.14.  
 
Nanga anafa ndi angati? ______     1 
A.15.   Anafa ndi chiani? 
                          
____________________  
____________________ 
 
Sindikudziwa…. 
   1 
    
2 
A.16.  
Ndinu woyembekezera? 
Eya………………….. 
Ayi…………………… 
   1 
   2 
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B. Kudziwa za Bipii 
   
B.17. Bipii imayenda mu mtundu, 
nzoona? 
Eya........... 
Ayi............. 
Sindikudziwa......... 
  1    
   2   3 
B.18. Bipii ndi yosaciritsika, nzoona? Eya…………. 
Ayi…………… 
Sindikudziwa...... 
  1 
  2 
  3 
B.19. 
 
 
Bipii ndiyotheka bora kuvome 
reza, n'kumamwa mankhwala. 
Eya.................. 
Ayi................... 
Sindikudziwa....... 
  1 
  2 
  3 
B.20. Ndi vuto lanji linga pezeke ngati 
Bipii ikukwerabe?  
 
Sitoloko.................. 
Kufa mtima............ 
Kusawona.bwino....... 
Impyo kufoka.......... 
Kufa 
mwadzidzidzi......... 
  1 
  2  
  3 
  4 
  5 
B.21. Chimayambitsa Bipii sicidziwika, 
koma pali zoifulumizitsa, 
Nzoona? 
Eya.....................  
Ayi...................... 
 
Sindikudziwa......... 
  1 
  2 
  
 3 
 
B.22. 
 
 
 
 
 
 
 
 
Ndi zinthu ziti zimene 
zimafulumizitsa chiyambi ca 
Bipii? 
 
 
 
 
 
 
Kusuta fodya... 
Kumwa mowa 
Nkhawa……… 
Kunenepatsa…… 
Osachita fizo….. 
Kudya za mchere 
wambiri 
Somba za kapenta  
Kudya 
sugawambiri....                  
Zina (nenani)...... 
 
 
  1 
  2 
  3 
  4 
  5 
  6 
   
  7 
  8 
  9 
B.23. Pali zinanso zofulumizitsa, 
Nzoona? 
Eya..................... 
Ayi........................ 
Sindikudziwa........... 
  1 
  2 
  3 
 
B.24. 
 
 
 
Ndi ziti zinazo,culani 
 
 
zokudya…………..... 
Kutopa... 
Malo achilendo.. 
Nkhawa.................... 
   
  1 
  2 
  3 
  4 
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B.25. 
 
 
 
 
 
 
 
 
 
 
 
Mwa izi, ndi ziti, zimene 
mukuganiza kuti zinakufulumizita 
kuyamba  kwa Bipii yanu? 
Kusuta fodya. 
Kumwa mowa... 
Nkhawa……………..
Kunenepetsa…… 
Posacita fizo..... 
Kudya za mchere,    
Kudya za Suga 
Zokudya..somba za 
kapeta.......... 
Kutopa.... 
Malo a chilendo 
Zina (nenani)..... 
 
 
  1    
  
Mojowa 
  2 
  3 
  4 
  5 
  6 
  7 
  8 
  9 
 10 
 11 
 12 
B.26.  
Kodi Bipii yanu anaizindikira 
bwanji? 
 
 
Anandiyeza ku 
cipatala OPD. 
Ku sikelo....... 
Ndikukayamba 
ncito..... 
Ndikupereka magazi. 
Ndikugula insuransi... 
Zina (nenani)........ 
 
 
 
   1 
   2 
   3 
   4 
   5 
   6 
B.27. 
 
Kuti idziwike Bipii munkamva 
chiani mthupi? 
 
 
 
Chizungurilre…….... 
Mutu................... 
Mabalu nkhutu........ 
Mtima kuthamanga... 
Kukomoka...... 
Zina (nenani)....... 
 
 
   1  
   2 
   3 
   4 
   5 
   6 
B.28. Munalandilako uphungu wa 
Bipii? 
Eya…………….. 
Ayi…………........ 
 
  1 
  2 
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C :Kudziwa mankhwala a Bipii.  
 
 
C.29. 
 
Panopa  mukumwa 
mankwala ati 
      a, dzina  
      b, mlingo 
      c, kangati? 
 
 
Chongani zonse achula). 
 
 
 
Dzina mling
o  
 Kangati 
Hydrochloro 
thiazide (HCT) 
  
Frusemide   
PropraAyirol   
AteAyiral   
Nifedipine   
Aldomet   
Zina (nenani) 
Description of 
pills: small 
round pink 
white pills 
  
 
kodi  
 
1a,b,c  
  
  
2a,b,c    
3a,b,c  
4a,b,c  
5a,b,c  
6a,b,c  
7a,b,c  
   
C.30. Ena ndi ati,amene 
mukumwaso 
a,dzina 
b, mlingo 
c, kangati? 
 
Panadol   
Indocid   
Diclofenac   
Aspirin   
Herbs   
Nutrition 
supplements 
  
Zina (nenani) 
 
  
 
1a,b,c 
 2a,b,c 
 3a,b,c 
 4a,b,c 
 5a,b.c  
  
 6a,b,c  
 8a,b,c 
  
C.31. 
 
 
 
 Eya……………… 
Ayi……………… 
  
 
      1 
      2 
 
 
C.32. Dzulo munadya chiyani 
m'mawa? 
 
 ________________________ 
 
       
     1 
 
C.33. Nanga masana?Probe! 
mgaiwa 
 
 _________________________ 
 
 
     1 
 
C.34. Nanga madzulo?Probe !  
_________________________ 
 
     1 
C.35. 
 
ndi zakudya ziti anati 
muzidya kulingana ndi 
Palibe……………………... 
Mchere wochepa............................. 
      1 
      2 
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bipii? 
  
Zopanda mafuta….......................... 
Zopanda sipaisi........................ 
Zosakhutitsa kwambiri............ 
Za Masamba............... 
Nthochi............................. 
Zina (nenani).................... 
 
 
      3 
      4 
      5 
      6 
      7 
      8 
 
C.36. 
 
Ndi zakudya ziti anati 
musadye? 
 
(Chongani zonse achula) 
 
Mchere wambiri…........................ 
Nyama ya mafutat …………........... 
Zakudya za sipaisi............................. 
Zokhutitsa kwambiri.............. 
Mowa..................................... 
Fodya................................ 
Zina (nenani)…….................. 
 
 
      
      1  
      2 
      3  
      4 
      5 
      6 
      7 
36 a. Tandiuzeni zomwe mumakonda kudya pabanja panu nthawi zambiri: 
M'mawa: __________     ____________   ___________  ________        1           
Masana     : ____________   ____________   __________  _________  2 
Madzulo   : __________   ____________   __________  __________     3       
 
D.37. A pasta anakupemphereranipo Bipii? Eya…….............. 
Ayi……............... 
       1   Ayi 
jowa  
D. 38 
       2 
D.38. Ataku pempererani munapezako 
bwanji? 
Eya……............. 
Ayi………........... 
       1  
       2  
D.39. Munadwalapo malungo? Eya………......... 
Ayi………........... 
       1  Ayi 
jowa 40-
41 
 
 
 
 
 
 
 
 
 Ayi 
       2 
D.40. 
 
 
Ngati munadwalapo, ndi chaka chiti?   
_____________ 
        
      1 
        
D.41. Mwamwa kangati mankhwala a 
malungo  pa miyezi itatu yapitayi?  
Ayi………………. 
Kmodzi 
.kawiri......................... 
Katatu....................... 
 
       1 
       2 
       3 
 
       4 
D.42. Munadwalapo njoka za m’mima? Ay....................        1 
D. Za umoyo chikhalidwe ndi uchembere 
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kangati? .Kamodzi................ 
Zina (nenani).......... 
       2 Jowa 
43, 44 
 
 
 
 
 
 
 
  
       3 
D.43. munadwalako njoka za m'mimba miyezi 
itatu yapitayi? 
 
_____________ 
        
       1 
D.44. Munamwako mankhwala a njoka myezi 
itatuyi, ngati e! mankwala anji? 
Eya........................... 
Ayi............................. 
  
______________ 
       1 
       2 
        
 
       3 
D.45. Munalandilako mankhwala a kansa 
miyezi itatu yapitayi, mtundu wanji? 
Eya.......................... 
Ayi............................ 
 
 
_______________ 
       1   
        2 
        
        
       3 
       
D.46. Mukulandila mankhwala a tibii? Eya…………………. 
Ayi………………….. 
      1 
      2 
D.47.          
 
Mwalandilako mankhwala a chikasu 
m'maso miyezi itatuyi? 
Eya....................... 
Ayi........................ 
      1 
      2 
D.48. Mwadwalako likodzo miyezi itatuyi? Eya…………………. 
Ayi…………………… 
Sindikudziwa 
      1 Ayi 
jowa 
D.49.  
      2 
      3 
D.49. Ndi kangati mwalandila   mankhwala a 
likodzo?  
1 time………………… 
3 times……………… 
6 times……………… 
N/A........................... 
      1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Ayi 
jowa 
 
54-57 
 
 
      2 
      3 
      4 
D.50. Mumasuta ndudu zingati pa tsiku?      _____________    
  
     1           
       
D.51. Mumamwa mowa ungati pamulungu?         
      ___________ 
 
      1 
 
       
 
D.52. 
 
Mumawonjezera mcere oculuka bwanji 
mu zakudya?   
 
Ayi.………….... 
Pangono 
Tisipuni hafu 
Tisipuni 
       
      1        
      2 
      3 
      4 
D.53. Mai anu alipo? Eya............................ 
Ayi............................. 
      1 
      2 
D.54 Ali ndi zaka zingati?     __________ years       1 
 
D.55. Amamwa mankhwala a Bipii? Eya............................. 
Ayi.............................. 
      1 
      2 
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D.56. 
 
Anayamba afa ziwalo? Eya........................... 
Ayi............................ 
      1  
 
 
      2 
D.57. Anakomokapo, hati ataki? Eya............................ 
Ayi.............................                            
      1 
      2 
D.58.  If Ayit alive what was the 
cause of death,  
Stroke........................ 
 heart condition.......... 
Other (Specify........... 
      1 
      2 
      3 
 
 
Ngat  amai palibe anamwalira ndi 
hiyani? 
Sitoloko....................... 
Kufa mtima.......... 
Sindikudziwa ………. 
Zina (nenani).......... 
 
     1  
 
 
 
      2 
      3 
      4 
D.59 Anamwalira ali ndi zaka zingati? 
 
 
__________Zaka 
       
      1 
D.60. Nanga bamboo alipo?  Eya………………… 
Ayi……................... 
      1     Ayi, 
jowa 
D.62-64 
      2 
D.61. Ali ndi zaka zingati?  
___________years 
       
      1 
D.62. Amamwa mankhwala a Bipii? Eya............................ 
Ayi.............................. 
      1 
      2 
D.63. 
 
Anayamba afa ziwalo? 
 
Eya........................... 
Ayi............................. 
      1 
      2 
       
D.64. Anakomokapo, hati ataki? Eya............................ 
Ayi............................. 
      1 
      2 
D.65. Ngati bambo palibe, anafa ndichani? Sitoloko....................... 
Kufa mtima.......... 
Sindikudziwa………… 
Zina (nenani).......... 
      1 
      2 
      3 
D.66.  Anafa  pa zaka zingati? _________ 
Sindikudziwa 
      1  
 
D.67.  
Azilongo anu ena anafa? 
Eya………………… 
Ayi………………….. 
      1 Ayi 
jowa       2 
 
D.68. 
 
a)Anafa pa zaka zingati? 
b) Ama mwa mankhwala anji a Bipii?  
c) Anafa ndi chani? 
. 
  
 
Ag
e? 
 
 
On 
B/P 
drugs? 
 
 
Anafa 
ndi 
ciani? 
            
 
 
 
 
 
 
 
 
 
 
1st            
1a,b,c 
2nd       
2a,b,c 
3rd     3a,b,c 
Zina 
(nena
ni) 
    4a,b,c 
D.69. Pali abale anu ena omwe anafa? Eya............................... 1     
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..................... 
Ayi................................
...................... 
 2                                                                
D.70. a)Anafa pa zaka zingati?  
b) Mankhwala anji a Bipii?  
c) Anamwalira ndi chiyani? 
. 
1st           
1a,b,c 
 
2nd     
2a,b,c 
3 rd     
3a,b,c 
Other 
(specif
y 
    
4a,b,c 
D.71. Mwamwako mankhwala a makolo athu 
pa miyezi itatuyi? 
Eya………………….... 
Ayi…………………...... 
N/A………………….... 
      1  
       2 
      3 
D.72. Munapeza bwiAyi mutamwa a makolo? Eya…………………. 
Ayi…………………… 
N/A 
      1 
      2 
      3 
 
D.72a.  Tandifotokozeleni m'mene mumamwera mankhwala anu a Bipii pa masiku 
atatu?______________________________________________ 
      ________________________________________________________________ 
D.73. kodi Mumaphatikiza a zitsamba ndi a  
ku kiliniki? 
Eya………………….. 
Ayi…………………… 
N/A…………………... 
     1 
      2 
      3 
D.74. Mumawapeza bwanji mankhwala a 
zitsamba? 
 
Parents…………….. 
Friend……………… 
Neighbour ………….. 
Herbalist…………… 
Spouse……………… 
Self………………… 
N/A………………… 
Zina (nenani)…… 
 
      1 
      2 
      3 
      4 
      5  
      6 
      7 
      8 
 
         
 
    E. The Health Belief Model Concepts 
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Perceived susceptibility  
                 Zochita: Awerengereni, iwo aziyankha  mafunso Esu.75-77a             
                Sikelo:  Inde = 3          aYI = 2        Sindikudziwa = 1                             3 2 1     Kodi                                                                                          
 Item      
Esu.75. kukhala ndi Bipii kukundiika pa ciopysezo cobvutika maso 
ngati sindimwa mankhwala. 
    
1 
 
Esu.76. Bipii ikundiika pa ciopysezo cobvutika mtima ngati sindimwa 
mankhwala 
    
1 
 
Esu.77. Bipii ikhoza kundi pangitsa ciopysezo cozizila ziwalo ngati 
sindimwa mankhwala. 
    
1 
 
77a.   Fotokozani ngati mukuwona kuti mukhoza kupeza mavuto kamba ka Bipii. 
_____________________________________ 
          _________________________________________________________ 
 Perceived severity 
  Zochita: Awerengereni, iwo aziyankha  mafunso Esev.78-80a             
Sikelo:  Inde = 3                     Ayi = 2              Sindikudziwa = 1             3  2  1   Kodi 
 
 Item       
Esev.78. Anthu ena amafa ziwalo mpaka kumwalira osadziwa kuti ali ndi 
Bipii. 
      1  
Esev.79. Zotsatila zake za Bipii ndi zooAyinga moyo.       1  
Esev.80. Imfa ya abale ndi abwenzi atafa ziwalo imandi fulumiza kumwa 
mapilisi anga a Bipii. 
      1  
80a.    Mukuganiza kuti zotsatila za Bipii ndi zoopsya bwanji? 
____________________________ 
            __________________________________________________________________  
________________________________________________________________________  
Perceived benefits   
   Zochita: Awerengereni, iwo aziyankha  mafunso Ebe 81- 83          
                Sikelo:  Inde = 3              Ayi = 2          Sindikudziwa = 1                       3 2 1   Kodi                                                                                        
Ebe.81. Maekisasaizi orimbisa thupi ndi kucepe tsako sikelo 
zandithandiza kuti ndipewe zotsatila za Bipii. 
   1  
Ebe.82. Mankhwala amene ndikumwa ndimamva nawo bwiAyi opanda 
vuto. 
   1  
Ebe.83. Kucepetsa mchere kumandithandiza kucepetsa kuthamanga kwa 
mtima. 
   1  
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Perceived barriers 
Zochita: Awerengereni, iwo aziyankha  mafunso Eba.84-86, 86.1-86.10             
                Sikelo:  Inde = 3                Ayi = 2           Sindikudziwa = 1                          3 2 1  Kodi                                                                                          
Eba.84. Kudikila kwa nthawi yaitali ku kiliniki kumandipangitsa zoti 
ndisakatenge ena mankwala akatha. 
     1  
Eba.85.  
       85a. 
       85b. 
       85c. 
       85d. 
Tulo..... ……….    
 Mankhwala a Bipii amandipangitsa weak/kuzizila m’nkhongoAyi                                                                                 
Kutopa............................................................................K 
Kudwala kwambiri……………………………………… 
Ziina nenani ……………………………………                                                                                                                       
 
     1 
2
  3 
  4 
5
 
Eba.86.   Kutalika kwa ku kiliniki/ kumandijombetsa,ngati ndilibe ya basi.      1  
86.1 Mwapezana ndi zovuta zanji mutamwa mankhwala a Bipii pa myezi itatu 
yapitayi?________________________________ 
86.2 Munamvako mutu kupweteka pa miyezi itatu 
yapitayi?______________________________________ 
86.3 Mutuwo umawawa nthawi yake yiti-
yiti?_____________________________________________________________  
86.4 Munachita chiyani kuti mutuwo 
usiye?______________________________________________________________   
 86.5 Munawawuza za mutuwu a dotolo ndi a nesi aku kiliniki?_____________ 
86.6 Adotolo anathandizapo 
bwanji?____________________________________________________________ 
86.7 Thandizolo lakukwanilani?________________ 
86.8 Pali mabvuto enanso, amene mumaaona mukamwa mapilisi a Bipii? 
___________________________________________________________________ 
86.9 Kodi kumatheka kuti mankhwala amatha ku kiliniki?______________________ 
86.10 Ndiye mumatani zikatere, fotokozani?__________________________ 
Cues to action 
                Zochita: Awerengereni, iwo aziyankha  mafunso Eca.87-90             
                Sikelo:  Inde = 3               Ayi = 2          Sindikudziwa = 1                             3 2 1 Kodi                                                                                           
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Eca.87. Health education about high blood pressure motivates me to 
adhere to treatment/ Uphungu wa za Bipii umandisuntha  kutsatila 
mankhwala anga bwiAyi-bwiAyi.  
   1  
Eca.88. Uphungu kucokera kwa abale ndi abwenzi, umandithandizira 
kumwa mankhwala anga moyenerela. 
   1  
Eca.89. Mantha poopa bvuto la imphyso limandipangitsa kumwa 
mankhwala anga moyenerela. 
   1  
Eca.90. Mantha, poopa bvuto la kugwa ndi mtima, amandipangitsa kumwa 
mankhwala anga moyenerela. 
   1  
 
Self-efficacy 
              Zochita: Awerengereni, iwo aziyankha  mafunso Esef.91- 93, 93a-93b            
                Sikelo:  Inde = 3               Ayi = 2        Sindikudziwa = 1                                3 2 1    Kodi                                                                                   
Esef.91. Ndiri nako kuthekera, kusamalira Bipii yanga.     
1 
 
Esef.92.  Ndikumvetsa kufunikira kwa kumwa mankhwala a Bipii 
moyenerera kuti ndisamalire Bipii yanga. 
    
1 
 
Esef.93 Ndikhonza kukwanitsa kusamalira Bipii yanga.     
1 
 
93a. Chima kulimbikitsani ndi chiyani kuti muzilondoloza  bwiAyi kamwedwe ka mankhwala 
anu? 
____________________________________________________________________ 
93b.Kodi mwapanga masewero otani, olimbitsa thupi, mulungu wapitawu? 
____________________________________________________________________ 
 
F. Morisky Medication Adherence Scale MMAS-8:  F94-101. 
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8. Ndi kangati mumabvutikila, kukumbukila, kumwa mankhwala anu onse?                
 Chonde zungulitsani nambala yokhoza) 
 
              Sindinaiwalepo/ mwa nthawi yake…................4 
              Mwakamodzi-kamodzi......................................3 
     Nthawi zina........................................................2 
     Kawiri-kawiri.......................................................1 
    Nthawi zonse ....………….......…………..............0  
 
 
  
©Morisky Medication Adherence Scale (MMAS-8-Item). This is a generic adherence scale and the name of 
the health concern can be substituted in each question item.  You have said that you are taking 
medications for high blood pressure. Individual people have given several issues concerning their 
medication–taking behavior and we are interested in your experience. There is Ayi right or wrong 
answer.  Please answer each question according to your  personal experience with your high blood 
pressure medication 
                                                                 (Please tick the correct number)                                                   Ayi-1      Eya-0 
2. Kodi nthawi zina mumaiwala kumwa mapilisi anu a Bipii?   
5. Anthu nthawi zina amadumphitsa kumwa mankhwala awo pa zifukwa  zina osati kuiwala.  
Polingalira pa masabata awiri apitawa, panali masiku ena omwe simunamwe mankhwala  
anu a Bipii? 
 
 
 
 
6.  Modi munayamba mwachepetsapo, kapena kusiya kumwa mankhwala anu, 
musanamuuze dotolo wanu, chifukwa choti munabva kudwalika kwambiri mutamwa 
mankhwalawo? 
  
7. Mukakhala paulendo kapena kuchoka pa nyumba, nthawi zina mumaiwala kunyamula 
mankhwala anu a Bipii? 
  
      5. Munamwa mankhwala a Bipii         dzulo?   
6. Mukamva ngati kuti nthenda yanu ya Bipii, yasinthako, kodi nthawi zina mumasiya kumwa 
mankhwala anu? 
  
7. Kumwa mankhwala tsiku ndi tsiku ndizosowetsa mtendere ndithu kwa anthu ena. Kodi 
inuyo mumamva kubvutika, kuti  mutsatire ndondomeko yomwela mankhwala  anu a 
Bipii? 
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  Annexure F: Participant information for consent  
Participation information sheet 
Factors influencing treatment adherence in hypertensive patients at Queen Elizabeth 
Central Hospital, Blantyre, Malawi 
Dear Participant, 
I wish to invite you to participate in a research study on Factors influencing treatment 
adherence in hypertensive patients at Queen Elizabeth Central Hospital, Blantyre, 
Malawi 
I am Mary Kachingwe-Sisya Mbeba, a PhD in Health Studies student at University of South 
Africa. In fulfillment of my PhD, I am conducting a research study on," Factors influencing 
treatment adherence in hypertensive patients at Queen Elizabeth Central Hospital, 
Blantyre, Malawi". 
The study will investigate the treatment adherence levels and the factors influencing 
treatment adherence in hypertensive patients at Queen Elizabeth Central Hospital, Blantyre. 
The study will provide information that may enable nurses to identify treatment adherence 
levels in hypertension patients and factors that influence treatment adherence. This might 
assist nurses with development of strategies to help hypertensive patients prevent 
complications of hypertension, strokes, heart failure and sudden deaths. Your participation in 
the study will provide information about what factors influence hypertensive patients' 
treatment adherence and their level of adherence hence develop strategies to assist them. 
You have been selected to participate in the study because you have hypertension, you are 
taking anti-hypertensive drugs and you are attending the QECH hypertension clinic. 
Your participation in the study is voluntary. You may withdraw from participating at any time 
you feel so and there will be no penalty or loss of benefits to which the subject is otherwise 
entitled. Withdrawal will not affect your care in anyway.  
The study and its procedures have been approved by the appropriate people and research 
committee at, University of South Africa, College of Medicine, Kamuzu College of Nursing 
and Queen Elizabeth Central Hospital. The study procedures do not have any foreseeable 
risks to you and your family.  If at all a certain question in the questionnaire makes the patient 
uncomfortable, will be told not to answer it and go to the next, if the patient seems disturbed   
the interview will be discontinued and patient withdrawn from participation. The researcher 
will provide a researcher developed pamphlet on "Basic information about hypertension" to 
the subjects after the research as a benefit.    
The procedure and expected duration of the subject's participation in the research 
The study procedure includes the researcher asking you questions from the questionnaire 
and you responding, there is no experiment no other procedure. The interview will take 
approximately 45 minutes. Code numbers will be used for identification so that data is not 
linked to your name. The gathered information will be kept by the researcher and only those 
people who are directly involved in the study, researcher and supervisor will have access.  
After data analysis the gathered information will be destroyed by burning them.  
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You are free to ask any questions about the study or about being a participant and you may 
call: The Chairperson,  
        College of Medicine Research and Ethics Committee 
        Private Bag 360,Chichiri, Blanytre 3.Tel: 01 871 911 
 
Mary Kachingwe-Sisya Mbeba   Prof. VJ. EHlers (1)                Dr. M. Hami (2) 
Kamuzu College of Nursing,       University of South Africa,     Kamuzu College of Nursing, 
P.O. Box 415, Blantyre               P.O. Box 0003                       P.O. Box 415, Blantyre  
Cell: 0888895764                       Tel: (012) 4296731                Cell: 088851485  
 
 
 
 
Consent form                                
I have read / been explained about this consent form and I voluntarily agree and consent to 
take part in this study. 
Participant signature/ thumb print.................................... Date................................. 
I have explained the study information to the participant above and have sought her 
understanding for informed consent. 
Investigator’s signature....................................................Date................................................... 
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Afukunnexure G: Uthenga kwa olowa mukafuku 
MUTU: Zinthu zokhudza kalondolozedwe ka kamwedwe ka mankhwala ka anthu odwala 
nthenda ya Biipi-(yothamanga magazi) pa Queen Elizabeth Central Hospital. 
Ine Mary Kachingwe-Sisya Mbeba ndine wophunzira ku sukulu ya ukachenjede ku South 
Africa  ndipo ndikupanga maphunziro a udotolo. Muli kuyitanidwa kuti mutenge nawo mbali 
pa kafukufuku wofuna kufufuza  zinthu zokhudza kalondolozedwe ka  kamwedwe ka 
mankhwala ka anthu odwala nthenda ya biipi-(yothamanga magazi) pa Queen Elizabeth 
Central Hospital. 
Musanapange chiganizo chotengapo mbali pa kafukufukuyu ndipofunika kuti mumvetsetse 
cholinga cha kafukufukuyu kuti chidzafunike ndichani. Mukhoza kutifunsa ngati pali china 
chake chimene simunamvetsetse kapena ngati mukufuna kudziwa zambiri. 
Cholinga cha kafukufuku ndi kufuna kudziwa  zinthu zomwe zimakhudza kalondoledwe ka 
mankwala ka anthu odwala nthenda ya Biipi pa Queen Elizabeth Central Hospital.  
Ndipofunika kufufuza kuti odwala Biipiwa kwenikweni amalondola bwanji kamwedwe ka 
mankhwala awo ndipo zimawathandiza kutheka kapena kulephela ndi chiyani.  Zotsatira za 
kafukufukuyu zidzathandiza kupeza njira zomwe zingathandizire odwala Biipiwa pamodzi ndi 
anamwino kuti palembedwe ndondomeko zoyenera zothandiza kalongosoledwe ka 
kamwedwe ka mankhwala, kuti matenda a Biipiwa asamafike povuta kuti mpaka achite 
stroke kapena kupezekanso ndi nthenda ya mtima kapena kukomoka mpaka kufa kumene . 
Inuyo mwasankhidwa  kutenga mbali mukafukufukuyu chifukwa mukudwala nthenda ya Biipi, 
mukumwa mankhwala komanso muma samalidwa ndi kupeza chithandizo ku kiliniki ya Biipi 
ya pa Queen Elizabeth Central Hospital. 
Ndikufuna kwanu kusankha kutenga mbali pa kafukufukuyu kapena ayi. Muli ndi ufulu wosiya 
kutengapo mbali nthawi iliyonse popanda kupereka zifukwa, ndipo simuzalipitsidwa ayi. 
Ndipo izi sizingasokoneze konse chithandizo chomwe inu mukulandila. 
Kafukufukuyu anawunikidwa bwino lomwe ndi akadaulo a sukulu ya ku South Africa komanso 
College of Medicine, awa ndi mabungwe omwe amayimilira ndi kuteteza anthu odzipereka 
kutenga mbali mu kafukufuku, ndipo palibe kuopsya kwina kulikonse mukatengapo mbali. 
Koma muzangofunsidwa mafunso pa nthenda  iyi ya Biipi. Ndipo pakakhala funso limene 
mwina inu simukufuna kuyankha cifukwa coti lakuipilani muzangonena tizalisiya limenelo. 
kaya ngati pali funso loti lakuipilani kwambiri muzangonena ndiye kuti tizangolekelathu 
kupitiliza mafunsowo. 
Mukavomereza kutenga nawo mbali pa kafukufukuyu mudzafunsidwa mafunso okhudzana 
ndi  matenda a Biipi, komanso mankwala omwe mukumwa nkumalemba mayankho pa 
cipepala . Muli kupemphedwa kuyakha mafunso mmene mukudziwira ndi moona mtima. 
Opangitsa kafukufuku azilemba papepara la mndandanda wa mafunso, ndipo mafunsowa 
adzatenga nthawi yokwana pafupifupi mpindi 45. Pa chipepara cha mayankho anu 
tizalembapo nambala osati dzina lanu ayi. Pakutero sitidzanena kuti izi ananena ndi auje  
chifukwa pakhala palibe dzina lanu. Komanso mapepala oyankhidwawo adzatsekeledwa ndi 
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kuagwira okhaokha amene akucita kafukufukuyu. Tikadzamaliza kafukufuku ndi kulemba  
lipoti zimapepala zonsezi tizaziocha .  
 
Ngati muli ndi mafunso okhudza kafukufukuyu muli omasuka kufunsa mafunso anu kwa; 
A pa Mpando a Komiti ya ku College of Medicine Research and Ethics Committee 
Private Bag 360, Chichiri 
 
 
Mary Kachingwe-Sisya Mbeba    Prof. VJ. EHlers (1)                  Dr. M. Hami (2) 
Kamuzu College of Nursing,        University of South Africa,       Kamuzu College of Nursing, 
P.O. Box 415, Blantyre                 P.O. Box 392; 0003                 P.O. Box 415, Blantyre  
Cell: 0888895764                         Tel: (012) 4296731                   Cell: 088851485  
 
 
 
 
Kalata ya chilorezo kutengapo mbali mukafukufuku 
Ndamvetsetsa za kafukufukuyu ndipo ndavomereza kutengapo mbali mu kafukufukuyu 
mwakufuna kwanga ndi popanda kukakamizidwa. 
.....................................................                         ............................................... 
Chizindikiro  cha wotenga mbali                                                           Tsiku. 
Ndafotokoza za kafukufukuyu kwa wotengapo mbali ndipo wamvetsetsa zokhudza bwino 
lomwe zonse zokhudza kafukufuku. 
............................................................                         ............................................... 
Mwini kafukufuku                                                                                   Tsiku. 
 
Zikomo potengapo mbali mukafukufukuyu.!!! 
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ANNEXURE H: Approval of MMAS-8 Translation to Chichewa version 
RESUBMISSION OF MMAS-8, FORWARD TRANSLATION AND BACKWARD 
TRANSLATION, 27th February 2012 
   Inbox   
  mary mbeba  Mon, Feb 27, 2012 at 10:01 PM  
 
   
Donald E. Morisky  
<dmorisky@ucla.edu>  
Sat, Mar 3, 2012 at 7:16 PM  
To: mary mbeba <marymbeba@kcn.unima.mw>  
Reply | Reply to all | Forward | Print | Delete | Show original  
Hi Mary and hope you are doing well.  Please write the name of the language in the respective 
document and confirm that it is indeed Chichewa (National language) of Malawi. The backward 
translation is almost perfect and very rarely do I get an exact replicate of the original English 
version.  I approve of this version and please let me know if there are other languages that you 
have translated the MMAS-8 scale so I can review. 
 
Best wishes 
 
Dr. Morisky 
- Show quoted text - 
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ANNEXURE I: Permission to use MMAS-8 
Re: Greetings 
   Inbox   
   
Donald E. Morisky  
<dmorisky@ucla.edu>  
Thu, Jan 5, 2012 at 12:49 AM  
To: Fahad Saleem <fahaduob@gmail.com>, marymbeba@kcn.unima.mw  
Reply | Reply to all | Forward | Print | Delete | Show original  
Greetings Fahad and Mary and I am so sorry that you had to go through so much trouble in trying 
to reach me.  I am thankful to Fahad who sent me this note and I really commend you Mary for 
your diligence and perseverence in pursuing my approval of your dissertation project.  I give you 
permission to use the copyrighted MMAS-8 in your doctoral studies, provided you abide with the 
copyright laws, cite our research, and send me a report of your findings upon completion of your 
research.  I wish you the very best of success in your adherence research. You have an outstanding 
Mentor, Dr. Fahad Saleem, and I know you will have an outstanding performance. 
 
Best wishes, 
dmorisky 
 Donald E. Morisky, Sc.D., M.S.P.H., Sc.M.  
Professor and Program Director, Doctoral Training in the Social and Behavioral Determinants of 
HIV/AIDS Prevention 
Department of Community Health Sciences 
UCLA School of Public Health 
650 Charles E. Young Drive South 
Box 951772 
46-071 CHS 
Los Angeles, CA 90095-1772 
email: dmorisky@ucla.edu 
Phone: (310) 825-8508 
Fax:     (310) 794-1805  
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ANNEXURE J: Letter of support and recognition from Kamuzu College of Nursing 
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ANNEXURE K: QECH Protocol for hypertension: diagnosis and treatment     
1. Measure the blood pressure correctly 
     Ensure patient has rested for 10 minutes before measurement. 
      Use correct cuff size, a fat patient may need a large cuff. 
      Hypertension is only diagnosed if the blood pressure (BP) is >140/90 mmHg 
        on 3 separate occasions. 
2. Classify (grade) hypertension and make a treatment plan 
       Mild = systolic BP of 140-159 mmHg and diastolic BP of 90-99 mmHg;  
                        Treatment is change of lifestyle for 3 months then review. 
       Moderate = systolic BP of 160-179 mmHg and a diastolic BP of 100-109 mmHg 
                            Treatment is change of lifestyle and drugs. 
      Severe = systolic BP of >180 mmHg and a diastolic BP of >110 mmHg. 
                             Treatment is change of lifestyle and drugs. 
3. General advice for all patients with hypertension 
Lifestyle changes 
-Avoid Blufen and others like Indocid and Diclofenac 
Stop smoking + reduce alcohol intake 
Increase exercise + reduce salt intake 
Remember the three C's 
 Come to clinic regularly; comply with treatment, continuous supply of tablets 
4. Medication for hypertension-follow in sequence, increase drugs to achieve 
     target BP of <130/80 mmHg 
       HCT-12.5mg Once daily (Do not increase above 25mg 
        Nifedipine- Slow release (SR) 20mg twice daily 
         Lisinopril- 10-20mg once daily (Max dose 80mg OD) 
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Propranolol- 40-80mg BD 
If already on HCT +Propranolol, add Nifedipine then Lisinopril etc 
Medication for use in difficult hypertension (Consult senior doctor) 
METHYLDOPA - 500mg TDS MAX 
Spironolactone - 25mg OD IF K+ >5MMOL/I 
5. Investigating hypertension 
Patients <40 years old or any age with BP persistently >160/100 and compliant with 3 or 
more drugs should have the following tests: 
Urine dips for blood/protein 
Na, K, BUN, Creatinine 
Renal ultrasound 
Consult a senior doctor if results abnormal 
6. Follow up 
Stable hypertension (Compliant and good control)-see 3 monthly 
Poor control or compliance-review in 1 month or sooner if indicated 
Ensure reliability access to medications via QECH or local health centre. 
 
 
                                                                            Dreyer 2011, September. 
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ANNEXURE L: Training program for research assistants  
Training for two days on a Wednesday and a Thursday pending Friday      
Wednesday: Day one morning: will cover objectives of the training, research title,  
   purpose, objectives and research ethics, thus, informed consent,  
   confidentiality, privacy, anonymity, and respect for people   
   respondent, recruitment and selection, communication skills,  
    welcoming respondents, creation of rapport, verification of    
   eligibility, starting and ending the actual interview, listening skills. 
Day one afternoon: understanding the items in the questionnaire, interviewing skills,  
    coding, and documentation of data.  
Methods of training: Discussions, Questions and answers, Practice of one-on-one, 
   role plays on good interviewer.   
Thursday: Day two morning:  Field trip to Ndirande to do pre-tests. 
   The researcher and nine assistants will use Ndirande health centre, 
   out patients department with permission to do a pre-test of the  
   questionnaire on two respondents each. This will be done during  
   the two days training. Respondents with similar characteristics set  
   out in the inclusion criteria will be selected with the help of the  
   nurse-in-charge of the Ndirande Health Centre. The flaws that will  
   be identified during the pre test will be used to refine the   
   questionnaire.  
Day two afternoon: Plenary and feedback on questionnaire. 
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ANNEXURE M: Ethical Clearance Certificate from COMREC 
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ANNEXURE N: Permission from pre-test site 
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ANNEXURE O: Altman’s Nomogram (1991:459) for calculating sample size 
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ANNEXURE P:  
ANNEXURE O, Source: Malawi/WHO STEPS Survey (2010:8) 
 
